Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files).

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ~~(Check one):~~

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Number of shares of Allergan plc’s Ordinary Shares outstanding on ~~July 30, 2018: 339,444,422.~~May 3, 2019: 327,801,905. There is no trading market for securities of Warner Chilcott Limited, all of which are indirectly wholly owned by Allergan plc.

This Quarterly Report on Form 10-Q is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc. The information in this Quarterly Report on Form 10-Q is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q and, to the extent applicable, is therefore filing this form with a reduced disclosure format.

	June 30,		December 31,		March 31,		December 31,
	2018		2017		2019		2018
ASSETS
Current assets:
Cash and cash equivalents	$	1,674.7	$	1,817.2	$	788.5	$	880.4
Marketable securities		21.5		4,632.1		995.2		1,026.9
Accounts receivable, net		2,760.8		2,899.0		2,731.2		2,868.1
Inventories		922.5		904.5		943.2		846.9
Current assets held for sale						45.7		34.0
Prepaid expenses and other current assets		724.2		1,123.9		785.5		819.1
Total current assets		6,103.7		11,376.7		6,289.3		6,475.4
Property, plant and equipment, net		1,761.4		1,785.4		1,781.1		1,787.0
Right of use asset - operating leases						455.4		-
Investments and other assets		297.9		267.9		1,979.5		1,970.6
Non current assets held for sale		180.4		81.6		897.2		882.2
Deferred tax assets		899.9		319.1		1,032.6		1,063.7
Product rights and other intangibles		49,928.3		54,648.3		42,264.6		43,695.4
Goodwill		49,687.2		49,862.9		43,336.6		45,913.3
Total assets	$	108,858.8	$	118,341.9	$	98,036.3	$	101,787.6
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	4,683.8	$	5,541.4	$	4,634.4	$	4,787.2
Income taxes payable		93.0		74.9		126.9		72.4
Current portion of long-term debt and capital leases		1,348.5		4,231.8
Current portion of long-term debt						3,971.8		868.3
Current portion of lease liability - operating						116.1		-
Total current liabilities		6,125.3		9,848.1		8,849.2		5,727.9
Long-term debt and capital leases		24,002.0		25,843.5
Long-term debt						19,554.1		22,929.4
Lease liability - operating						415.2		-
Other long-term liabilities		753.4		886.9		804.4		882.0
Other taxes payable		1,576.6		1,573.9		1,618.2		1,615.5
Deferred tax liabilities		5,137.5		6,352.4		5,235.6		5,501.8
Total liabilities		37,594.8		44,504.8		36,476.7		36,656.6
Commitments and contingencies (Refer to Note 19)
Commitments and contingencies (Refer to Note 20)
Equity:
Preferred shares, $0.0001 par value per share, zero and 5.1 million shares authorized, issued and outstanding, respectively	$	-	$	4,929.7
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 339.3 million and 330.2 million shares issued and outstanding, respectively		-		-
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 327.8 million and 332.6 million shares issued and outstanding, respectively					$	-	$	-
Additional paid-in capital		57,567.7		54,013.5		55,742.8		56,510.0
Retained earnings		12,082.9		12,957.2		4,582.8		7,258.9
Accumulated other comprehensive income		1,592.9		1,920.7		1,216.4		1,345.2
Total shareholders’ equity		71,243.5		73,821.1		61,542.0		65,114.1
Noncontrolling interest		20.5		16.0		17.6		16.9
Total equity		71,264.0		73,837.1		61,559.6		65,131.0
Total liabilities and equity	$	108,858.8	$	118,341.9	$	98,036.3	$	101,787.6

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2018			2017			2019			2018
Net revenues	$	4,124.2		$	4,007.4		$	7,796.3		$	7,580.3		$	3,597.1		$	3,672.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		481.8			550.2			1,004.6			1,000.6			497.8			522.8
Research and development		689.2			489.4			1,163.9			1,249.3			435.0			474.7
Selling and marketing		853.4			935.2			1,653.4			1,804.3			804.0			800.0
General and administrative		334.1			459.8			630.0			775.9			308.3			295.9
Amortization		1,697.1			1,757.9			3,394.7			3,493.9			1,399.4			1,697.6
Goodwill impairments														2,467.0			-
In-process research and development impairments		276.0			703.3			798.0			1,043.3			-			522.0
Asset sales and impairments, net		259.6			14.0			272.7			21.4			(5.2	)		13.1
Total operating expenses		4,591.2			4,909.8			8,917.3			9,388.7			5,906.3			4,326.1
Operating (loss)		(467.0	)		(902.4	)		(1,121.0	)		(1,808.4	)		(2,309.2	)		(654.0	)

Interest income		6.3			16.6			23.6			41.9			21.3			17.3
Interest (expense)		(230.0	)		(277.4	)		(480.6	)		(567.1	)		(201.8	)		(250.6	)
Other income / (expense), net		215.4			(133.5	)		136.6			(2,056.3	)		13.8			(78.8	)
Total other (expense), net		(8.3	)		(394.3	)		(320.4	)		(2,581.5	)		(166.7	)		(312.1	)
(Loss) before income taxes and noncontrolling interest		(475.3	)		(1,296.7	)		(1,441.4	)		(4,389.9	)		(2,475.9	)		(966.1	)
(Benefit) for income taxes		(5.2	)		(581.2	)		(687.4	)		(1,113.3	)		(68.6	)		(682.2	)
Net (loss) from continuing operations, net of tax		(470.1	)		(715.5	)		(754.0	)		(3,276.6	)
(Loss) from discontinued operations, net of tax		-			(8.4	)		-			(11.5	)
Net (loss)		(470.1	)		(723.9	)		(754.0	)		(3,288.1	)		(2,407.3	)		(283.9	)
(Income) attributable to noncontrolling interest		(2.4	)		(2.0	)		(4.6	)		(3.0	)		(0.7	)		(2.2	)
Net (loss) attributable to shareholders		(472.5	)		(725.9	)		(758.6	)		(3,291.1	)		(2,408.0	)		(286.1	)
Dividends on preferred shares		-			69.6			46.4			139.2			-			46.4
Net (loss) attributable to ordinary shareholders	$	(472.5	)	$	(795.5	)	$	(805.0	)	$	(3,430.3	)	$	(2,408.0	)	$	(332.5	)

(Loss) per share attributable to ordinary shareholders - basic:
Continuing operations	$	(1.39	)	$	(2.35	)	$	(2.39	)	$	(10.20	)
Discontinued operations		-			(0.02	)		-			(0.03	)
Net (loss) per share - basic	$	(1.39	)	$	(2.37	)	$	(2.39	)	$	(10.23	)
(Loss) per share attributable to ordinary shareholders - diluted:
Continuing operations	$	(1.39	)	$	(2.35	)	$	(2.39	)	$	(10.20	)
Discontinued operations		-			(0.02	)		-			(0.03	)
Net (loss) per share - diluted	$	(1.39	)	$	(2.37	)	$	(2.39	)	$	(10.23	)

Dividends per ordinary share	$	0.72		$	0.70		$	1.44		$	1.40
(Loss) per share attributable to ordinary shareholders
Basic													$	(7.25	)	$	(0.99	)
Diluted													$	(7.25	)	$	(0.99	)

Weighted average shares outstanding:
Basic		339.1			335.2			336.9			335.2			332.0			334.6
Diluted		339.1			335.2			336.9			335.2			332.0			334.6

	Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2019			2018
Cash Flows From Operating Activities:
Net (loss)	$	(754.0	)	$	(3,288.1	)	$	(2,407.3	)	$	(283.9	)
Reconciliation to net cash provided by operating activities:
Depreciation		105.2			81.2			47.5			56.1
Amortization		3,394.7			3,493.9			1,399.4			1,697.6
Provision for inventory reserve		45.4			48.7			18.8			14.2
Share-based compensation		127.4			148.5			52.3			72.5
Deferred income tax benefit		(1,359.6	)		(1,478.8	)		(229.7	)		(1,026.4	)
Goodwill impairments								2,467.0			-
In-process research and development impairments		798.0			1,043.3			-			522.0
Loss on asset sales and impairments, net		272.7			21.4
Net income impact of other-than-temporary loss on investment in Teva securities		-			1,978.0
Gain on sale of Teva securities, net		(60.9	)		-
Amortization of inventory step-up		-			87.8
Gain on sale of business		(53.0	)		-
(Gain) / loss on asset sales and impairments, net								(5.2	)		13.1
Loss on sale of Teva securities, net								-			77.7
Non-cash extinguishment of debt		4.0			(8.2	)		0.3			-
Cash charge related to extinguishment of debt		(13.1	)		170.5
Amortization of deferred financing costs		11.9			13.2			4.6			6.3
Non-cash lease expense								30.1			-
Contingent consideration adjustments, including accretion		(101.8	)		15.2			18.7			5.3
Other, net		(0.3	)		(22.6	)		(10.3	)		6.5
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		90.3			(139.0	)		132.4			259.1
Decrease / (increase) in inventories		(113.3	)		(95.1	)		(128.3	)		(52.7	)
Decrease / (increase) in prepaid expenses and other current assets		39.3			10.5			36.2			(0.6	)
Increase / (decrease) in accounts payable and accrued expenses		(40.4	)		(207.5	)		(199.8	)		(231.6	)
Increase / (decrease) in income and other taxes payable		365.4			673.7			60.0			336.6
Increase / (decrease) in other assets and liabilities		(59.4	)		(23.5	)		(52.7	)		(13.5	)
Net cash provided by operating activities		2,698.5			2,523.1			1,234.0			1,458.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(106.5	)		(137.2	)		(64.8	)		(46.4	)
Additions to product rights and other intangibles		-			(586.3	)		(7.5	)		-
Additions to investments		(1,455.9	)		(6,787.9	)		(538.2	)		(1,455.9	)
Proceeds from sale of investments and other assets		5,651.3			13,197.5			569.1			4,889.5
Payments to settle Teva related matters		(466.0	)		-			-			(466.0	)
Proceeds from sales of property, plant and equipment		11.5			4.3			17.2			11.1
Acquisitions of businesses, net of cash acquired		-			(5,290.4	)		(80.6	)		-
Net cash provided by investing activities		3,634.4			400.0
Net cash (used in) / provided by investing activities								(104.8	)		2,932.3
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		709.0			3,023.0			-			709.0
Payments on debt, including finance lease obligations and credit facility								(159.4	)		(4,322.1	)
Payments of contingent consideration and other financing								(2.0	)		(9.3	)
Proceeds from stock plans								9.7			35.5
Proceeds from forward sale of Teva securities		465.5			-			-			372.3
Debt issuance and other financing costs		-			(17.5	)
Payments on debt, including capital lease obligations and credit facility		(5,366.8	)		(5,579.2	)
Cash charge related to extinguishment of debt		13.1			(170.5	)
Proceeds from stock plans		69.2			124.7
Payments of contingent consideration and other financing		(10.6	)		(505.1	)
Payments to settle Teva related matters		(234.0	)		-			-			(234.0	)
Repurchase of ordinary shares		(1,572.1	)		(35.2	)		(829.2	)		(1,439.6	)
Dividends paid		(563.7	)		(611.9	)		(246.1	)		(319.5	)
Net cash (used in) financing activities		(6,490.4	)		(3,771.7	)		(1,227.0	)		(5,207.7	)
Effect of currency exchange rate changes on cash and cash equivalents		15.0			11.5			5.9			(5.3	)
Net (decrease) in cash and cash equivalents		(142.5	)		(837.1	)		(91.9	)		(822.4	)
Cash and cash equivalents at beginning of period		1,817.2			1,724.0			880.4			1,817.2
Cash and cash equivalents at end of period	$	1,674.7		$	886.9		$	788.5		$	994.8
Supplemental Disclosures of Cash Flow Information
Cash paid during the year for:
Income taxes other, net of refunds	$	336.1		$	(250.7	)	$	105.4		$	35.7
Interest	$	520.9		$	626.9		$	252.0		$	344.4
Schedule of Non-Cash Investing and Financing Activities:
Conversion of mandatory convertible preferred shares	$	4,929.7		$	-		$	-		$	4,929.7
Settlement of Teva Shares	$	465.5		$	-
Settlement of secured financing	$	(465.5	)	$	-
Non-cash equity issuance for the acquisition of Zeltiq net assets	$	-		$	8.5
Deferred consideration for the acquisition of Zeltiq	$	-		$	13.5
Dividends accrued	$	1.4		$	24.6		$	1.4		$	1.4

															Retained			Accumulated
												Additional			Earnings/			Other
	Ordinary Shares					Preferred Shares						Paid-in-			(Accumulated			Comprehensive			Noncontrolling
	Shares			Amount		Shares			Amount			Capital			Deficit)			Income / (Loss)			Interest		Total
BALANCE, December 31, 2017		330.2		$	-		5.1		$	4,929.7		$	54,013.5		$	12,957.2		$	1,920.7		$	16.0	$	73,837.1
Implementation of new accounting pronouncements		-			-		-			-			-			424.7			(63.0	)		-		361.7
BALANCE, January 1, 2018		330.2		$	-		5.1		$	4,929.7		$	54,013.5		$	13,381.9		$	1,857.7		$	16.0	$	74,198.8
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(286.1	)		-			-		(286.1	)
Other comprehensive income, net of tax		-			-		-			-			-			-			183.8			-		183.8
Share-based compensation		-			-		-			-			72.5			-			-			-		72.5
Ordinary shares issued under employee stock plans		0.7			-		-			-			35.5			-			-			-		35.5
Dividends declared		-			-		-			-			-			(296.3	)		-			-		(296.3	)
Conversion of Mandatory Preferred Shares		17.8			-		(5.1	)		(4,929.7	)		4,929.7			-			-			-		-
Repurchase of ordinary shares under the share repurchase programs		(9.6	)		-		-			-			(1,540.0	)		-			-			-		(1,540.0	)
Repurchase of ordinary shares		(0.1	)		-		-			-			(24.3	)		-			-			-		(24.3	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			2.1		2.1
BALANCE, March 31, 2018		339.0		$	-		-		$	-		$	57,486.9		$	12,799.5		$	2,041.5		$	18.1	$	72,346.0

BALANCE, December 31, 2018		332.6		$	-		-		$	-		$	56,510.0		$	7,258.9		$	1,345.2		$	16.9	$	65,131.0
Implementation of new accounting pronouncement		-			-		-			-			-			(22.0	)		-			-		(22.0	)
BALANCE, January 1, 2019		332.6		$	-		-		$	-		$	56,510.0		$	7,236.9		$	1,345.2		$	16.9	$	65,109.0
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(2,408.0	)		-			-		(2,408.0	)
Other comprehensive (loss), net of tax		-			-		-			-			-			-			(128.8	)		-		(128.8	)
Share-based compensation		-			-		-			-			52.3			-			-			-		52.3
Ordinary shares issued under employee stock plans		0.7			-		-			-			9.7			-			-			-		9.7
Dividends declared		-			-		-			-			-			(246.1	)		-			-		(246.1	)
Repurchase of ordinary shares under the share repurchase programs		(5.3	)		-		-			-			(799.7	)		-			-			-		(799.7	)
Repurchase of ordinary shares		(0.2	)		-		-			-			(29.5	)		-			-			-		(29.5	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			0.7		0.7
BALANCE, March 31, 2019		327.8		$	-		-		$	-		$	55,742.8		$	4,582.8		$	1,216.4		$	17.6	$	61,559.6

	June 30,		December 31,		March 31,			December 31,
	2018		2017		2019			2018
ASSETS
Current assets:
Cash and cash equivalents	$	1,673.5	$	1,816.3	$	786.7		$	878.6
Marketable securities		21.5		4,632.1		995.2			1,026.9
Accounts receivable, net		2,760.8		2,899.0		2,731.2			2,868.1
Receivables from Parents		5,833.4		5,797.4		814.1			640.9
Inventories		922.5		904.5		943.2			846.9
Current assets held for sale						45.7			34.0
Prepaid expenses and other current assets		722.9		1,123.0		780.9			818.7
Total current assets		11,934.6		17,172.3		7,097.0			7,114.1
Property, plant and equipment, net		1,761.4		1,785.4		1,781.1			1,787.0
Right of use asset - operating leases						455.4			-
Investments and other assets		297.9		267.9		1,979.5			1,970.6
Non current receivables from Parents		3,964.0		3,964.0		-			-
Non current assets held for sale		180.4		81.6		897.2			882.2
Deferred tax assets		896.8		316.0		1,032.6			1,063.7
Product rights and other intangibles		49,928.3		54,648.3		42,264.6			43,695.4
Goodwill		49,687.2		49,862.9		43,336.6			45,913.3
Total assets	$	118,650.6	$	128,098.4	$	98,844.0		$	102,426.3
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	4,681.6	$	5,515.6	$	4,634.3		$	4,787.4
Payables to Parents		2,379.7		2,340.6		3,034.9			2,829.2
Income taxes payable		92.5		74.9		126.9			72.4
Current portion of long-term debt and capital leases		1,348.5		4,231.8
Current portion of long-term debt						3,971.8			868.3
Current portion of lease liability - operating						116.1			-
Total current liabilities		8,502.3		12,162.9		11,884.0			8,557.3
Long-term debt and capital leases		24,002.0		25,843.5
Long-term debt						19,554.1			22,929.4
Lease liability - operating						415.2			-
Other long-term liabilities		753.4		886.9		804.4			882.0
Other taxes payable		1,576.2		1,573.5		1,612.0			1,615.5
Deferred tax liabilities		5,140.5		6,349.4		5,235.6			5,501.8
Total liabilities		39,974.4		46,816.2		39,505.3			39,486.0
Commitments and contingencies (Refer to Note 19)
Commitments and contingencies (Refer to Note 20)
Equity:
Members' capital		72,935.1		72,935.1		64,752.1			65,797.9
Retained earnings		4,127.7		6,410.4		(6,647.4	)		(4,219.7	)
Accumulated other comprehensive income		1,592.9		1,920.7		1,216.4			1,345.2
Total members’ equity		78,655.7		81,266.2		59,321.1			62,923.4
Noncontrolling interest		20.5		16.0		17.6			16.9
Total equity		78,676.2		81,282.2		59,338.7			62,940.3
Total liabilities and equity	$	118,650.6	$	128,098.4	$	98,844.0		$	102,426.3

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2018			2017			2019			2018
Net revenues	$	4,124.2		$	4,007.4		$	7,796.3		$	7,580.3		$	3,597.1		$	3,672.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		481.8			550.2			1,004.6			1,000.6			497.8			522.8
Research and development		689.2			489.4			1,163.9			1,249.3			435.0			474.7
Selling and marketing		853.4			935.2			1,653.4			1,804.3			804.0			800.0
General and administrative		299.5			447.7			593.6			762.0			306.1			294.1
Amortization		1,697.1			1,757.9			3,394.7			3,493.9			1,399.4			1,697.6
Goodwill impairments														2,467.0			-
In-process research and development impairments		276.0			703.3			798.0			1,043.3			-			522.0
Asset sales and impairments, net		259.6			14.0			272.7			21.4			(5.2	)		13.1
Total operating expenses		4,556.6			4,897.7			8,880.9			9,374.8			5,904.1			4,324.3
Operating (loss)		(432.4	)		(890.3	)		(1,084.6	)		(1,794.5	)		(2,307.0	)		(652.2	)

Interest income		71.8			37.2			142.1			88.6			21.3			70.3
Interest (expense)		(230.0	)		(277.4	)		(480.6	)		(567.1	)		(201.8	)		(250.6	)
Other income / (expense), net		215.4			(133.5	)		136.6			(2,056.3	)		13.8			(78.8	)
Total other income / (expense), net		57.2			(373.7	)		(201.9	)		(2,534.8	)
Total other (expense), net														(166.7	)		(259.1	)
(Loss) before income taxes and noncontrolling interest		(375.2	)		(1,264.0	)		(1,286.5	)		(4,329.3	)		(2,473.7	)		(911.3	)
(Benefit) for income taxes		(5.2	)		(581.2	)		(687.4	)		(1,113.3	)		(68.7	)		(682.2	)
Net (loss) from continuing operations, net of tax		(370.0	)		(682.8	)		(599.1	)		(3,216.0	)
(Loss) from discontinued operations, net of tax		-			(8.4	)		-			(11.5	)
Net (loss)		(370.0	)		(691.2	)		(599.1	)		(3,227.5	)		(2,405.0	)		(229.1	)
(Income) attributable to noncontrolling interest		(2.4	)		(2.0	)		(4.6	)		(3.0	)		(0.7	)		(2.2	)
Net (loss) attributable to members	$	(372.4	)	$	(693.2	)	$	(603.7	)	$	(3,230.5	)	$	(2,405.7	)	$	(231.3	)

	Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2019			2018
Cash Flows From Operating Activities:
Net (loss)	$	(599.1	)	$	(3,227.5	)	$	(2,405.0	)	$	(229.1	)
Reconciliation to net cash provided by operating activities:
Depreciation		105.2			81.2			47.5			56.1
Amortization		3,394.7			3,493.9			1,399.4			1,697.6
Provision for inventory reserve		45.4			48.7			18.8			14.2
Share-based compensation		127.4			148.5			52.3			72.5
Deferred income tax benefit		(1,359.6	)		(1,478.8	)		(229.7	)		(1,026.4	)
Goodwill impairments								2,467.0			-
In-process research and development impairments		798.0			1,043.3			-			522.0
Loss on asset sales and impairments, net		272.7			21.4
Net income impact of other-than-temporary loss on investment in Teva securities		-			1,978.0
Gain on sale of Teva securities, net		(60.9	)		-
Amortization of inventory step up		-			87.8
Gain on sale of business		(53.0	)		-
(Gain) / loss on asset sales and impairments, net								(5.2	)		13.1
Loss on sale of Teva securities, net								-			77.7
Non-cash extinguishment of debt		4.0			(8.2	)		0.3			-
Cash charge related to extinguishment of debt		(13.1	)		170.5
Amortization of deferred financing costs		11.9			13.2			4.6			6.3
Non-cash lease expense								30.1			-
Contingent consideration adjustments, including accretion		(101.8	)		15.2			18.7			5.3
Other, net		(0.3	)		(22.6	)		(10.3	)		6.5
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		90.3			(139.0	)		132.4			259.1
Decrease / (increase) in inventories		(113.3	)		(95.1	)		(128.3	)		(52.7	)
Decrease / (increase) in prepaid expenses and other current assets		40.6			13.1			40.4			0.1
Increase / (decrease) in accounts payable and accrued expenses		(38.2	)		(179.2	)		(199.5	)		(229.1	)
Increase / (decrease) in income and other taxes payable		365.4			673.7			60.0			336.6
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents		(181.0	)		(43.5	)		(79.3	)		64.8
Net cash provided by operating activities		2,735.3			2,594.6			1,214.2			1,594.6
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(106.5	)		(137.2	)		(64.8	)		(46.4	)
Additions to product rights and other intangibles		-			(586.3	)		(7.5	)		-
Additions to investments		(1,455.9	)		(6,787.9	)		(538.2	)		(1,455.9	)
Proceeds from sale of investments and other assets		5,651.3			13,197.5			569.1			4,889.5
Payments to settle Teva related matters		(466.0	)		-			-			(466.0	)
Proceeds from sales of property, plant and equipment		11.5			4.3			17.2			11.1
Acquisitions of businesses, net of cash acquired		-			(5,290.4	)		(80.6	)		-
Net cash provided by investing activities		3,634.4			400.0
Net cash (used in) / provided by investing activities								(104.8	)		2,932.3
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		709.0			3,023.0			-			709.0
Payments on debt, including finance lease obligations and credit facility								(159.4	)		(4,322.1	)
Payments of contingent consideration and other financing								(2.0	)		(9.3	)
Proceeds from forward sale of Teva securities		465.5			-			-			372.3
Debt issuance and other financing costs		-			(17.5	)
Payments on debt, including capital lease obligations and credit facility		(5,366.8	)		(5,579.2	)
Cash charge related to extinguishment of debt		13.1			(170.5	)
Payments of contingent consideration and other financing		(10.6	)		(505.1	)
Payments to settle Teva related matters		(234.0	)		-			-			(234.0	)
Dividends to Parents		(2,103.7	)		(611.9	)		(1,045.8	)		(1,859.5	)
Net cash (used in) financing activities		(6,527.5	)		(3,861.2	)		(1,207.2	)		(5,343.6	)
Effect of currency exchange rate changes on cash and cash equivalents		15.0			11.5			5.9			(5.3	)
Net (decrease) in cash and cash equivalents		(142.8	)		(855.1	)		(91.9	)		(822.0	)
Cash and cash equivalents at beginning of period		1,816.3			1,713.2			878.6			1,816.3
Cash and cash equivalents at end of period	$	1,673.5		$	858.1		$	786.7		$	994.3
Schedule of Non-Cash Investing and Financing Activities:
Settlement of Teva Shares	$	465.5		$	-
Settlement of secured financing	$	(465.5	)	$	-
Non-cash dividends to Parents	$	-		$	4,203.9

	Members' Capital
	Shares		Amount			Retained Earnings			Accumulated Other Comprehensive Income / (Loss)			Noncontrolling Interest		Total
BALANCE, December 31, 2017		100.0	$	72,935.1		$	6,410.4		$	1,920.7		$	16.0	$	81,282.2
Implementation of new accounting pronouncements		-		-			424.7			(63.0	)		-		361.7
BALANCE, January 1, 2018		100.0	$	72,935.1		$	6,835.1		$	1,857.7		$	16.0	$	81,643.9
Comprehensive (loss):
Net (loss) attributable to members		-		-			(231.3	)		-			-		(231.3	)
Other comprehensive income, net of tax		-		-			-			183.8			-		183.8
Dividends to Parents		-		-			(1,859.5	)		-			-		(1,859.5	)
Movement in noncontrolling interest		-		-			-			-			2.1		2.1
BALANCE, March 31, 2018		100.0	$	72,935.1		$	4,744.3		$	2,041.5		$	18.1	$	79,739.0

BALANCE, December 31, 2018		100.0	$	65,797.9		$	(4,219.7	)	$	1,345.2		$	16.9	$	62,940.3
Implementation of new accounting pronouncement		-		-			(22.0	)		-			-		(22.0	)
BALANCE, January 1, 2019		100.0	$	65,797.9		$	(4,241.7	)	$	1,345.2		$	16.9	$	62,918.3
Comprehensive (loss):
Net (loss) attributable to members		-		-			(2,405.7	)		-			-		(2,405.7	)
Other comprehensive (loss), net of tax		-		-			-			(128.8	)		-		(128.8	)
Dividends to Parents		-		(1,045.8	)		-			-			-		(1,045.8	)
Movement in noncontrolling interest		-		-			-			-			0.7		0.7
BALANCE, March 31, 2019		100.0	$	64,752.1		$	(6,647.4	)	$	1,216.4		$	17.6	$	59,338.7

Allergan plc is a global pharmaceutical ~~company~~leader focused on developing, manufacturing and commercializing branded pharmaceutical,~~(“brand”, “branded” or “specialty brand”)~~, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products ~~for the~~primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system ~~eye care, medical aesthetics~~ and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. gastroenterology. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities.

The accompanying consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, ~~2017~~2018 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying consolidated financial statements. The accompanying year end consolidated balance sheet was derived from the audited financial statements included in the Annual Report. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive (loss) / income and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. All intercompany transactions and balances have been eliminated in consolidation. The Company’s results of operations, comprehensive (loss) / income and cash flows for the interim periods are not necessarily indicative of the results of operations, comprehensive (loss) / income and cash flows that it may achieve in future periods.

NOTE 2 –— Reconciliation of Warner Chilcott Limited results to Allergan plc results

Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group (together with other direct or indirect parents of Warner Chilcott Limited, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited disclosures relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions):

	As of June 30, 2018							As of December 31, 2017							As of March 31, 2019						As of December 31, 2018
	Allergan plc		Warner Chilcott Limited		Difference			Allergan plc		Warner Chilcott Limited		Difference			Allergan plc		Warner Chilcott Limited		Difference		Allergan plc		Warner Chilcott Limited		Difference
Cash and cash equivalents	$	1,674.7	$	1,673.5	$	1.2		$	1,817.2	$	1,816.3	$	0.9		$	788.5	$	786.7	$	1.8	$	880.4	$	878.6	$	1.8
Prepaid expenses and other current assets		724.2		722.9		1.3			1,123.9		1,123.0		0.9			785.5		780.9		4.6		819.1		818.7		0.4
Deferred tax assets		899.9		896.8		3.1			319.1		316.0		3.1
Accounts payable and accrued liabilities		4,683.8		4,681.6		2.2			5,541.4		5,515.6		25.8			4,634.4		4,634.3		0.1		4,787.2		4,787.4		(0.2	)
Income taxes payable		93.0		92.5		0.5			74.9		74.9		-
Other taxes payables		1,576.6		1,576.2		0.4			1,573.9		1,573.5		0.4
Deferred tax liabilities		5,137.5		5,140.5		(3.0	)		6,352.4		6,349.4		3.0
Other taxes payable																1,618.2		1,612.0		6.2		1,615.5		1,615.5		-
Total equity		71,264.0		78,676.2		(7,412.2	)		73,837.1		81,282.2		(7,445.1	)		61,559.6		59,338.7		2,220.9		65,131.0		62,940.3		2,190.7

	Three Months Ended June 30, 2017									Six Months Ended June 30, 2017									Three Months Ended March 31, 2019									Three Months Ended March 31, 2018
	Allergan plc			Warner Chilcott Limited			Difference			Allergan plc			Warner Chilcott Limited			Difference			Allergan plc			Warner Chilcott Limited			Difference			Allergan plc			Warner Chilcott Limited			Difference
General and administrative expenses	$	459.8		$	447.7		$	12.1		$	775.9		$	762.0		$	13.9		$	308.3		$	306.1		$	2.2		$	295.9		$	294.1		$	1.8
Operating (loss)		(902.4	)		(890.3	)		(12.1	)		(1,808.4	)		(1,794.5	)		(13.9	)		(2,309.2	)		(2,307.0	)		(2.2	)		(654.0	)		(652.2	)		(1.8	)
Interest income		16.6			37.2			(20.6	)		41.9			88.6			(46.7	)		21.3			21.3			-			17.3			70.3			(53.0	)
(Loss) before income taxes and noncontrolling interest		(1,296.7	)		(1,264.0	)		(32.7	)		(4,389.9	)		(4,329.3	)		(60.6	)		(2,475.9	)		(2,473.7	)		(2.2	)		(966.1	)		(911.3	)		(54.8	)
Net (loss) from continuing operations, net of tax		(715.5	)		(682.8	)		(32.7	)		(3,276.6	)		(3,216.0	)		(60.6	)
Net (loss)		(723.9	)		(691.2	)		(32.7	)		(3,288.1	)		(3,227.5	)		(60.6	)		(2,407.3	)		(2,405.0	)		(2.3	)		(283.9	)		(229.1	)		(54.8	)
Dividends on preferred shares		69.6			-			69.6			139.2			-			139.2			-			-			-			46.4			-			46.4
Net (loss) attributable to ordinary shareholders/members		(795.5	)		(693.2	)		(102.3	)		(3,430.3	)		(3,230.5	)		(199.8	)		(2,408.0	)		(2,405.7	)		(2.3	)		(332.5	)		(231.3	)		(101.2	)

The ~~difference~~differences between general and administrative expenses in the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017 was~~were due to corporate related expenses incurred byat Allergan plc. ~~Movements~~The differences in total equity were due to historical differences in the results of operations of the companies and differences in equity awards.

~~As of June 30,~~During the three months ended March 31, 2018, the difference in interest income between Allergan plc and ~~December 31, 2017,~~ Warner Chilcott Limited ~~had $5.8~~was due to $5.7 billion and $4.0 billion in Receivables from the ~~Parents. As of June 30, 2018~~Parents and ~~December 31, 2017, Warner Chilcott Limited had $4.0 billion in~~ Non-current Receivables from the ~~Parents.~~Parents, respectively. These ~~receivables~~Receivables were related to intercompany loans between Allergan plc and subsidiaries of Warner Chilcott ~~Limited. These loans are interest-bearing loans with varying term dates~~Limited and ~~cause~~caused a difference in interest income between the two ~~entities. Total interest income recognized~~entities in the prior year. These Receivables were contributed to the Parents during the ~~three~~year ended December 31, 2018 as an equity contribution and six months ended June 30, 2018 was $65.5 million and $118.5 million, respectively. Total interest income recognized during the three and six months ended June 30, 2017 was $20.6 million and $46.7 million, respectively.were reclassified from receivables to equity.

The following are interim updates to certain of the policies described in “Note 4” of the notes to the Company’s audited consolidated financial statements for the year ended December 31, ~~2017~~2018 included in the Annual Report.

~~On January 1, 2018, we adopted~~In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. ~~2014-09, "Revenue from Contracts~~2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with ~~Customers" (“Topic 606”)~~a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement.

On January 1, 2019, the Company adopted the new standard using the modified retrospective ~~method~~transition approach applied to ~~those contracts which were not completed as~~all leases existing at the effective date of initial application of January 1, ~~2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior~~2019. Prior period amounts are not adjusted and continue to be reported in accordance with ~~our~~ historical accounting ~~practices. The impact~~practices and the disclosures under the new standard are not required for dates and periods prior to ~~revenues for~~January 1, 2019.

When evaluating whether a contract contains a lease under the ~~three~~new standard, Allergan considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and ~~six months ended June 30, 2018 was not significant as a result~~(2) the Company obtains substantially all of the ~~adoption.~~economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The ~~adoption of this guidance~~Company does not have ~~a material impact on~~the right to use an identified asset if the supplier has the substantive right to substitute the asset throughout the period without the Company’s ~~financial position or results~~approval.

The new standard provides a number of ~~operations as the Company’s sales primarily are governed by standard bill and ship terms of pharmaceutical products to customers.~~

optional practical expedients in transition. The Company ~~applies~~elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company.

This standard has a significant impact on our consolidated balance sheet but did not have a significant impact on our consolidated statements of operations. The most significant effects relate to the recognition of ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases.

Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as ~~defined~~follows ($ in ~~Topic 606 to recognize the incremental costs of obtaining contracts~~millions):

The cumulative effective adjustment as ~~an expense when incurred if the amortization period~~ of the ~~assets~~effective date of $22.0 million was recorded to opening retained earnings. The Company has an immaterial amount of finance leases.

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the lease recognition exemption for all leases with lease terms of 12 months or less. For leases that qualify under this exception, the Company ~~otherwise would have recognized is one year~~will not recognize ROU assets or ~~less. These costs which are included~~lease liabilities and did not recognize ROU assets or lease liabilities for existing short-term leases of those assets in ~~selling, general, and administrative expenses are consistent with the accounting prior to the adoption of Topic 606.~~transition. The Company also elected ~~to use~~ the practical expedient to not ~~adjust~~separate lease and non-lease components for leases of real estate, fleet, IT and office equipment.

Refer to “NOTE 13 – Leases” for further information related to the ~~promised~~Company’s leases.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of ~~consideration for~~ the ~~effects~~reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the ~~time value of money for contracts in which the anticipated period between when~~stranded tax effects, the Company ~~transfers~~elected not to reclassify the ~~goods or services~~income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the ~~customer and when~~TCJA are released from accumulated other comprehensive income using either the ~~customer pays is equal to one year~~specific identification approach or ~~less.~~the portfolio approach based on the nature of the underlying item.

The Company adopted ASU ~~No.~~ 2016-01, which now requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. Under the previous guidance, changes in the fair value of equity securities were recognized through other comprehensive income.

OnFinancial Instruments on January 1, 2018. The new standard required modified retrospective adoption through 2018 beginning Retained Earnings and Accumulated Other Comprehensive Income. This was incorrectly recorded as a loss through Other Comprehensive Income of $63.0 million during the ~~Company adopted ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Previously, GAAP prohibited the recognition of current~~quarter ended March 31, 2018. This was corrected during 2018 and ~~deferred income taxes for an intra-entity asset transfer until the asset~~therefore, has been sold to an outside party. This prohibition on recognition was an exception to the principle of comprehensive recognition of current and deferred income taxes in GAAP. The amendment to the guidance eliminated the exception for an intra-entity transfer of an asset other than inventory and required an entity to recognize the income tax consequences when the transfer occurs.

~~The following represents the~~no impact on the ~~Company's~~annual consolidated financial statements. The Company has determined that the adjustment was not material to any previously reported interim period. The Consolidated ~~Balance Sheet as a result of the adoption on January 1, 2018 of these accounting pronouncements ($ in millions):~~

~~On January 1, 2018, the Company adopted ASU 2016-15,~~ Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. This standard amends and adjusts how cash receipts and cash payments are presented and classified in the statement of cash flows. As a result of the guidance, the Company retrospectively applied the standard which resulted in a reclassification of debt extinguishment costs from cash flows from operating activities to cash flows from financing activities. As a result of the guidance cash flows from operating activities increased by $170.5 million and cash flows from financing activities decreased by $170.5 million in the six months ended June 30, 2017. Cash flows from operating activities will increase by $205.6 million and cash flows from financing activities will decrease by $205.6 millionComprehensive (Loss) for the ~~year~~quarter ended ~~December~~March 31, ~~2017.~~2018 has been adjusted to correct for this error.

~~On January 1, 2018,~~ the Company adopted ASU No. 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost. Upon adoption, the Company recorded other components of the net periodic benefit cost with “other income / (expense), net.”

ASU No. 2014-09, “Revenue from Contracts with Customers” (“Topic ~~606~~606”) provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”).

The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the ~~customer.~~

~~Prior to the achievement of performance obligations, shipping and handling costs associated with outbound freight for a product to be transferred to a~~ customer ~~are accounted for~~ as ~~a fulfillment cost and are included in selling and marketing expenses.~~

~~Other revenues earned are mainly comprised of royalty income from licensing of intellectual property. Royalty income~~that is ~~recognized~~ when the ~~licensee’s subsequent sale occurs.~~customer has obtained control of significantly all of the economic benefits.

Refer to “NOTE 8 ~~–Reportable~~– Reportable Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.

A contract with a customer states the final terms of the sale, including the description, quantity, and price of each product purchased. The Company’s payment terms vary by the type and location of the customer and the products offered. A customer agrees to a stated rate and price in the contract and given that most of the products sold contain variable consideration, the amount of revenue recognized incorporates adjustments for SRAs as appropriate.

The Company offers discounts and rebates to certain customers who participate in various programs that are referred to as SRA allowances as described further below in the section “Provisions for SRAs”. Such discounting and rebating activity is included as part of the Company’s estimate of the transaction price and is accounted for as a reduction to gross sales. At time of sale, the Company records the related SRA adjustments to sales as described further below in the section “Provisions for SRAs”. The Company performs a level of validation each period to assess the adequacy of the liability or contra receivable recorded to reflect actual activity and will adjust the reserve balances accordingly.

As is customary in the pharmaceutical industry, certain customers may receive cash-based incentives or credits, which are variable consideration accounted for as SRAs. The Company estimates SRA amounts based on the expected amount to be provided to customers, which reduces the revenues recognized. The Company believes that there will not be significant changes to our estimates of variable consideration. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. These provisions are estimated based on historical payment experience, the historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provisions has been applied on a consistent basis and no material revenue adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates.

~~Chargebacks~~ — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by such wholesaler customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback credits. We continually monitor current pricing trends and wholesaler inventory levels to ensure the contra-receivable for future chargebacks is fairly stated.

~~Rebates~~ — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally contractually offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states and authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision.

~~Cash Discounts~~ — Cash discounts are provided to customers that pay within a specific time period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for a cash discount.

~~Returns and Other Allowances~~ ~~— The Company’s provision for returns and other allowances include returns, promotional allowances and loyalty cards.~~

Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are generally not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns.

Promotional allowances are credits with no discernable benefit offered to Allergan that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms.

~~Loyalty cards allow end-user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel.~~

The following table summarizes the activity from ~~continuing~~ operations in the Company’s major categories of SRA ($ in millions):

The following table summarizes the balance sheet classification of our SRA reserves ($ in millions):

	June 30, 2018		December 31, 2017		March 31, 2019		December 31, 2018
Contra accounts receivable	$	202.9	$	250.6	$	204.1	$	207.7
Accounts payable and accrued expenses		2,158.3		2,179.9		2,505.5		2,359.9
Total	$	2,361.2	$	2,430.5	$	2,709.6	$	2,567.6

The SRA provisions recorded to reduce gross product sales to net product sales ~~excluding discontinued operations,~~ were as follows ($ in millions):

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2018			2017			2019			2018
Gross product sales	$	6,095.5		$	5,888.4		$	11,711.6		$	11,270.8		$	5,659.9		$	5,616.1
Provisions to reduce gross product sales to net product sales		(2,087.3	)		(1,977.3	)		(4,122.4	)		(3,869.9	)		(2,139.7	)		(2,035.1	)
Net product sales	$	4,008.2		$	3,911.1		$	7,589.2		$	7,400.9		$	3,520.2		$	3,581.0
Percentage of SRA provisions to gross sales		34.2	%		33.6	%		35.2	%		34.3	%		37.8	%		36.2	%

At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. The Company assesses the probability that the Company will collect the consideration to which it will be entitled in exchange for the goods sold. In evaluating collectability, the Company considers the customer’s ability and intention to pay consideration when it is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectible ~~receivables~~after sale to the customer to reflect allowances for doubtful accounts.

~~Practical Expedients~~ Provision for bad debts, included in general and ~~Exemptions~~

~~The Company generally~~administrative expenses, ~~sales commissions when incurred because the amortization period is one year or less. These costs are recorded within selling~~were $3.4 million and ~~marketing expenses.~~

The Company does not adjust the promised amount of consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is equal to one year or less.

~~The Company tests goodwill and intangible assets with indefinite lives for impairment annually~~$10.1 million in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assetsthree months ended March 31, 2019 and ~~liabilities, including the existing goodwill and intangible assets, to those reporting units.~~

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test.

Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share.

~~Prior to Allergan’s annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04,~~ ~~Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment~~ which eliminated step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation to measure goodwill impairment loss as of January 1, 2018. A goodwill impairment loss under the new guidance is instead measured using a single step test based on the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. Based on the Company’s impairment test, no impairments were noted.

Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development (“R&D”) costs, selling and marketing costs and other costs which may be allocated), determination of the appropriate discount rate in order to measure the risk inherent in each future cash flow stream, assessment of each asset’s life cycle, potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results.

Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life.

~~The Company performed its annual goodwill impairment test during the second quarter of~~ 2018, by evaluating its five Reporting Units. In performing this test, the Company utilized long-term growth rates for its Reporting Units ranging from 1.0% to 2.0% in its estimation of fair value and discount rates ranging from 8.5% to 10.0%, which is an increase versus the prior year discount rates of 7.5% to 8.5% to reflect changes in market conditions. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management. Changes in the key assumptions by management can change the results of testing.respectively.

Of the Reporting Units tested, the Company’s US Eye Care Reporting Unit, which is a component of its US Specialized Therapeutics Segment and has an allocated goodwill balance of $9,824.8 million and its General Medicine Reporting Unit are the most sensitive to a change in future valuation assumptions. These Reporting Units had the lowest level of headroom. While management believes the assumptions used are reasonable and commensurate with the views of a market participant, changes in key assumptions for these Reporting Units, including increasing the discount rate, lowering revenue forecasts, lowering the operating margin or lowering long-term growth rate, could result in a future impairment.

The Company performed its annual IPR&D impairment test in the second quarter of 2018. Based on events occurring or decisions made within the quarter ended June 30, 2018, the Company recorded the following impairments:

~~During the second quarter of 2017, the Company performed its annual IPR&D impairment test and recorded the following IPR&D impairments:~~

The Company computes EPS in accordance with Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. ~~Diluted EPS also includes the impact of ordinary share equivalents issued (or issuable in 2017) upon the mandatory conversion of the Company’s preferred shares which occurred on March 1, 2018.~~ Ordinary share equivalents have been excluded where their inclusion would be ~~anti-dilutive to continuing operations.~~anti-dilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS ~~consisted of the following~~follows ($ in millions, except per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2018			2017			2019			2018
Net (loss):
Net (loss) attributable to ordinary shareholders excluding income from discontinued operations, net of tax	$	(472.5	)	$	(787.1	)	$	(805.0	)	$	(3,418.8	)
(Loss) from discontinued operations, net of tax		-			(8.4	)		-			(11.5	)
Net (loss) attributable to ordinary shareholders	$	(472.5	)	$	(795.5	)	$	(805.0	)	$	(3,430.3	)	$	(2,408.0	)	$	(332.5	)

Basic weighted average ordinary shares outstanding		339.1			335.2			336.9			335.2			332.0			334.6

Basic EPS:
Continuing operations	$	(1.39	)	$	(2.35	)	$	(2.39	)	$	(10.20	)
Discontinued operations	$	-		$	(0.02	)	$	-		$	(0.03	)
Net (loss) per share	$	(1.39	)	$	(2.37	)	$	(2.39	)	$	(10.23	)	$	(7.25	)	$	(0.99	)

Dividends per ordinary share	$	0.72		$	0.70		$	1.44		$	1.40		$	0.74		$	0.72

Diluted weighted average ordinary shares outstanding		339.1			335.2			336.9			335.2			332.0			334.6

Diluted EPS:
Continuing operations	$	(1.39	)	$	(2.35	)	$	(2.39	)	$	(10.20	)
Discontinued operations	$	-		$	(0.02	)	$	-		$	(0.03	)
Net (loss) per share	$	(1.39	)	$	(2.37	)	$	(2.39	)	$	(10.23	)	$	(7.25	)	$	(0.99	)

Stock awards to purchase ~~2.2~~2.4 million ordinary shares for both the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. ~~Stock awards~~The impact of the 5.3 million shares repurchased in the three months ended March 31, 2019 on basic EPS was 0.7 million weighted average shares. The impact of the 9.6 million shares repurchased in the three months ended March 31, 2018 on basic EPS was 2.0 million weighted average shares.

The Company’s preferred shares were mandatorily converted to ~~purchase 3.9 million and 4.2 million~~ ordinary shares ~~for the three and six months ended June 30, 2017, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive.~~

on March 1, 2018. The weighted average impact of ordinary share equivalents of ~~5.8~~11.7 million for the ~~six~~three months ended ~~June 30,~~March 31, 2018, which would result from the mandatory conversion of the Company’s preferred shares at the beginning of the period, were not included in the calculation of diluted EPS as their impact would be anti-dilutive. The ~~Company’s preferred shares were converted to ordinary shares on March 1, 2018. The~~ weighted average impact of ~~ordinary share equivalents of 17.6 million for the three and six months ended June 30, 2017, which were anticipated to result from~~ the mandatory conversion of the Company’s preferred shares ~~were not included~~into ordinary shares was 6.2 million in the ~~calculation of diluted EPS as their impact would be anti-dilutive.~~three months ended March 31, 2018.

Refer to “NOTE 1516 –Shareholders’ Equity” for further discussion on the Company’s ~~Share Repurchase Program.~~share repurchase programs.

Research and development (“R&D”) activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any.

As of March 31, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including but not limited to the following:

We also have a number of products in development as part of our life-cycle management strategy for our existing product portfolio.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, which states that a lessee should recognize the assets and liabilities that arise from leases. This update is effective for fiscal years beginning after December 15,August 2018, including interim periods within those fiscal years. While the Company has not yet completed its assessment, the adoption of the guidance is anticipated to have a material impact on the Company’s financial position.

~~In June 2016,~~ the FASB issued ASU No. ~~2016-13, Financial Instruments~~2018-15, Intangibles – ~~Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended~~Goodwill and Other – Internal-Use Software (Subtopic 350-40), relating to ~~improve financial reporting by requiring timelier recording of credit losses on loans~~a customer's accounting for implementation, set-up, and other ~~financial instruments held~~upfront costs incurred in a cloud computing arrangement that is hosted by ~~financial institutions~~a vendor (i.e., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and ~~other organizations. The ASU~~cash flow classification of the capitalized implementation costs and related amortization expense, and requires ~~the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions,~~additional quantitative and ~~reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates.~~qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application ~~will be permitted for all organizations for fiscal years, and interim periods within those fiscal years, beginning~~is permitted. The Company can choose to adopt the new guidance (1) prospectively to eligible costs incurred on or after ~~December 15, 2018.~~the date this guidance is first applied or (2) retrospectively. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations.

In March 2017, The FASB issued ASU No. 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities. The ASU shortens the amortization period for certain callable debt securities held at a premium and requires the premium to be amortized to the earliest call date, but does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The amendments are effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Entities are required to apply the amendments on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The entity is required to provide disclosures about a change in accounting principle in the period of adoption. The Company is evaluating the impact these amendments will have on our financial position and results of operations.

In August ~~2017,~~2018, the FASB issued ASU No. ~~2017-12, Derivatives and Hedging (Topic 815) — Targeted Improvements to Accounting for Hedging Activities. The amendments~~2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) – Disclosure Framework - Changes to the ~~guidance will better align an entity’s risk management activities~~Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The revisions to the disclosure requirements affect only the year-end financial ~~reporting for hedging relationships through~~statements of plan sponsors, as there are no changes related to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in theinterim financial statements. The amendments also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. The amendments areASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, ~~2018.~~2020. Early ~~adoption~~application is ~~permitted~~permitted. The ASU provisions will be applied on a retrospective basis to all periods presented. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of operations.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes, adds and modifies certain disclosure requirements for fair value measurements in ~~any interim period or~~Topic 820. The Company will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU is effective for fiscal years, ~~before~~and interim periods within those fiscal years, beginning after December 15, 2019. The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective ~~date~~date. The Company is permitted to early adopt either the entire ASU or only the provisions that eliminate or modify the requirements. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of ~~the amendments.~~operations.

The following are the significant transactions that were completed or announced in the ~~six~~three months ended ~~June 30, 2018.~~March 31, 2019.

As of June 30, 2018, the Company determined that certain assets related to a non-strategic medical dermatology product was deemed held for sale based on the Company’s intention and ability to dispose of the related assets. As a result, the Company recorded an impairment of $252.0 million to the anticipated sale value and reclassified the “product rights and other intangibles, net” balance of $130.5 million to “non-current assets held for sale.”

On April 6, 2018, the Company completed the acquisition of Elastagen Pty Ltd, which was accounted for as an asset acquisition as the purchase primarily related to one asset. An upfront expense of $96.1 million was expensed as a component of R&D during the three and six months ended June 30, 2018. Under the terms of the agreement, Elastagen Pty Ltd is eligible to receive additional consideration of up to $165.0 million.

On January 31, 2018, the Company completed the acquisition of Repros Therapeutics, Inc., which was accounted for as an asset acquisition as the purchase primarily related to one asset. A net charge of $33.2 million was expensed as a component of R&D during the six months ended June 30, 2018.

~~On April 28, 2017~~March 26, 2019, the Company acquired ~~Zeltiq~~^® ~~Aesthetics,~~Envy Medical, Inc. (“~~Zeltiq”~~Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of ~~$2,405.4~~$81.4 million, ~~(the “Zeltiq Acquisition”). Zeltiq~~which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities. The transaction was ~~focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform (Coolsculpting~~^®).treated as a business combination. The ~~Zeltiq Acquisition combined Zeltiq’s body contouring business~~acquisition combines Envy’s skin care product portfolio with the Company’s leading ~~portfolio of~~ medical ~~aesthetics.~~aesthetics business.

NOTE 5 — Assets ~~Acquired and Liabilities Assumed at Fair Value~~Held for Sale

The Zeltiq Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date.

The following ~~table summarizes the final fair values of~~represents the assets ~~acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date~~held for sale ($ in millions):

The fair value of inventories acquired included an acquisition accounting fair market value step-up of $22.9 million which was recognized as a component of cost of sales as the inventory acquired was sold to the Company’s customers in the year ended December 31, 2017, including $11.9 million in the three and six months ended June 30, 2017.

Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-affected by the statutory tax rates of applicable jurisdictions.

~~On July 27, 2015, the Company announced that it entered into a~~ ~~divestiture agreement for our global generics business~~As of March 31, 2019 and ~~certain other assets to Teva Pharmaceutical Industries Ltd. (“Teva”) (the “Teva Transaction”)~~, which closed on August 2, 2016. On October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva for $500.0 million. The Company recognized a combined gain on the sale of the Anda Distribution business and the sale of the global generics business of $15,932.2 million.

In October 2016, pursuant to our agreement with Teva, Teva provided the Company with its proposed estimated adjustment to the closing date working capital balance. The Company disagreed with Teva’s proposed adjustment, and, pursuant to our agreement with Teva, each of the Company’s and Teva’s proposed adjustments were submitted to arbitration to determine the working capital amount in accordance with GAAP as applied by the Company consistent with past practice.

~~On January~~December 31, 2018, Allergan ~~plc~~concluded that its Anti-Infectives business met the criteria for held for sale based on management’s intent and ~~Teva entered into a Settlement Agreement and Mutual Releases (the “Agreement”) pursuant~~ability to ~~which~~divest the ~~Company made a one-time payment of $700.0 million to Teva;~~business within the Company and Teva jointly dismissed their working capital dispute arbitration, and the Company and Teva released all actual or potential indemnification and other claims under the Master Purchase Agreement, dated July 26, 2015, by and between the Company and Teva, that were known as of the date of the Agreement. The Company recorded a pre-tax charge of $466.0 million as a component of other (expense) / income, net from discontinued operations relating to the settlement in the year ended December 31, 2017. The one-time payment of $700.0 million is shown in the Consolidated Statement of Cash Flows as both a cash outflow in investing activities of $466.0 million and a cash outflow in financing cash flows of $234.0 millionnext twelve months. Assets held for ~~the portion of the payment which was outstanding greater than one year.~~sale also includes miscellaneous properties.

	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended March 31,
	2018		2017			2018		2017			2019			2018
Teva Share Activity	$	138.6	$	-		$	60.9	$	(1,978.0	)	$	-		$	(77.7	)
Sale of business		53.0		-			53.0		-
Debt extinguishment other		9.1		-			9.1		-			(0.3	)		-
Debt extinguishment costs as part of the debt tender offer		-		(161.5	)		-		(161.5	)
Dividend income		-		34.1			-		68.2
Naurex recovery		-		-			-		20.0
Other income / (expense), net		14.7		(6.1	)		13.6		(5.0	)		14.1			(1.1	)
Other income / (expense), net	$	215.4	$	(133.5	)	$	136.6	$	(2,056.3	)	$	13.8		$	(78.8	)

Other income / (expense), net includes the mark to market gains of $10.4 million on equity securities held by the Company during the three months ended March 31, 2019.

During the three ~~and six~~ months ended ~~June 30,~~March 31, 2018, the Company recorded the following movements in its investment in Teva securities ~~(defined herein as “Teva~~(“Teva Share Activity”) ($ in millions except per share information):

Shares

Carrying
Value
per Share

Market
Price

Proceeds Received

Value of
Marketable
Securities

Unrealized
Gain / (Loss) as
a Component
of Other
Comprehensive
Income

Gain / (Loss)
Recognized
in Other
Income/
(Expense),
Net

Derivative Instrument (Liability)/
Asset

Retained Earnings

Teva securities as of
   December 31, 2017

95.9

$
17.60

$
18.95

n.a.

$
1,817.7

$
129.3

$
-

$
(62.9
)

$
-

Impact of ASU No. 2016-01

-

-

-

-

-

(129.3
)

-

-

129.3

Settlement of initial accelerated
   share repurchase ("ASR"), net

(25.0
)

18.95

16.53

*

413.3

(473.8
)

-

2.5

62.9

-

Forward sale entered into during
   the three months ended
   March 31, 2018

**

n.a.

n.a.

372.3

n.a.

-

19.0

(353.3
)

-

Open market sales

(11.5
)

n.a.

19.95

229.9

(218.5
)

-

11.5

-

-

Other fair value movements during
   the three months ended
   March 31, 2018

-

n.a.

n.a.

n.a.

(110.7
)

-

(110.7
)

-

-

Teva securities as of and for the
   three months ended
   March 31, 2018

59.4

$
17.09

$
17.09

$
1,015.5

$
1,014.7

$
-

$
(77.7
)

$
(353.3
)

$
129.3

Settlement of forward sale entered
   into during the three months
   ended March 31, 2018, net

(25.0
)

17.09

18.61

***

93.2

(427.3
)

-

19.2

353.3

-

Open market sales

(34.4
)

n.a.

20.55

706.8

(587.4
)

-

119.4

-

-

Teva securities as of
   and for the six months
   ended June 30, 2018

-

$
-

$
-

$
1,815.5

$
-

$
-

$
60.9

$
-

$
129.3

* Market price represents average price over the life of the contract.  On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48.

** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares.  The forward sale transaction settled during the second quarter of 2018.  As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities were reported on the Company's balance sheet until the contract settled on May 7, 2018.

*** Market price represents average price over the life of the contract.  On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62.

	Shares			Carrying Value per Share		Market Price			Proceeds Received		Value of Marketable Securities			Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			Gain / (Loss) Recognized in Other Income/ (Expense), Net			Derivative Instrument (Liability)/ Asset			Retained Earnings
Teva securities as of December 31, 2017		95.9		$	17.60	$	18.95		n.a.		$	1,817.7		$	129.3		$	-		$	(62.9	)	$	-
Impact of ASU No. 2016-01		-			-		-			-		-			(129.3	)		-			-			129.3
Settlement of initial accelerated share repurchase ("ASR")		(25.0	)		18.95		16.53	*		413.3		(473.8	)		-			2.5			62.9			-
Forward sale entered into during the three months ended March 31, 2018	**			n.a.		n.a.				372.3	n.a.				-			19.0			(353.3	)		-
Open market sales		(11.5	)	n.a.			19.95			229.9		(218.5	)		-			11.5			-			-
Other fair value movements during the three months ended March 31, 2018		-		n.a.		n.a.			n.a.			(110.7	)		-			(110.7	)		-			-
Teva securities as of and for the three months ended March 31, 2018***		59.4		$	17.09	$	17.09		$	1,015.5	$	1,014.7		$	-		$	(77.7	)	$	(353.3	)	$	129.3

* Market price represented average price over the life of the contract. On the date of settlement of January 17, 2018, the closing stock price of Teva securities was $21.48.
** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares. The forward sale transaction settled during the second quarter of 2018; the final settlement value of the shares was based on the volume weighted average price of the Teva shares plus a premium. As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities continued to be reported on the Company's books until the contract settled. The Company recorded the cash proceeds as a secured liability as well as a $19.0 million marked-to-market value of the bifurcated derivative component of the agreement in prepaid expenses and other current assets as of March 31, 2018.
***The Company sold the remaining Teva securities during the second quarter of 2018.

~~During the three and six months ended June 30, 2017, the Company recorded the following movements in its investment in Teva securities ($ in millions except per share information):~~

During the three and six months ended June 30, 2018, the Company completed the sale of a non-strategic asset group held for sale as of December 31, 2017, which was deemed a business based on the applicable guidance at the time, for $55.0 million in cash plus deferred consideration of $20.0 million. As a result of this transaction, the Company recognized a gain of $53.0 million.

During the three and six months ended June 30, 2018, the Company repurchased $455.9 million of senior notes in the open market. As a result of the debt extinguishment, the Company recognized a net gain of $9.1 million, within “Other income / (expense)” for the cash discount received of $13.1 million, including the non-cash write-off of premiums and debt fees related to the repaid notes of $4.0 million.

~~During the three and six months ended June 30, 2018, the Company redeemed and retired the following senior notes ($ in millions):~~

On May 30, 2017, the Company completed the repurchase of certain debt securities issued for cash under a previously announced tender offer. During the three and six months ended June 30, 2017, as a result of the debt extinguishment, the Company recognized a loss of $161.5 million, within “Other income / (expense)” for the early tender payment and non-cash write-off of premiums and debt fees related to the repurchased notes, including $170.5 million of a make-whole premium.

During the three and six months ended June 30, 2017, the Company received dividend income of $34.1 million and $68.2 million, respectively, on the 100.3 million Teva ordinary shares acquired as a result of the Teva Transaction. On February 8, 2018, Teva suspended all dividends on ordinary shares.

On August 28, 2015, the Company acquired certain products in early stage development of Naurex, Inc. (“Naurex”) in an all-cash transaction, which was accounted for as an asset acquisition. The Company received a purchase price reduction of $20.0 million in the six months ended June 30, 2017 based on the settlement of an open contract dispute.

The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant.

The Company recognizes share-based compensation expense for granted awards over the applicable vesting period.

~~Cash-settled performance-based awards are recorded as a liability. These cash-settled performance-based awards are measured against pre-established total shareholder returns metrics.~~

All restricted stock and restricted stock units (whether time-based or performance-based) are granted and expensed using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions:

	2018 Grants	2017 Grants	2019 Grants	2018 Grants
Dividend yield	1.8 - 1.9%	1.2%	2.2%	1.5%
Expected volatility	27.0%	27.0%	23.5%	27.0%
Risk-free interest rate	2.2 - 2.8%	2.0 - 2.3%	2.6%	2.2 - 2.9%
Expected term (years)	7.0	7.0	7.0	7.0

Share-based compensation expense recognized in the Company’s results of operations for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ was as follows ($ in millions):

	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2018		2017		2018		2017		2019		2018
Equity-based compensation awards	$	54.9	$	85.8	$	127.4	$	148.5	$	52.3	$	72.5
Cash-settled awards in connection with the Zeltiq Acquisition		-		31.5		-		31.5
Non-equity settled awards other		-		-		-		13.1
Total share-based compensation expense	$	54.9	$	117.3	$	127.4	$	193.1	$	52.3	$	72.5

Included in the share-based compensation awards for the three and six months ended June 30, 2018 and 2017 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Zeltiq Acquisition, the Allergan Acquisition, and the acquisition of Forest Laboratories, Inc. (the “Forest Acquisition”) as follows ($ in millions):

Unrecognized future share-based compensation expense was ~~$431.7~~$516.0 million as of ~~June 30, 2018, including $18.6 million from the Zeltiq Acquisition and $12.1 million from the Allergan Acquisition.~~March 31, 2019. This amount will be recognized as an expense over a remaining weighted average period of ~~1.7~~1.8 years. Share-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis.

The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, ~~2017~~2018 through ~~June 30, 2018~~March 31, 2019 (in millions, except per share data):

	Shares			Weighted Average Grant Date Fair Value			Weighted Average Remaining Contractual Term (Years)		Aggregate Grant Date Fair Value			Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)		Aggregate Grant Date Fair Value
Restricted shares / units outstanding at December 31, 2017		2.0		$	237.72			1.8	$	484.1
Restricted shares / units outstanding at December 31, 2018													2.5		$	190.27		1.6	$	472.9
Granted		1.4			140.43					196.6			1.4			139.66				197.8
Vested		(0.5	)		(251.60	)				(125.8	)		(0.6	)		210.69				(123.9	)
Forfeited		(0.2	)		(205.00	)				(41.0	)		-			208.11				(8.4	)
Restricted shares / units outstanding at June 30, 2018		2.7		$	190.48			2.0	$	513.9
Restricted shares / units outstanding at March 31, 2019													3.3		$	162.75		2.0	$	538.4

The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, ~~2017~~2018 through ~~June 30, 2018~~March 31, 2019 (in millions, except per share data):

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value		Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2017		7.3		$	120.94		5.2	$	312.7
Outstanding, vested and expected to vest at December 31, 2018											6.3		$	122.74		4.4	$	69.0
Granted		0.2			150.82						0.3			140.16
Exercised		(0.6	)		105.85						(0.2	)		64.49
Cancelled		(0.1	)		244.14						-			223.68
Outstanding, vested and expected to vest at June 30, 2018		6.8		$	122.06		4.8	$	303.6
Outstanding, vested and expected to vest at March 31, 2019											6.4		$	124.43		4.5	$	140.4

The Company’s businesses are organized into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments.

The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level:

The Company defines segment net revenues as product sales and other revenue derived from ~~branded~~our products or licensing agreements.

Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales within segment contribution excludes non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles.

Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs.

General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation costs and professional services costs which are general in nature and attributable to the segment.

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30, 2017													Three Months Ended March 31, 2019
		US Specialized Therapeutics			US General Medicine			International			Total				US Specialized Therapeutics			US General Medicine			International			Total
Net revenues		$	1,715.0		$	1,427.7		$	858.5		$	4,001.2			$	1,542.9		$	1,249.9		$	801.5		$	3,594.3

Operating expenses:
Cost of sales⁽¹⁾			128.8			203.2			125.0			457.0				120.1			190.5			109.7			420.3
Selling and marketing			356.8			288.1			238.9			883.8				356.8			210.5			237.6			804.9
General and administrative			49.8			41.3			28.3			119.4				54.6			43.8			25.7			124.1
Segment contribution		$	1,179.6		$	895.1		$	466.3		$	2,541.0			$	1,011.4		$	805.1		$	428.5		$	2,245.0
Contribution margin			68.8	%		62.7	%		54.3	%		63.5	%			65.6	%		64.4	%		53.5	%		62.5	%
Corporate⁽²⁾												478.8													258.0
Research and development												489.4													435.0
Amortization												1,757.9													1,399.4
In-process research and development impairments												703.3
Goodwill impairments																									2,467.0
Asset sales and impairments, net												14.0													(5.2	)
Operating (loss)											$	(902.4	)											$	(2,309.2	)
Segment operating margin												(22.6	)%
Operating margin																									(64.2	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $6.2 million.
⁽²⁾Corporate includes net revenues of $2.8 million.														⁽²⁾Corporate includes net revenues of $2.8 million.

		Six Months Ended June 30, 2018													Three Months Ended March 31, 2018
		US Specialized Therapeutics			US General Medicine			International			Total				US Specialized Therapeutics			US General Medicine			International			Total
Net revenues		$	3,405.3		$	2,543.7		$	1,812.9		$	7,761.9			$	1,578.6		$	1,223.7		$	864.0		$	3,666.3

Operating expenses:
Cost of sales⁽¹⁾			282.9			384.4			260.3			927.6				134.2			182.6			120.9			437.7
Selling and marketing			656.5			480.3			491.9			1,628.7				313.2			225.5			245.7			784.4
General and administrative			98.3			73.6			65.3			237.2				50.2			38.9			31.4			120.5
Segment contribution		$	2,367.6		$	1,605.4		$	995.4		$	4,968.4			$	1,081.0		$	776.7		$	466.0		$	2,323.7
Contribution margin			69.5	%		63.1	%		54.9	%		64.0	%			68.5	%		63.5	%		53.9	%		63.4	%
Corporate⁽²⁾												460.1													270.3
Research and development												1,163.9													474.7
Amortization												3,394.7													1,697.6
In-process research and development impairments												798.0													522.0
Asset sales and impairments, net												272.7													13.1
Operating (loss)											$	(1,121.0	)											$	(654.0	)
Segment operating margin												(14.4	)%
Operating margin																									(17.8	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $34.4 million.
⁽²⁾Corporate includes net revenues of $5.8 million.														⁽²⁾Corporate includes net revenues of $5.8 million.

The following table presents our net revenue disaggregated by geography for our international segment for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

	Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
	2018		2017		2018		2017			2019		2018
Europe	$	413.3	$	378.1	$	811.7	$	704.7		$	354.4	$	398.4
Asia Pacific, Middle East and Africa		283.6		236.3		524.4		448.4			250.7		240.8
Latin America and Canada		230.8		215.6		442.9		398.4			178.2		212.1
Other*		21.2		28.5		33.9		44.3			18.2		12.7
Total International	$	948.9	$	858.5	$	1,812.9	$	1,595.8		$	801.5	$	864.0
*Includes royalty and other revenue
* Includes royalty and other revenue									* Includes royalty and other revenue

The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

	Three Months Ended June 30, 2018								Three Months Ended March 31, 2019
	US Specialized Therapeutics		US General Medicine		International		Total		US Specialized Therapeutics		US General Medicine		International		Total
Botox^®	$	658.5	$	-	$	276.0	$	934.5	$	627.1	$	-	$	241.3	$	868.4
Juvederm^® Collection										129.7		-		157.8		287.5
Restasis^®		318.2		-		16.0		334.2		231.7		-		10.4		242.1
Juvederm^® Collection		139.8		-		156.1		295.9
Linzess^®/Constella^®		-		191.8		6.4		198.2		-		161.3		5.5		166.8
Vraylar^®										-		143.7		-		143.7
Lumigan^®/Ganfort^®		73.0		-		100.5		173.5		57.7		-		85.1		142.8
Bystolic^® / Byvalson^®		-		148.1		0.6		148.7		-		128.3		0.4		128.7
Lo Loestrin^®										-		125.8		-		125.8
Alphagan^®/Combigan^®		98.1		-		44.6		142.7		83.0		-		37.6		120.6
Lo Loestrin^®		-		127.8		-		127.8
Eye Drops		53.8		-		72.4		126.2		49.4		-		55.4		104.8
Breast Implants		75.9		-		39.9		115.8
Vraylar^™		-		114.2		-		114.2
Alloderm ^®		107.1		-		2.3		109.4		95.0		-		1.6		96.6
Ozurdex ^®		27.6		-		67.9		95.5		30.3		-		63.1		93.4
Viibryd^®/Fetzima^®										-		85.0		2.1		87.1
Breast Implants										61.2		-		11.2		72.4
Coolsculpting ^® Consumables		71.9		-		18.5		90.4		47.8		-		17.8		65.6
Viibryd^®/Fetzima^®		-		86.7		1.6		88.3
Zenpep^®		-		55.5		-		55.5		-		63.0		-		63.0
Carafate ^® / Sulcrate ^®		-		54.3		0.7		55.0		-		54.3		0.6		54.9
Armour Thyroid										-		50.0		-		50.0
Viberzi^®										-		37.2		0.3		37.5
Skin Care										34.7		-		2.7		37.4
Asacol^®/Delzicol^®										-		24.7		10.3		35.0
Teflaro^®										-		33.5		0.2		33.7
Saphris^®										-		31.9		-		31.9
Avycaz^®										-		29.7		-		29.7
Coolsculpting ^® Systems & Add On Applicators										15.1		-		10.6		25.7
Namzaric^®										-		23.4		-		23.4
Savella^®										-		20.7		-		20.7
Liletta^®										-		14.8		-		14.8
Canasa^®/Salofalk^®		-		45.0		4.5		49.5		-		10.2		3.6		13.8
Armour Thyroid		-		49.2		-		49.2
Coolsculpting ^® Systems & Add On Applicators		36.4		-		12.4		48.8
Viberzi^®		-		44.9		0.3		45.2
Asacol^®/Delzicol^®		-		32.6		12.4		45.0
Saphris^®		-		33.8		-		33.8
Teflaro^®		-		32.4		0.6		33.0
Namzaric^®		-		31.8		-		31.8
Avycaz^®		-		23.5		-		23.5
SkinMedica^®		20.8		-		2.0		22.8
Rapaflo^®		19.7		-		1.6		21.3		11.8		-		0.6		12.4
Dalvance^®										-		12.0		-		12.0
Namenda^®										-		9.5		-		9.5
Kybella^® / Belkyra^®										7.3		-		1.6		8.9
Aczone^®		21.1		-		0.1		21.2		1.6		-		-		1.6
Savella^®		-		19.1		-		19.1
Dalvance^®		-		17.7		1.3		19.0
Latisse^®		13.5		-		2.1		15.6
Liletta^®		-		15.5		-		15.5
Lexapro^®		-		14.5		-		14.5
Kybella^® / Belkyra^®		11.2		-		2.3		13.5
Estrace^® Cream		-		13.1		-		13.1
Tazorac^®		6.4		-		0.2		6.6
Namenda XR^®		-		3.4		-		3.4
Minastrin^® 24		-		0.8		-		0.8
Other		73.7		164.3		105.6		343.6		59.5		190.9		81.7		332.1
Total segment revenues	$	1,826.7	$	1,320.0	$	948.9	$	4,095.6	$	1,542.9	$	1,249.9	$	801.5	$	3,594.3
Corporate revenues								28.6								2.8
Total net revenues							$	4,124.2							$	3,597.1

Three Months Ended June 30, 2017

US Specialized
Therapeutics

US General
Medicine

International

Total

Botox^®

$
574.0

$
-

$
242.1

$
816.1

Restasis^®

336.4

-

17.3

353.7

Juvederm^® Collection

126.2

-

137.3

263.5

Lumigan^®/Ganfort^®

79.0

-

94.4

173.4

Linzess^®/Constella^®

-

167.8

5.5

173.3

Bystolic^® / Byvalson^®

-

150.7

0.5

151.2

Alphagan^®/Combigan^®

96.4

-

42.7

139.1

Eye Drops

50.7

-

70.7

121.4

Namenda XR^®

-

118.7

-

118.7

Lo Loestrin^®

-

113.0

-

113.0

Breast Implants

61.3

-

41.1

102.4

Estrace^® Cream

-

90.1

-

90.1

Alloderm ^®

84.6

-

2.3

86.9

Viibryd^®/Fetzima^®

-

85.2

0.7

85.9

Ozurdex ^®

24.9

-

51.2

76.1

Vraylar^™

-

66.3

-

66.3

Coolsculpting ^® Consumables

47.9

-

12.5

60.4

Carafate ^® / Sulcrate ^®

-

59.2

0.7

59.9

Asacol^®/Delzicol^®

-

45.6

12.8

58.4

Zenpep^®

-

50.5

-

50.5

Saphris^®

-

43.0

-

43.0

Canasa^®/Salofalk^®

-

38.4

4.3

42.7

Armour Thyroid

-

42.0

-

42.0

Viberzi^®

-

41.3

0.1

41.4

Coolsculpting ^® Systems & Add On Applicators

31.0

-

10.2

41.2

Aczone^®

41.0

-

0.1

41.1

Namzaric^®

-

33.4

-

33.4

Teflaro^®

-

33.0

-

33.0

Rapaflo^®

25.7

-

1.7

27.4

Savella^®

-

26.0

-

26.0

SkinMedica^®

25.4

-

-

25.4

Dalvance^®

-

15.2

1.2

16.4

Latisse^®

13.3

-

2.4

15.7

Kybella^® / Belkyra^®

12.7

-

2.0

14.7

Avycaz^®

-

14.5

-

14.5

Lexapro^®

-

13.1

-

13.1

Tazorac^®

12.8

-

0.2

13.0

Minastrin^® 24

-

11.4

-

11.4

Liletta^®

-

6.6

-

6.6

Other

71.7

162.7

104.5

338.9

Total segment revenues

$
1,715.0

$
1,427.7

$
858.5

$
4,001.2

Corporate revenues

6.2

Total net revenues

$
4,007.4

	Six Months Ended June 30, 2018								Three Months Ended March 31, 2018
	US Specialized Therapeutics		US General Medicine		International		Total		US Specialized Therapeutics		US General Medicine		International		Total
Botox^®	$	1,231.0	$	-	$	520.8	$	1,751.8	$	572.5	$	-	$	244.8	$	817.3
Restasis^®		574.0		-		34.3		608.3		255.8		-		18.3		274.1
Juvederm^® Collection		262.6		-		302.2		564.8		122.8		-		146.1		268.9
Lumigan^®/Ganfort^®										66.8		-		100.4		167.2
Linzess^®/Constella^®		-		351.1		12.0		363.1		-		159.3		5.6		164.9
Lumigan^®/Ganfort^®		139.8		-		200.9		340.7
Bystolic^® / Byvalson^®		-		280.9		1.1		282.0		-		132.8		0.5		133.3
Alphagan^®/Combigan^®		182.3		-		88.8		271.1		84.2		-		44.2		128.4
Eye Drops										46.2		-		68.8		115.0
Lo Loestrin^®		-		242.4		-		242.4		-		114.6		-		114.6
Eye Drops		100.0		-		141.2		241.2
Breast Implants		136.6		-		84.0		220.6		60.7		-		44.1		104.8
Alloderm ^®		206.6		-		4.5		211.1		99.5		-		2.2		101.7
Vraylar^™		-		198.6		-		198.6
Ozurdex ^®		53.1		-		132.3		185.4		25.5		-		64.4		89.9
Vraylar^®										-		84.4		-		84.4
Viibryd^®/Fetzima^®		-		158.4		3.1		161.5		-		71.7		1.5		73.2
Coolsculpting ^® Consumables		125.3		-		26.6		151.9		53.4		-		8.1		61.5
Carafate ^® / Sulcrate ^®		-		110.3		1.4		111.7		-		56.0		0.7		56.7
Zenpep^®		-		108.4		-		108.4		-		52.9		-		52.9
Asacol^®/Delzicol^®										-		38.2		11.7		49.9
Armour Thyroid		-		97.4		-		97.4		-		48.2		-		48.2
Asacol^®/Delzicol^®		-		70.8		24.1		94.9
Canasa^®/Salofalk^®		-		83.6		8.7		92.3		-		38.6		4.2		42.8
Namenda^®										-		40.6		-		40.6
Viberzi^®										-		35.9		0.1		36.0
Skin Care										31.9		-		3.8		35.7
Coolsculpting ^® Systems & Add On Applicators		70.1		-		13.5		83.6		33.7		-		1.1		34.8
Viberzi^®		-		80.8		0.4		81.2
Namzaric^®										-		33.4		-		33.4
Saphris^®		-		66.5		-		66.5		-		32.7		-		32.7
Namzaric^®		-		65.2		-		65.2
Teflaro^®		-		64.6		0.6		65.2		-		32.2		-		32.2
Rapaflo^®		42.5		-		2.8		45.3		22.8		-		1.2		24.0
Avycaz^®		-		45.3		-		45.3		-		21.8		-		21.8
Namenda XR^®		-		43.9		-		43.9
SkinMedica^®		38.9		-		3.6		42.5
Savella^®		-		39.0		-		39.0		-		19.9		-		19.9
Aczone^®		37.1		-		0.2		37.3		16.0		-		0.1		16.1
Latisse^®		27.3		-		4.3		31.6
Dalvance^®		-		29.6		1.3		30.9		-		11.9		-		11.9
Lexapro^®		-		29.2		-		29.2
Kybella^® / Belkyra^®										8.2		-		1.4		9.6
Liletta^®		-		23.6		-		23.6		-		8.1		-		8.1
Kybella^® / Belkyra^®		19.4		-		3.7		23.1
Estrace^® Cream		-		19.5		-		19.5
Tazorac^®		15.8		-		0.4		16.2
Minastrin^® 24		-		6.0		-		6.0
Namenda^® IR		-		0.1		-		0.1
Other		142.9		328.5		196.1		667.5		78.6		190.5		90.7		359.8
Total segment revenues	$	3,405.3	$	2,543.7	$	1,812.9	$	7,761.9	$	1,578.6	$	1,223.7	$	864.0	$	3,666.3
Corporate revenues								34.4								5.8
Total net revenues							$	7,796.3							$	3,672.1

Six Months Ended June 30, 2017

US Specialized
Therapeutics

US General
Medicine

International

Total

Botox^®

$
1,083.4

$
-

$
446.7

$
1,530.1

Restasis^®

645.2

-

31.2

676.4

Juvederm^® Collection

246.0

-

259.5

505.5

Lumigan^®/Ganfort^®

153.3

-

180.3

333.6

Linzess^®/Constella^®

-

315.4

10.4

325.8

Bystolic^® / Byvalson^®

-

290.5

1.0

291.5

Alphagan^®/Combigan^®

182.8

-

85.0

267.8

Namenda XR^®

-

240.7

-

240.7

Eye Drops

98.5

-

136.0

234.5

Lo Loestrin^®

-

212.8

-

212.8

Breast Implants

115.6

-

78.7

194.3

Estrace^® Cream

-

163.5

-

163.5

Viibryd^®/Fetzima^®

-

157.7

1.1

158.8

Ozurdex ^®

47.4

-

102.3

149.7

Alloderm ^®

138.7

-

3.5

142.2

Asacol^®/Delzicol^®

-

103.2

24.9

128.1

Vraylar^™

-

119.9

-

119.9

Carafate ^® / Sulcrate ^®

-

117.9

1.4

119.3

Zenpep^®

-

97.0

-

97.0

Canasa^®/Salofalk^®

-

76.7

8.7

85.4

Aczone^®

81.6

-

0.1

81.7

Saphris^®

-

80.3

-

80.3

Armour Thyroid

-

79.3

-

79.3

Viberzi^®

-

72.8

0.1

72.9

Teflaro^®

-

63.6

-

63.6

Coolsculpting ^® Consumables

47.9

-

12.5

60.4

Namzaric^®

-

57.0

-

57.0

Rapaflo^®

51.6

-

3.7

55.3

SkinMedica^®

53.4

-

-

53.4

Minastrin^® 24

-

52.5

-

52.5

Savella^®

-

50.3

-

50.3

Coolsculpting ^® Systems & Add On Applicators

31.0

-

10.2

41.2

Tazorac^®

36.2

-

0.4

36.6

Kybella^® / Belkyra^®

27.8

-

3.5

31.3

Latisse^®

26.9

-

4.3

31.2

Lexapro^®

-

26.5

-

26.5

Dalvance^®

-

24.8

1.2

26.0

Avycaz^®

-

25.8

-

25.8

Liletta^®

-

13.8

-

13.8

Namenda^® IR

-

0.1

-

0.1

Other

129.7

331.4

189.1

650.2

Total segment revenues

$
3,197.0

$
2,773.5

$
1,595.8

$
7,566.3

Corporate revenues

14.0

Total net revenues

$
7,580.3

~~Unless included above, no product represents ten percent or more of total net revenues.~~

Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or ~~market (net~~net realizable ~~value).~~value. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results.

	June 30,		December 31,		March 31,		December 31,
	2018		2017		2019		2018
Raw materials	$	339.6	$	326.9	$	332.9	$	303.2
Work-in-process		147.9		158.1		211.8		145.7
Finished goods		552.8		527.8		523.0		520.2
		1,040.3		1,012.8		1,067.7		969.1
Less: inventory reserves		117.8		108.3		124.5		122.2
Total Inventories	$	922.5	$	904.5	$	943.2	$	846.9

Accounts payable and accrued expenses consisted of the following ($ in millions):

					March 31,		December 31,
	June 30, 2018		December 31, 2017		2019		2018
Accrued expenses:
Accrued third-party rebates	$	1,666.1	$	1,713.7	$	1,941.1	$	1,832.1
Accrued returns and other allowances						564.4		527.8
Accrued payroll and related benefits		550.7		635.6		431.1		694.3
Accrued returns and other allowances		492.2		466.2
Accrued R&D expenditures		320.1		165.9		221.7		215.5
Accrued pharmaceutical fees		220.4		186.4		160.8		145.3
Royalties payable						156.9		155.1
Interest payable		202.5		245.9		141.2		191.4
Royalties payable		157.3		189.2
Litigation-related reserves and legal fees		132.6		78.3		137.1		92.0
Accrued non-provision taxes		67.4		76.5		71.3		68.5
Accrued selling and marketing expenditures						66.6		61.1
Accrued severance, retention and other shutdown costs		63.6		132.8		36.7		71.6
Accrued selling and marketing expenditures		60.9		53.0
Current portion of contingent consideration obligations		6.5		56.2		9.4		8.3
Contractual commitments (including amounts due to Teva)		5.2		705.4
Dividends payable		1.4		24.6		1.4		1.4
Contractual commitments						-		4.3
Other accrued expenses		451.1		487.2		338.0		368.7
Total accrued expenses	$	4,398.0	$	5,216.9	$	4,277.7	$	4,437.4
Accounts payable		285.8		324.5		356.7		349.8
Total accounts payable and accrued expenses	$	4,683.8	$	5,541.4	$	4,634.4	$	4,787.2

Goodwill for the Company’s reporting segments consisted of the following ($ in millions):

As of ~~June 30,~~December 31, 2018, the net asset value of the General Medicine Reporting Unit equaled fair value. On March 6, 2019, Allergan announced negative topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major Depressive Disorder (MDD). These results represented a triggering event for the Company’s General Medicine Reporting Unit.

In the three months ended March 31, 2019, primarily as a result of the impairment indicator noted above and a delay in clinical studies and anticipated launch of brazikumab, the Company recorded a $2,467.0 million goodwill impairment charge to its General Medicine Reporting Unit.

No impairment indicators were noted for the Company’s other Reporting Units as of March 31, 2019. The fair value of the Company’s General Medicine Reporting Unit and other reporting units includes anticipated product launches in the next three years. Negative events regarding these pipeline assets including, but not limited to, Abicipar, Atogepant, Bimatoprost SR, Cariprazine, and Ubrogepant, as well as other next generation aesthetic products could lead to further goodwill impairment charges. Allergan’s General Medicine Reporting Unit’s asset value equals fair value as of March 31, 2019, while its US Eye Care Reporting Unit has headroom of less than 10%.

As of March 31, 2019 and December 31, ~~2017,~~2018, the gross balance of goodwill, prior to the consideration of impairments, was ~~$49,704.5~~$48,662.0 million and ~~$49,880.2~~$48,771.7 million, respectively.

Product rights and other intangible assets consisted of the following ($ in millions):

Cost Basis	Balance as of December 31, 2017		Impairments			Held for Sale			Foreign Currency Translation			Balance as of June 30, 2018		Balance as of December 31, 2018		Additions		IPR&D to CMP Transfers			Foreign Currency Translation / Other			Balance as of March 31, 2019
Intangibles with definite lives:
Product rights and other intangibles	$	73,892.5	$	-		$	(430.0	)	$	(191.7	)	$	73,270.8	$	70,235.1	$	74.9	$	75.6		$	(160.0	)	$	70,225.6
Trade name		690.0		-			-			-			690.0		690.0		-		-			-			690.0
Total definite lived intangible assets	$	74,582.5	$	-		$	(430.0	)	$	(191.7	)	$	73,960.8	$	70,925.1	$	74.9	$	75.6		$	(160.0	)	$	70,915.6
Intangibles with indefinite lives:
IPR&D	$	5,874.1	$	(798.0	)	$	-		$	-		$	5,076.1	$	5,048.1	$	-	$	(75.6	)	$	-		$	4,972.5
Total indefinite lived intangible assets	$	5,874.1	$	(798.0	)	$	-		$	-		$	5,076.1	$	5,048.1	$	-	$	(75.6	)	$	-		$	4,972.5
Total product rights and other intangibles	$	80,456.6	$	(798.0	)	$	(430.0	)	$	(191.7	)	$	79,036.9	$	75,973.2	$	74.9	$	-		$	(160.0	)	$	75,888.1

Accumulated Amortization	Balance as of December 31, 2017			Amortization			Impairments			Held for Sale		Foreign Currency Translation		Balance as of June 30, 2018			Balance as of December 31, 2018			Amortization			IPR&D to CMP Transfers		Foreign Currency Translation / Other		Balance as of March 31, 2019
Intangibles with definite lives:
Product rights and other intangibles	$	(25,593.6	)	$	(3,355.7	)	$	(258.8	)	$	299.5	$	53.7	$	(28,854.9	)	$	(31,985.0	)	$	(1,379.4	)	$	-	$	53.7	$	(33,310.7	)
Trade name		(214.7	)		(39.0	)		-			-		-		(253.7	)		(292.8	)		(20.0	)		-		-		(312.8	)
Total definite lived intangible assets	$	(25,808.3	)	$	(3,394.7	)	$	(258.8	)	$	299.5	$	53.7	$	(29,108.6	)	$	(32,277.8	)	$	(1,399.4	)	$	-	$	53.7	$	(33,623.5	)
Total product rights and other intangibles	$	(25,808.3	)	$	(3,394.7	)	$	(258.8	)	$	299.5	$	53.7	$	(29,108.6	)	$	(32,277.8	)	$	(1,399.4	)	$	-	$	53.7	$	(33,623.5	)
Net Product Rights and Other Intangibles	$	54,648.3												$	49,928.3		$	43,695.4									$	42,264.6

~~Refer to the “Annual Testing” section in “NOTE 3 – Summary of Significant Accounting Policies” for the IPR&D impairments that the Company recorded in~~Three Months Ended March 31, 2018

~~Additionally~~March 31, 2018, the Company impaired its ~~RAR-related~~retinoic acid receptor-related orphan receptor gamma (“RORyt”) IPR&D project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc. by $522.0 million as a result of negative clinical data related to the oral psoriasis indication received in March 2018.

Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of ~~June 30, 2018~~March 31, 2019 over the remainder of ~~2018~~2019 and each of the next five years is estimated to be as follows ($ in millions):

	Amortization Expense		Amortization Expense
2018 remaining	$	3,070.5
2019	$	5,988.2
2019 remaining			$	4,188.7
2020	$	5,684.5	$	5,344.1
2021	$	4,742.6	$	4,416.5
2022	$	4,382.1	$	4,069.2
2023	$	3,968.8	$	3,659.9
2024			$	2,828.8

The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimates, potential impairments, accelerated amortization or other events. Additional amortization may occur as products are approved. In addition, the Company has certain currently marketed products for which operating contribution performance has been below that which was originally assumed in the products’ initial valuations, and certain IPR&D projects which are subject to delays in timing or other events which may negatively impact the asset’s value. The Company, on a quarterly basis, monitors the related intangible assets for these products for potential impairments. It is reasonably possible that impairments may occur in future periods, which may have a material adverse effect on the Company’s results of operations and financial position.

			Balance As of						Fair Market Value As of								Balance As of						Fair Market Value As of
	Issuance Date / Acquisition Date	Interest Payments	June 30, 2018			December 31, 2017			June 30, 2018		December 31, 2017			Guarantor	Issuance Date / Acquisition Date	Interest Payments	March 31, 2019			December 31, 2018			March 31, 2019		December 31, 2018
Senior Notes:
Floating Rate Notes
$500.0 million floating rate notes due March 12, 2018 ⁽¹⁾	March 4, 2015	Quarterly	$	-		$	500.0		$	-	$	500.6
$500.0 million floating rate notes due March 12, 2020 ⁽²⁾	March 4, 2015	Quarterly		500.0			500.0			504.7		508.1
$500.0 million floating rate notes due March 12, 2020 ⁽¹⁾														⁽⁴⁾	March 4, 2015	Quarterly		500.0			500.0			503.8		501.9
				500.0			1,000.0			504.7		1,008.7						500.0			500.0			503.8		501.9
Fixed Rate Notes
$3,000.0 million 2.350% notes due March 12, 2018	March 4, 2015	Semi-annually		-			3,000.0			-		3,001.9
$250.0 million 1.350% notes due March 15, 2018	March 17, 2015	Semi-annually		-			250.0			-		249.7
$500.0 million 2.450% notes due June 15, 2019	June 10, 2014	Semi-annually		491.2			500.0			489.1		499.7
$3,500.0 million 3.000% notes due March 12, 2020	March 4, 2015	Semi-annually		3,459.3			3,500.0			3,443.6		3,528.4		⁽⁴⁾	March 4, 2015	Semi-annually		2,623.8			2,706.7			2,622.0		2,694.8
$650.0 million 3.375% notes due September 15, 2020	March 17, 2015	Semi-annually		650.0			650.0			648.5		661.3		⁽⁵⁾	March 17, 2015	Semi-annually		650.0			650.0			653.1		648.7
$750.0 million 4.875% notes due February 15, 2021	July 1, 2014	Semi-annually		450.0			450.0			461.9		474.3		⁽⁶⁾	July 1, 2014	Semi-annually		450.0			450.0			461.3		459.4
$1,200.0 million 5.000% notes due December 15, 2021	July 1, 2014	Semi-annually		1,200.0			1,200.0			1,242.1		1,282.6		⁽⁶⁾	July 1, 2014	Semi-annually		1,200.0			1,200.0			1,247.9		1,234.8
$3,000.0 million 3.450% notes due March 15, 2022	March 4, 2015	Semi-annually		2,940.5			3,000.0			2,891.8		3,044.5		⁽⁴⁾	March 4, 2015	Semi-annually		2,878.2			2,940.5			2,896.9		2,891.0
$1,700.0 million 3.250% notes due October 1, 2022	October 2, 2012	Semi-annually		1,700.0			1,700.0			1,650.3		1,703.0		⁽⁵⁾	October 2, 2012	Semi-annually		1,700.0			1,700.0			1,699.8		1,652.2
$350.0 million 2.800% notes due March 15, 2023	March 17, 2015	Semi-annually		350.0			350.0			329.9		341.6		⁽⁵⁾	March 17, 2015	Semi-annually		350.0			350.0			349.0		332.8
$1,200.0 million 3.850% notes due June 15, 2024	June 10, 2014	Semi-annually		1,188.8			1,200.0			1,165.0		1,232.3		⁽⁴⁾	June 10, 2014	Semi-annually		1,036.7			1,036.7			1,048.6		1,021.0
$4,000.0 million 3.800% notes due March 15, 2025	March 4, 2015	Semi-annually		3,915.0			4,000.0			3,801.3		4,067.1		⁽⁴⁾	March 4, 2015	Semi-annually		3,020.7			3,027.5			3,050.6		2,956.0
$2,500.0 million 4.550% notes due March 15, 2035	March 4, 2015	Semi-annually		2,385.0			2,500.0			2,261.1		2,631.9		⁽⁴⁾	March 4, 2015	Semi-annually		1,789.0			1,789.0			1,748.0		1,690.7
$1,000.0 million 4.625% notes due October 1, 2042	October 2, 2012	Semi-annually		456.7			456.7			418.8		471.2		⁽⁵⁾	October 2, 2012	Semi-annually		456.7			456.7			432.2		412.4
$1,500.0 million 4.850% notes due June 15, 2044	June 10, 2014	Semi-annually		1,441.0			1,500.0			1,389.0		1,606.2		⁽⁴⁾	June 10, 2014	Semi-annually		1,079.4			1,079.4			1,070.6		1,019.1
$2,500.0 million 4.750% notes due March 15, 2045	March 4, 2015	Semi-annually		1,123.3			1,200.0			1,080.1		1,277.3		⁽⁴⁾	March 4, 2015	Semi-annually		881.0			881.0			867.2		836.6
				21,750.8			25,456.7			21,272.5		26,073.0						18,115.5			18,267.5			18,147.2		17,849.5

Euro Denominated Notes
€700.0 million floating rate notes due June 1, 2019 ⁽²⁾														⁽⁴⁾	May 26, 2017	Quarterly		785.3			802.7			785.5		794.9
€700.0 million floating rate notes due November 15, 2020 ⁽³⁾														⁽⁴⁾	November 15, 2018	Quarterly		785.3			802.7			782.6		791.3
€750.0 million 0.500% notes due June 1, 2021	May 26, 2017	Annually		876.3			900.4			867.7		895.8		⁽⁴⁾	May 26, 2017	Annually		841.4			860.0			844.7		849.7
€500.0 million 1.500% notes due November 15, 2023														⁽⁴⁾	November 15, 2018	Annually		560.9			573.4			575.2		572.4
€700.0 million 1.250% notes due June 1, 2024	May 26, 2017	Annually		817.9			840.4			792.4		831.1		⁽⁴⁾	May 26, 2017	Annually		785.3			802.7			789.2		775.5
€500.0 million 2.625% notes due November 15, 2028														⁽⁴⁾	November 15, 2018	Annually		560.9			573.4			593.6		573.4
€550.0 million 2.125% notes due June 1, 2029	May 26, 2017	Annually		642.6			660.3			619.1		657.8		⁽⁴⁾	May 26, 2017	Annually		617.0			630.7			618.8		594.7
€700.0 million floating rate notes due June 1, 2019 ⁽³⁾	May 26, 2017	Quarterly		817.9			840.4			810.8		837.2
				3,154.7			3,241.5			3,090.0		3,221.9						4,936.1			5,045.6			4,989.6		4,951.9
Total Senior Notes Gross				25,405.5			29,698.2			24,867.2		30,303.6						23,551.6			23,813.1			23,640.6		23,303.3
Unamortized premium				76.6			88.9			-		-						58.1			64.3			-		-
Unamortized discount				(74.8	)		(81.7	)		-		-						(61.8	)		(64.5	)		-		-
Total Senior Notes Net				25,407.3			29,705.4			24,867.2		30,303.6					$	23,547.9		$	23,812.9		$	23,640.6	$	23,303.3
Other Indebtedness
Debt Issuance Costs				(107.2	)		(121.5	)										(86.7	)		(92.1	)
Margin Loan				-			459.0
Other				41.0			29.7											64.7			69.3
Total Other Borrowings				(66.2	)		367.2											(22.0	)		(22.8	)
Capital Leases				9.4			2.7										n.a.				7.6
Total Indebtedness			$	25,350.5		$	30,075.3										$	23,525.9		$	23,797.7

⁽¹⁾ Interest on the 2018 floating rate note is three month USD LIBOR plus 1.080% per annum
⁽²⁾ Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum
⁽³⁾ Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum
⁽¹⁾ Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum													⁽¹⁾ Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum
⁽²⁾ Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum													⁽²⁾ Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum
⁽³⁾ Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum													⁽³⁾ Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum
⁽⁴⁾ Guaranteed by Warner Chilcott Limited, Allergan Capital S.à r.l. and Allergan Finance, LLC													⁽⁴⁾ Guaranteed by Warner Chilcott Limited, Allergan Capital S.à r.l. and Allergan Finance, LLC
⁽⁵⁾ Guaranteed by Allergan plc and Warner Chilcott Limited													⁽⁵⁾ Guaranteed by Allergan plc and Warner Chilcott Limited
⁽⁶⁾ Guaranteed by Allergan plc													⁽⁶⁾ Guaranteed by Allergan plc

Fair market value in the table above is determined in accordance with Fair Value Leveling (defined below) under Level 2 based upon quoted prices for similar items in active markets.

Companies are required to use a fair value hierarchy as defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”) which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value (“Fair Value Leveling”). There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants.

The following represents the significant activity during the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 to the Company’s total indebtedness:

~~The~~

During the three months ended March 31, 2019, the Company ~~repaid scheduled maturities on~~redeemed and retired the following senior notes ~~of $3,750.0 million; and~~($ in millions):

	Three Months Ended March 31, 2019
Tranche	Face Value Retired		Cash Paid for Retirement		Remaining Value at March 31, 2019
3.000% due 2020	$	82.9	$	82.9	$	2,623.8
3.450% due 2022		62.3		62.3		2,878.2
3.800% due 2025		6.8		6.8		3,020.7
Total	$	152.0	$	152.0	$	8,522.7

~~The Company prepaid $459.0 million of indebtedness under the Company’s margin loan.~~

Annual Debt Maturities

As of ~~June 30, 2018,~~March 31, 2019, annual debt maturities of senior notes gross were as follows ($ in millions):

Total Payments

2018 remaining

$
-

2019

1,309.1

2020

4,609.3

2021

2,526.3

2022

4,640.5

2023

350.0

2024 and after

11,970.3

Total senior notes gross

$
25,405.5

Capital leases

9.4

Debt issuance costs

(107.2
)
Other short-term borrowings

41.0

Unamortized premium

76.6

Unamortized discount

(74.8
)
Total Indebtedness

$
25,350.5

	Total Payments
2019 remaining	$	785.3
2020		4,559.1
2021		2,491.4
2022		4,578.2
2023		910.9
2024		1,822.0
2025 and after		8,404.7
Total senior notes gross	$	23,551.6

Amounts represent total anticipated cash payments assuming scheduled repayments.

NOTE 13 — Leases

Leases are accounted for under ASC Topic 842. The Company has entered into various lease contracts, mainly operating leases for the use of real estate, fleet, and operating equipment. The Company leases certain assets to limit exposure to the risks of ownership as well as to reduce administrative burdens inherent in the ownership of assets.

Term

As of March 31, 2019, the remaining terms for leases other than real estate leases are between 1 and 9 years as of March 31, 2019. For real estate leases, the remaining lease terms are between 1 and 14 years as of March 31, 2019.

The Company has an option for certain lease contracts, mainly for real estate lease contracts, to renew the lease term beyond the noncancelable lease period. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU asset if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial consequences of a decision to extend or not to extend a lease in determining if the renewal option is reasonably certain to be exercised.

Discount Rate

The Company is primarily a lessee, not a lessor. The Company discounts future lease payments to calculate the present value when determining the lease classification and measuring the lease liability. The rate utilized is either the implicit rate or the incremental borrowing rate. The incremental borrowing rate is not a commonly quoted rate and is derived through a combination of inputs including the Company’s credit rating and the impact of full collateralization. The incremental borrowing rate is based on the Company’s collateralized borrowing capabilities over a similar term of the lease payments. The Company utilizes the consolidated group incremental borrowing rate for all leases as the Company has centralized treasury operations.

Other

The Company does not have any material residual value guarantee terms in its lease contracts. The Company does not have material variable leases.

The Company has chosen to separate lease and non-lease components for its plant operations and research and development equipment. The Company allocates the contract consideration to the lease component using the standalone price from our supplier.

As of March 31, 2019, the Company had the following operating ROU assets and lease liabilities ($ in millions):

	March 31, 2019
	ROU Asset		Lease Liability
Real estate	$	295.8	$	361.0
Fleet		102.7		102.7
Other		56.9		67.6
Total operating leases	$	455.4	$	531.3

	March 31, 2019
Current lease liability - operating	$	116.1
Long-term lease liability - operating		415.2
Total lease liability - operating	$	531.3

Capital leases are not material as of March 31, 2019.

For the three months ended March 31, 2019, the Company noted the following lease expense ($ in millions):

	Three Months Ended March 31, 2019
Operating lease expense*	$	32.3
Sublease (income)		(3.4	)
Net operating lease expense	$	28.9
* Includes short-term and variable lease expenses of $0.9 million.

As of March 31, 2019, the Company had the following lease commitments ($ in millions):

	Total Payments
2019 remaining	$	93.1
2020		111.6
2021		86.6
2022		57.0
2023		43.9
2024		37.5
2025 and after		148.1
Total undiscounted cash flows	$	577.8
Future interest		(46.5	)
Total lease liability - operating	$	531.3

As of March 31, 2019, the weighted average remaining lease term for operating leases was 7.2 years with a weighted average discount rate of 2.7%.

The ROU assets obtained in exchange for operating lease obligations were $23.4 million for the three months ended March 31, 2019. The cash paid for amounts included in the measurement of operating lease liabilities as of March 31, 2019 was $40.8 million.

As of December 31, 2018, the Company had operating leases for certain facilities, vehicles and equipment. Total property rental expense for operating leases for the year ended December 31, 2018 was $63.2 million. Total fleet rental expense for operating leases for the year ended December 31, 2018 was $41.1 million. The Company also had de minimis capital leases for certain facilities and equipment. As of December 31, 2018, the future anticipated property lease rental payments under both capital and operating leases that had remaining terms in excess of one year were ($ in millions):

	Total Payments
2019	$	62.5
2020		52.5
2021		47.9
2022		43.3
2023		39.0
Thereafter		173.8
Total minimum lease payments	$	419.0

NOTE 1314 — Other Long-Term Liabilities

Other long-term liabilities consisted of the following ($ in millions):

	June 30,		December 31,		March 31,		December 31,
	2018		2017		2019		2018
Acquisition related contingent consideration liabilities	$	358.0	$	420.7	$	351.8	$	336.3
Long-term pension and post retirement liability		149.9		162.7		170.3		166.5
Legacy Allergan deferred executive compensation		105.2		113.8		94.5		90.8
Long-term contractual obligations		43.8		45.2
Accrued R&D milestone						75.0		75.0
Deferred revenue		33.8		37.9		33.5		36.1
Product warranties		28.7		28.7		28.8		27.9
Long-term severance and restructuring liabilities		13.0		53.1		10.9		14.2
Long-term contractual obligations						-		43.2
Other long-term liabilities		21.0		24.8		39.6		92.0
Total other long-term liabilities	$	753.4	$	886.9	$	804.4	$	882.0

The Company’s effective tax rate for the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 was ~~47.7%~~2.8%, compared to ~~25.4%~~70.6% for the ~~six~~three months ended ~~June 30, 2017.~~March 31, 2018. The effective tax rate for the ~~six~~three months ended ~~June 30,~~March 31, 2019 was favorably impacted by a tax benefit of $91.5 million related to excess tax over book basis in a U.S. subsidiary that will reverse in the foreseeable future. The effective tax rate was unfavorably impacted by a goodwill impairment charge of $2,467.0 million, for which no tax benefit was recorded.

The effective tax rate for the three months ended March 31, 2018 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by the additional U.S. tax on the earnings of certain non-U.S. subsidiaries which are considered Global Intangible Low Taxed Income (“GILTI”) and the tax impact of amortization of intangible assets at rates less than the Irish statutory rate. Additionally, the tax benefit for the ~~six~~three months ended ~~June 30,~~March 31, 2018 included tax benefits of $421.9 million related to the restructuring of an acquired business, ~~$231.0~~$117.5 million related to the impairment of ~~certain intangible assets~~ an IPR&D project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc. and ~~$79.8~~$89.7 million related to excess tax over book basis in a U.S. subsidiary ~~expected to~~that will reverse in the foreseeable future. ~~This was partially offset by tax detriments of $21.2 million for the gain on sale of investments and $25.9 million related to a change in the applicable tax rate on certain temporary differences.~~

The effective tax rate for the six months ended June 30, 2017 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by a pre-tax charge for the impairment of the Company’s investment in Teva Shares of $1,978.0 million and the tax impact of amortization of intangible assets, both at rates less than the Irish statutory rate. Additionally, the tax benefit for the six months ended June 30, 2017 included tax benefits of $288.1 million related to the impairment of certain intangible assets and $69.4 million related to the integration of an acquired business and debt restructuring. During the three months ended June 30, 2017, the Company determined that a temporary difference related to excess tax over book basis in a U.S. subsidiary will reverse in the foreseeable future and recorded a corresponding tax benefit of $179.6 million.

For the year ended December 31, 2017, the income tax effects of the Tax Cuts and Jobs Act (“TCJA”) were accounted for on a provisional basis pursuant to the guidance in Staff Accounting Bulletin (“SAB”) 118. In the fourth quarter of 2017, the Company recorded provisional deferred tax benefits of $2,340.4 million related to the change in Federal Corporate tax rates applicable to our deferred tax liabilities and $1,260.0 million related to the net reversal of prior amounts accrued for taxes on unremitted earnings of certain subsidiaries. The accounting for these amounts will be finalized during the measurement period upon the completion of the 2017 tax returns. The Company also recorded a provisional income tax expense of $728.1 million related to the tax on the deemed repatriation of deferred foreign earnings (“toll charge”) which is payable over eight years. The final toll charge is dependent on amounts that cannot be determined until the 2018 financial results of certain non-U.S. subsidiaries are completed.

The provisional estimates related to the TCJA recorded in the 2017 consolidated financial statements were based on all available information and the Company’s initial analysis and current interpretation of the legislation under the TCJA as of the time of the filing of the Company’s Form 10-K. These estimates represented amounts for which our accounting was incomplete but a reasonable estimate could be determined. Given the complexity of the TCJA, anticipated guidance from the U.S. Treasury and Internal Revenue Service (“IRS”) and the potential for additional guidance from the Securities and Exchange Commission (“SEC”) or the FASB, our accounting continues to be incomplete, and therefore the Company has not recorded any adjustments to these provisional estimates in the June 30, 2018 consolidated financial statements. Guidance from the SEC provides for a measurement period of up to one year from the enactment date of the TCJA for which adjustments to provisional amounts may be recorded as a component of tax expense or benefit in the period the adjustment is determined.

On August 1, 2018, the U.S. Treasury released proposed regulations regarding the one-time transition tax (i.e. toll charge) on the pre-2018 earnings of certain non-U.S. subsidiaries. The Company is evaluating the proposed regulations as part of its overall analysis of the TCJA’s impact pursuant to the guidance in SAB 118.

Due to the complexity of the new GILTI tax rules, we continue to evaluate this provision of the TCJA and the application of ASC-740 and are considering if deferred tax amounts should be recorded. Our accounting policies depend, in part, on analyzing our global income to determine whether we expect material tax liabilities resulting from the application of this provision and, if so, whether and when to record related current and deferred income taxes and whether such amounts can be reasonably estimated. Anticipated further guidance from the IRS may also clarify the manner in which the GILTI tax is computed. For these reasons, we are continuing to provisionally treat the GILTI tax as a period cost and have not made a final policy election on whether to record deferred taxes for this provision.

The Company conducts business globally and, as a result, it files U.S. federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is ~~more or less~~different than that reflected in the consolidated financial statements. Furthermore, the Company may ~~later~~ decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law.

The Company has several concurrent audits open and pending with the IRS as set forth below:

~~A summary of the changes in shareholders’ equity for the six months ended June 30, 2018 consisted of the following ($ in millions):~~

On ~~September 25, 2017, the Company’s Board of Directors approved a $2.0 billion share repurchase program. As of June 30, 2018, the Company has completed this share repurchase program, repurchasing~~ ~~12.2~~ ~~million shares under the program.~~

~~On July 26, 2018,~~January 29, 2019, the Company announced that its Board of Directors approved a ~~new~~ $2.0 billion share repurchase program, all of which ~~is anticipated to be~~remained outstanding as of March 31, 2019.

The Company’s Board of Directors previously approved a $2.0 billion share repurchase program in July 2018. As of March 31, 2019, the Company had completed by the ~~end of~~program and repurchased 12.5 million shares for $2.0 billion under the program, including $0.8 billion or 5.3 million shares in the three months ended March 31, 2019.

In the ~~six~~three months ended ~~June 30,~~March 31, 2018, ~~and 2017,~~ the Company paid $69.6 million ~~and $139.2 million, respectively,~~ of dividends on preferred shares. Each preferred share automatically converted to approximately 3.53 ordinary shares on March 1, 2018, for a total of 17,876,930 ordinary shares.

The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange ~~risks~~ and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. ~~As of June 30, 2018 and December 31, 2017, the Company had no material outstanding third-party foreign currency instruments.~~

Internationally, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars.

In November 2018, the Company entered into a 700.0 million Euro forward contract to buy Euros while selling USD. The derivative has a maturity of May 31, 2019. The derivative instrument is marked-to-market to the P&L, offsetting the revaluation (P&L) impact on the Euro 700.0 million variable interest debt. As of March 31, 2019, the fair value of the Euro forward contract of $16.6 million was recorded in accounts payable and accrued expenses. As of December 31, 2018, the fair value of the Euro forward contract of $5.9 million was recorded in prepaid expenses and other current assets. For the three months ended March 31, 2019, the Company recorded a loss of $22.5 million relating to this instrument in general and administrative expenses. As of March 31, 2019 and December 31, 2018, the Company had additional outstanding third-party foreign currency forward instruments of $43.4 million and $42.1 million, respectively. For the three months ended March 31, 2019, these additional outstanding third-party foreign currency forward instruments did not have material mark-to-market adjustments.

In January 2019, Allergan entered into $500.0 million notional floating to fixed interest rate swaps maturing on March 12, 2020 whereby it fixed the interest rates on $500.0 million floating rate notes due March 12, 2020 to an average interest rate of 3.98%. The swaps are being accounted for using hedge accounting treatment. As of March 31, 2019, the fair value of the interest rate swaps of $1.0 million was recorded in accounts payable and accrued expenses. For the three months ended March 31, 2019, the corresponding unrealized loss of $1.0 million was recorded in accumulated other comprehensive income / (loss).

In the normal course of business, we manage certain foreign exchange risks through a variety of strategies, including hedging. Our hedging strategies include the use of derivatives, as well as net investment hedges. For net investment hedges, the effective portion of the gains and losses on the instruments arising from the effects of foreign exchange are recorded in the currency translation adjustment component of accumulated other comprehensive income / (loss), consistent with the underlying hedged item. Hedging transactions are limited to an underlying exposure. As a result, any change in the value of our hedging instruments would be substantially offset by an opposite change in the value of the underlying hedged items. The Company does not use derivative instruments for trading or speculative purposes.

The Company is exposed to foreign exchange risk in its international operations from foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business, including the Euro Denominated Notes. In the ~~six~~three months ended ~~June 30, 2018,~~March 31, 2019, we used effective net investment hedges to partially offset the effects of foreign currency on our investments in certain of our foreign subsidiaries. The total notional amount of our instruments designated as net investment hedges was ~~$3.6~~$5.0 billion as of ~~June 30, 2018~~March 31, 2019 and $5.1 billion as of December 31, ~~2017.~~2018. During the three ~~and six~~ months ended ~~June 30, 2018,~~March 31, 2019, the impact of the net investment hedges onrecorded in other comprehensive ~~income~~loss was a gain of ~~$197.1~~$110.8 million, ~~and $102.0 million, respectively,~~ which primarily offset the currency impact of the Euro ~~denominated notes.~~Denominated Notes. During the three ~~and six~~ months ended ~~June 30, 2017,~~March 31, 2018, the impact of the net investment hedges on other comprehensive income was a loss of ~~$57.2 million.~~$95.1 million, which offset the currency impact of the Euro Denominated Notes.

Assets and liabilities that are measured at fair value using Fair Value Leveling or that are disclosed at fair value on a recurring basis as of ~~June 30, 2018~~March 31, 2019 and December 31, ~~2017~~2018 consisted of the following ($ in millions):

		Fair Value Measurements as of June 30, 2018 Using:									Fair Value Measurements as of March 31, 2019 Using:
		Total		Level 1		Level 2		Level 3			Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents*		$	1,249.9	$	1,249.9	$	-	$	-		$	331.4	$	83.0	$	248.4	$	-
Short-term investments			21.5		-		21.5		-			995.2		-		995.2		-
Deferred executive compensation investments			105.2		86.8		18.4		-			94.5		78.6		15.9		-
Royalty receivable												50.3		-		-		50.3
Investments and other			73.3		73.3		-		-			57.9		48.0		9.9		-
Total assets		$	1,449.9	$	1,410.0	$	39.9	$	-		$	1,529.3	$	209.6	$	1,269.4	$	50.3
Liabilities:
Deferred executive compensation liabilities		$	105.2	$	86.8	$	18.4	$	-		$	94.5	$	78.6	$	15.9	$	-
Contingent consideration obligations			364.4		-		-		364.4			361.2		-		-		361.2
Total liabilities		$	469.6	$	86.8	$	18.4	$	364.4		$	455.7	$	78.6	$	15.9	$	361.2

* Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.	* Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.									* Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.

~~Investments in securities as of June 30, 2018 and December 31, 2017 included the following ($ in millions):~~

Marketable securities and investments consist of ~~available-for-sale investments in~~ money market securities, U.S. treasury and agency securities. Unrealized gains or losses on marketable securities are recorded in interest income, while unrealized gains or losses on marketable debt securities are recorded in accumulated other comprehensive income. Investments and other include equity and debt securities of publicly traded companies for which market prices are readily available. Unrealized gains or losses on ~~marketable securities and~~long-term equity investments are recorded in ~~either interest income or~~ other income / (expense) ~~beginning January 1, 2018.~~, net. The Company’s marketable securities and other long-term investments ~~are classified as available-for-sale and~~ are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management.

The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions):

	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
(Income) / expense	2018			2017			2018			2017
Expense / (income)													2019		2018
Cost of sales	$	(128.8	)	$	(24.8	)	$	(125.4	)	$	(60.3	)	$	16.2	$	3.4
Research and development		21.7			9.3			23.6			75.5			2.5		1.9
Total	$	(107.1	)	$	(15.5	)	$	(101.8	)	$	15.2		$	18.7	$	5.3

In the three and six months ended June 30, 2018, cost of sales primarily relates to the Company’s True Tear product not achieving a milestone event, as well as a corresponding decrease in commercial forecasts.

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

Balance as of December 31, 2017

Net transfers

in to (out of)

Level 3

Purchases,

settlements,

and other net

Net accretion

and fair value

adjustments

Balance as of June 30, 2018

Balance as of December 31, 2018

Net transfers

in to (out of)

Level 3

Purchases,

settlements,

and other net

Net accretion

and fair value

adjustments

Balance as of March 31, 2019

Liabilities:

Contingent consideration

obligations

476.9

(10.7

)

(101.8

)

364.4

344.6

(2.1

)

18.7

361.2

Balance as of

December 31, 2016

Net transfers

in to (out of)

Level 3

Purchases,

settlements,

and other net

Net accretion

and fair value

adjustments

Foreign

currency

translation

Balance as of June 30, 2017

Balance as of December 31, 2017

Net transfers

in to (out of)

Level 3

Purchases,

settlements,

and other net

Net accretion

and fair value

adjustments

Balance as of

March 31, 2018

Liabilities:

Contingent consideration

obligations

1,172.1

(540.4

)

15.2

(8.3

)

638.6

476.9

(9.3

)

5.3

472.9

~~The following is~~During the three months ended March 31, 2019, the activity ~~during the six months ended June 30, 2018~~ in contingent consideration obligations by acquisition consisted of the following ($ in millions):

Business Acquisition	Balance as of December 31, 2017		Fair Value Adjustments and Accretion			Payments and Other			Balance as of June 30, 2018		Balance as of December 31, 2018		Fair Value Adjustments and Accretion		Payments and Other			Balance as of March 31, 2019
Tobira acquisition	$	227.8	$	22.7		$	-		$	250.5	$	255.0	$	2.3	$	-		$	257.3
Medicines 360 acquisition												43.1		13.9		(1.4	)		55.6
ForSight acquisition		46.3		0.9			-			47.2		24.1		0.2		0.1			24.4
Medicines 360 acquisition		44.4		(1.2	)		(2.1	)		41.1
Forest Acquisition		12.7		1.7			(1.0	)		13.4
Forest acquisition												13.6		2.3		(0.5	)		15.4
AqueSys acquisition		28.5		(23.2	)		-			5.3		5.4		-		-			5.4
Oculeve acquisition		90.1		(86.0	)		(0.1	)		4.0		1.7		-		-			1.7
Allergan Acquisition		18.7		(17.7	)		-			1.0
Metrogel acquisition		7.5		-			(7.5	)		-
Other		0.9		1.0			-			1.9		1.7		-		(0.3	)		1.4
Total	$	476.9	$	(101.8	)	$	(10.7	)	$	364.4	$	344.6	$	18.7	$	(2.1	)	$	361.2

The ~~Company has made contingent consideration milestone payments~~fair value measurement of ~~approximately $10.5 million~~the royalty receivable is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. There were no material changes noted in the ~~six~~fair value of the royalty receivable for the three months ended ~~June 30, 2018.~~March 31, 2019.

Restructuring activities for the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 were as follows ($ in millions):

		Severance and Retention			Share-Based Compensation			Other			Total			Severance and Retention			Other		Total
Reserve balance at December 31, 2017		$	166.0		$	-		$	19.9		$	185.9
Reserve balance at December 31, 2018														$	71.4		$	14.4	$	85.8
Charged to expense
Cost of sales			5.5			-			-			5.5			1.1			-		1.1
Selling and marketing			9.6			4.1			-			13.7
General and administrative			1.0			4.1			-			5.1			0.8			0.1		0.9
Total expense			16.1			8.2			-			24.3			1.9			0.1		2.0
Cash payments			(120.8	)		-			(4.6	)		(125.4	)		(38.1	)		-		(38.1	)
Non-cash adjustments	��		-			(8.2	)		-			(8.2	)		(2.1	)		-		(2.1	)
Reserve balance at June 30, 2018		$	61.3		$	-		$	15.3		$	76.6
Reserve balance at March 31, 2019														$	33.1		$	14.5	$	47.6

The Company recognized total restructuring charges of $6.4 million and $24.3 million, respectively, during the three and six months ended June 30, 2018. In December 2017, the Company approved a new restructuring program intended to optimize and restructure its operations while reducing costs and global headcount, in anticipation of loss of exclusivity of several key revenue-generating products in 2018. In

During the three months ended ~~June 30,~~March 31, 2018, the Company ~~recorded~~recognized restructuring charges of $17.9 million including severance and other employee related charges of ~~$6.4~~$14.6 million. ~~In the six months ended June 30, 2018, the Company recorded~~The majority of these restructuring severance ~~and other employee related charges of $21.6 million, which includes $8.2 million of share based compensation related to this program.~~

~~The Company recognized total restructuring charges of $119.0 million and $140.9 million, respectively,~~costs were paid during the three and six months ended June 30, 2017. As part of the Company’s internal optimization restructuring programs, the Company incurred severance and other restructuring costs relating to the commercial organization of $29.9 million as the Company intended to eliminate approximately 400 positions in the three months ended June 30, 2017. In addition, restructuring charges in the three months ended June 30, 2017 included $26.8 million of severance and restructuring costs related to a then-planned internal reduction of approximately 200 positions within the Company’s R&D organization.2018.

The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.

The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of ~~June 30, 2018,~~March 31, 2019, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $~~80.0~~75.0 million. As of December 31, ~~2017,~~2018, the Company’s consolidated balance sheet included accrued loss contingencies of approximately ~~$55.0~~$65.0 million.

The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam actions, antitrust, product liability, breach of contract, securities, patent infringement and trade practices), some of which present novel factual allegations and/or unique legal theories. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss. In those proceedings in which plaintiffs do request publicly quantified amounts of relief, the Company does not believe that the quantified amounts are meaningful because they are merely stated jurisdictional limits, exaggerated and/or unsupported by the evidence or applicable burdens of proof.

In matters involving the assertion or defense of the Company’s intellectual property, the Company believes it has meritorious claims and intends to vigorously assert or defend the patents or other intellectual property at issue in such litigation. Similarly, in matters where the Company is a defendant, the Company believes it has meritorious defenses and intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation or, in the case of patent enforcement matters, that a generic version of the product at issue will not be launched or enjoined. Failing to prevail in a litigation could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Combigan^®. On October 30, 2017, subsidiaries of the Company filed an action for infringement of U.S. Patent Number 9,770,453 (the “‘453 Patent”) against Sandoz, Inc. and Alcon Laboratories, Inc. (“Sandoz”) in the U.S. District Court for the District of New Jersey, in connection with the abbreviated new drug applications respectively filed with the FDA by Sandoz and Alcon, seeking approval to market a generic version of Combigan^®. On March 6, 2018, U.S. Patent Nos. 9,907,801 (the “‘801 Patent”) and 9,907,802 (the “‘802 Patent”) were added to the case. The ‘453, ‘801 and ‘802 Patents are listed in the Orange Book for Combigan^® and expire on April 19, 2022. A trial date has not been set. On July 13, 2018, the district court adopted Allergan’s proposed claim construction and granted Allergan’s motion for preliminary injunction against Sandoz. On August 1, 2018, the district court entered an order setting a preliminary injunction bond in the amount of $157,300,000 under Federal Rule of Civil Procedure 65(c), which Allergan posted. Sandoz has appealed the grant of the injunction, and the appeal is ongoing.

Fetzima^®. In October and November 2017, subsidiaries of the Company and Pierre Fabre Medicament S.A.S. brought actions for infringement of U.S. Patent Nos. RE43,879 (the “‘879 Patent”); 8,481,598 (the “‘598 Patent”); and 8,865,937 (the “‘937 Patent”) against MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, “MSN”), Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC (collectively, “Prinston”), Torrent Pharmaceuticals Limited and Torrent Pharma Inc. (collectively, “Torrent”), West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp. (collectively, “West-Ward”), Zydus Pharmaceuticals (USA) Inc. (“Zydus”), Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited (collectively, “Aurobindo”), and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals Private Limited (collectively, “Amneal”), in connection with abbreviated new drug applications, respectively filed with the FDA by MSN, Prinston, Torrent, West-Ward, Zydus, Aurobindo, and Amneal, each seeking approval to market generic versions of Fetzima® and challenging said patents. The ‘879 Patent expires in June 2023 (not including a pending application for patent term extension (“PTE”)), the ‘598 patent expires in March 2031, and the ‘937 Patent expires in May 2032. The case is currently in fact discovery, and no trial date has been set. Allergan entered into a settlement agreement with Amneal on December 18, 2018, and the case as against Amneal was dismissed.

In April 2019, subsidiaries of the Company and Pierre Fabre Medicament S.A.S. brought an action for infringement of the ‘879, ‘598 and ‘937 Patents against Micro Labs Ltd. and Micro Labs USA, Inc. (“Micro”) in connection with Micro’s abbreviated new drug application seeking approval to market a generic version of Fetzima^® and challenging said patents. No trial date has been set.

Juvéderm ^®. On February 26, 2019, subsidiaries of the Company filed a complaint for infringement of U.S. Patent Nos. 8,450,475 (the “‘475 Patent), 8,357,795 (the “‘795 Patent”), 8,822,676 (the “‘676 Patent”), 9,089,519 (the “‘519 Patent”), 9,238,013 (the “‘013 Patent”) and 9,358,322 (the “‘322 Patent”) in the U.S. District Court for the District of Delaware against Prollenium US Inc. and Prollenium Medical Technologies Inc. (collectively, “Prollenium”). The complaint seeks, among other things, a judgment that Defendants have infringed these patents by making, selling, offering to sell, and importing Prollenium’s Revanesse® Versa+TM product within and into the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement. No trial date has been set.

Kybella^®. On November 9, 2018, a subsidiary of the Company brought an action for infringement of U.S. Patent Nos. 8,101,593 (the “‘593 Patent”), 8,367,649 (the “‘649 Patent”) and 8,653,058 (the “‘058 Patent”) against Slayback Pharma LLC (“Slayback”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with the FDA by Slayback seeking approval to market a generic version of Kybella® and challenging said patents. The ‘593, ‘649, and ‘058 Patents expire in March 2030. On April 10, 2019, a subsidiary of the Company, together with Los Angeles Biomedical Research Institute at Harbor UCLA-Medical Center (“LA BioMed”) and The Regents of the University of California (the “Regents”) (all collectively, “Plaintiffs”), filed an amended complaint against Slayback asserting infringement of the ‘593, ‘649 and ‘058 Patents and U.S. Patent Nos. 7,622,130 (the “‘130 Patent”), 7,754,230 (the “‘230 Patent”), 8,298,556 (the “‘556 Patent”) and 8,846,066 (the “‘066 Patent”). The ‘130 and ‘230 Patents expire in December 2027 (not including pending applications for patent term extension (“PTE”)), the ‘556 Patent expires in August 2025, and the ‘066 Patent expires in February 2025. No trial date has been set.

Latisse^® IV. In December 2016, Sandoz announced the U.S. market launch of its generic copy of Latisse^®. In July 2017, subsidiaries of the Company and Duke University (collectively, “Plaintiffs”) filed a complaint for infringement of U.S. Patent Number 9,579,270 (“‘270 Patent”) against Defendants Sandoz Inc. (“Sandoz”) and Alcon Laboratories, Inc. (“Alcon”) in the U.S. District Court for the Eastern District of Texas (EDTX). The ‘270 patent expires in January 2021. In their complaint, Plaintiffs seek, among other things, a judgment that Defendants have infringed the ‘270 patent by making, selling, and offering to sell, and/or importing, their generic copy of Latisse^® within the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement. On April 3, 2018, the EDTX court issued an order, among other things, severing Plaintiff’s claims against Defendants and transferring Plaintiff’s claims against Alcon to the District Court of Delaware and Plaintiff’s claims against Sandoz to the District of Colorado. On October 5, 2018, the Delaware District Court entered an order dismissing the Delaware action against Alcon. The District of Colorado case against Sandoz is currently in fact discovery and a trial date has not yet been set.

Latisse^® V. On September 25, 2017, subsidiaries of the Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Alembic Pharmaceuticals, Ltd., Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. (collectively, “Alembic”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Alembic, seeking approval to market a generic version of Latisse^® and challenging the ‘270 patent. The Company subsidiaries and Duke entered into a settlement agreement with Alembic and the case was dismissed on April 4, 2019.

Latisse^® VI. On September 19, 2018, subsidiaries of the Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Akorn, Inc. and Hi-Tech Pharmacal Co., Inc. (collectively, “Akorn”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Akorn seeking approval to market a generic version of Latisse® and challenging the ‘270 patent. No trial date has been set.

Linzess^®. Beginning in November 2016 subsidiaries of the Company and Ironwood Pharmaceuticals, Inc. (collectively, “Plaintiffs”), brought multiple actions for infringement of some or all of U.S. Patent Nos. 7,304,036 (the “‘036 Patent”); 7,371,727 (the “‘727 Patent”); 7,704,947 (the “‘947 Patent”); 7,745,409 (the “‘409 Patent”); 8,080,526 (the “‘526 Patent”); 8,110,553 (the “‘553 Patent”); 8,748,573 (the “‘573 Patent”); 8,802,628 (the “‘628 Patent”); and 8,933,030 (the “‘030 Patent”) against Teva Pharmaceuticals USA, Inc. (“Teva”), Aurobindo Pharma Ltd. (“Aurobindo”), Mylan Pharmaceuticals Inc. (“Mylan”), Sandoz Inc. (“Sandoz”) and Sun Pharma Global FZE (“Sun”) in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva, Aurobindo, Mylan, Sandoz and Sun, each seeking approval to market generic versions of Linzess^® 145 mcg and 290 mcg capsules and challenging some or all of said patents (“November 2016 Action”). The ‘727, ‘947, ‘409, ‘526 and ‘553 Patents expire in January 2024; the ‘036 Patent expires in August 2026; and the ‘573, ‘628 and ‘030 Patents expire in 2031. In the November 2016 Action, expert discovery has been completed. Trial is scheduled for June 2019.

On October 20, 2017, November 30, 2017 and January 20, 2018, Plaintiffs brought actions for infringement of U.S. Patent No. 9,708,371 (the “‘371 Patent”) in the U.S. District Court for the District of Delaware against Teva, Mylan and Sandoz, respectively. The ‘371 Patent expires in 2033. The ‘371 patent actions have been consolidated with the November 2016 Action.

On February 2, 2018 and March 29, 2018, Plaintiffs brought actions for infringement of some or all of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘030 and ‘371 Patents against Teva and Mylan in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva and Mylan, each seeking approval to market generic versions generic versions of Linzess^® 72 mcg capsules (“72 mcg ANDA”) before the expiration said patents. The district court consolidated the 72 mcg ANDA actions with the November 2016 Action.

On September 4, 2018, Plaintiffs filed an amended complaint as to Mylan to assert the ‘628 patent against Mylan’s 72 mcg ANDA product.

Plaintiffs entered into a settlement agreement with Sun and certain Sun affiliates and the case against Sun was dismissed on January 18, 2018. Plaintiffs entered into a settlement agreement with Aurobindo and the case against Aurobindo was dismissed on May 7, 2018. Plaintiffs entered into a settlement agreement with Mylan and the case against Mylan was dismissed on December 27, 2018. Under the terms of the settlement agreement, Plaintiffs will provide a license to Mylan to market its generic versions of Linzess^® 145 mcg and 290 mcg in the United States beginning on February 5, 2030 (subject to FDA approval), and its generic version of Linzess^® 72 mcg in the United States beginning on August 5, 2030, or earlier in certain circumstances.

Restasis^®. Between August 2015 and July 2016, a subsidiary of the Company brought actions for infringement of U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”) and 9,248,191 (the “’191 patent”) in the U.S. District Court for the Eastern District of Texas against Akorn, Inc., Apotex, Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., InnoPharma, Inc., Famy Care Limited (“Famy Care”), TWi Pharmaceuticals, Inc. (“TWi”) and related subsidiaries and affiliates thereof.

The subsidiary entered into settlement agreements with Apotex, TWi, Famy Care and InnoPharma. As a result of certain of these settlements, Allergan will provide a license to certain parties to launch their generic versions of Restasis^® beginning on February 27, 2024, or earlier in certain circumstances. Additionally, under certain circumstances, the Company will supply and authorize certain parties to launch an authorized generic version of Restasis® on August 28, 2024 or earlier in certain circumstances.

On September 8, 2017, the Company assigned all Orange Book-listed patents for Restasis^® to the Saint Regis Mohawk Tribe (“the Tribe”), a recognized sovereign tribal government, and concurrently was granted an exclusive field-of-use license to practice the patents in the United States for all FDA-approved uses of the products under the Restasis® NDAs.

On October 16, 2017, the District Court issued a decision and final judgment finding that the asserted claims of the ‘111 patent, the ‘048 patent, the ‘930 patent and the ‘191 patent were infringed, but invalid on the ground of obviousness. The District Court also held that the asserted claims were not invalid as anticipated, for lack of enablement, or for improper inventorship. On November 13, 2018, the U.S. Court of Appeals for the Federal Circuit issued a decision affirming the district court’s finding of invalidity of the asserted claims of the ‘111, ‘048, ‘930 and ‘191 Patents. On March 6, 2019, the Federal Circuit denied Allergan and the Tribe’s petition for rehearing, and a mandate issued on March 13, 2019. On April 10, 2019, Allergan and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court.

On December 22, 2016, a subsidiary of the Company Allergan filed a complaint for infringement of the ’111 patent, ’162 patent, ’556 patent, ’048 patent, ’930 patent, and the ’191 patent in the U.S. District Court for the Eastern District of Texas against Deva Holding A.S. (“Deva”). On March 6, 2018, the district court granted in part and denied in part the parties’ joint motion for entry of a stipulated order, and stayed the case until such time as the Federal Circuit in the lead appeal case with Teva, Mylan and Akron issues a mandate. The parties’ stipulation provides that Deva will be bound by the outcome of that appeal.

On August 10 and September 20, 2018, a subsidiary of the Company and the Tribe filed complaints for infringement of the ’162 patent and the ’556 patent in the U.S. District Court for the District of Delaware against Saptalis and against Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals Co. India Private Limited (collectively, “Amneal”), respectively. The cases were voluntarily dismissed on January 2, 2019.

Restasis^® IPR. On June 6, 2016, a subsidiary of the Company received notification letters that Inter Partes Review of the USPTO (“IPR”) petitions were filed by Mylan Pharmaceuticals Inc. (“Mylan”) regarding U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”), and 9,248,191 (the “‘191 patent”), which patents expire on August 27, 2024. Mylan filed the IPR petition on June 3, 2016. On June 23, 2016, a subsidiary of the Company received a notification letter that an IPR petition and motion for joinder was filed by Argentum Pharmaceuticals LLC (“Argentum”) regarding the ’111 patent. On December 7, 2016, the Company entered into a settlement agreement with Argentum and Argentum’s petition was withdrawn. On December 8, 2016, the USPTO granted Mylan’s petitions to institute IPRs with respect to these patents. On January 6, 2017, each of Akorn and Teva filed, and on January 9, 2017 the USPTO received, IPR petitions with respect to these patents and motions for joinder with the Mylan IPR. The USPTO granted Teva’s and Akorn’s joinder motions on March 31, 2017.

On February 23, 2018, the USPTO issued orders denying the Tribe’s motion to dismiss (or terminate).

On July 20, 2018, the Federal Circuit affirmed the USPTO’s denial of the Tribe’s motion to dismiss and Allergan’s motion to withdraw. On August 20, 2018, the Tribe and Allergan filed a petition for rehearing en banc, which the Federal Circuit denied on October 22, 2018. On December 21, 2018, the Company and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court, which was denied on April 15, 2019.

Saphris^®. Between September 2014 and May 2015, subsidiaries of the Company brought actions for infringement of some or all of U.S. Patent Nos. 5,763,476 (the “‘476 patent”), 7,741,358 (the “‘358 patent”) and 8,022,228 (the “‘228 patent”) against Sigmapharm Laboratories, LLC (“Sigmapharm”), Hikma Pharmaceuticals, LLC (“Hikma”), Breckenridge Pharmaceutical, Inc. (“Breckenridge”), Alembic Pharmaceuticals, Ltd. (“Alembic”) and Amneal Pharmaceuticals, LLC (“Amneal”), and related subsidiaries and affiliates thereof in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug applications respectively filed with FDA by Sigmapharm, Hikma, Breckenridge, Alembic and Amneal, each seeking approval to market a generic versions of Saphris^® and challenging each of said patents. Including a 6-month pediatric extension of regulatory exclusivity, the ‘476 patent expires in December 2020, and the ‘358 and ‘228 patents expire in October 2026. In 2016, the parties agreed to dismiss all claims related to the ‘358 and ‘228 patents, leaving only the ‘476 patent at issue. On October 13, 2016, the court stayed trial as to Sigmapharm and extended the 30-month stay as to Sigmapharm. On June 30, 2017, the district court issued an opinion and order finding all asserted claims of the ‘476 patent valid, that claims 1, 2, 5 and 6 were infringed by Alembic, Amneal, Breckenridge and Hikma, and that claims 4, 9 and 10 were not infringed by Alembic and Breckenridge. On July 11, 2017, the district court entered a final judgment that ordered, among other things, that Alembic’s, Amneal’s, Breckenridge’s and Hikma’s respective ANDAs not be granted final approval by FDA earlier than the date of expiration of the ‘476 patent inclusive of any applicable adjustments, extensions or exclusivities. The case is currently on appeal.

On March 14, 2019, the Federal Circuit vacated the district court’s July 2017 judgment that claims 1 and 4 are not invalid and remanded for the district court to consider a fact question and its impact on the obviousness analysis. On April 15, 2019, Plaintiffs filed a combined petition for panel rehearing and rehearing en banc with respect to this issue. In its March 14, 2019 order, the Federal Circuit also vacated the judgment of non-infringement of claims 4, 9 and 10 as to Alembic and Breckenridge and remanded for the district court to consider their infringement under a revised claim construction.

A separate bench trial concerning Sigmapharm’s infringement of claim 1 of the ‘476 patent began on June 20, 2018, and on November 16, 2018, the court held that Sigmapharms’ proposed ANDA product would infringe claim 1 of the ‘476 patent On November 26, 2018, Sigmapharm sought relief from the November 16, 2018 decision. On November 30, 2018, the Company moved for entry of final judgment. Both motions are currently pending.

Botulinum Neurotoxin ITC Investigation. On January 30, 2019, subsidiaries of the Company and Medytox Inc. (collectively, “Complainants”) filed a complaint with the United States International Trade Commission (“ITC”) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and Evolus Inc. (collectively, “Respondents”) requesting the ITC commence an investigation with respect to the Respondents’ importation into the United States of Respondents’ botulinum neurotoxin products, including DWP-450 (also known as Jeuveau^TM), which Complainants assert were developed, made and/or imported using Medytox’s trade secrets. Complainants seek, among other things, a permanent exclusionary order and cease and desist orders covering Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. On February 28, 2019, the ITC instituted an investigation into Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. The ITC has scheduled a hearing for November 5-7, 2019 and has set May 29, 2020 as the target date for completion of the investigation.

Juvéderm^®. On April 5, 2017, a subsidiary of the Company brought an action for unfair competition, false advertising, dilution, conspiracy and infringement of Allergan’s Juvéderm^® trademarks in the U.S. District Court for the Central District of California against Dermavita Limited Partnership (“Dermavita”), Dima Corp. S.A. (“Dima Corp.”) and KBC Media Relations LLC (“KBC”). Dima Corp. had previously announced its acquisition of a license from Dermavita to develop and market in the U.S. cosmetic products under the Juvederm trademark. During June 2017, the Company entered into a settlement agreement with KBC. During July 2017, the Court preliminarily enjoined Dima Corp. from, inter alia, promoting or selling within the United States any product bearing the trademark Juvéderm^® or any other trademark confusingly similar to it. During January 2018, the Court granted Dermavita’s renewed motion to dismiss the Company’s complaint based on purported lack of personal jurisdiction. During January 2019, the Company subsidiary and Dima Corp. resolved the action and the Court entered a permanent injunction and final judgment in favor of the Company subsidiary and against Dima Corp. for trademark infringement, unfair competition, dilution and false advertising.

Subsidiaries of the Company requested a preliminary injunction against Dermavita, Dima Corp, Aesthetic Services, Jacqueline Sillam and Dimitri Sillam in the High Court of Paris, France. During June 2017, the Paris Court preliminarily enjoined the defendants, inter alia, to refrain from promoting or selling in France its Juvederm products, to transfer various domain names and to pay provisional damages to Allergan, on the basis that such use would infringe Allergan’s EU and French Juvéderm^® trademarks and would amount to unfair competition. This injunction has become final. A subsidiary of the Company has also filed against Dermavita, Dima Corp. and others a full action of trademark infringement in the Paris court. Dermavita has requested that the full action be stayed

pending the outcome of the Nanterre action and the EUIPO trademark proceedings, both mentioned below. The Paris court rejected Dermavita’s stay request and subsequently ordered the defendants to pay more than 75,000 Euros in liquidated damages for violation of the preliminary injunction mentioned above. Dermavita has filed an action against subsidiaries of the Company in the Nanterre, France court alleging that the subsidiaries have not used its Juvéderm trademark and requesting the court to revoke the Company’s trademark based on its purported lack of use or purportedly invalid license and assignment agreements. On February 21, 2019, the Nanterre Court ruled in the Company’s favor, holding that the license and assignment agreements were valid and that Allergan has used its trademark in commerce. Dermavita has appealed this decision.

On January 22, 2019, subsidiaries of the Company brought a related action for infringement of the Company’s Juvéderm^®trademarks against Aesthetic Services and Development Limited, Juvederm Elite Clinics SARL and Jamal Hamadi in the (UK) High Court of Justice. The case is in its early stages and no trial date has been set.

Furthermore, more than 150 trademark opposition and cancellation actions between Allergan and Dermavita have been filed in front of the USPTO, EUIPO and various other national and regional trademark offices around the world. Most of these actions remain pending; however, Allergan has received favorable decisions in more than ten (10) such actions.

~~Asacol~~Combigan^® ~~Litigation.~~ Two class action complaints were filed on June 22, 2015, and three more on September 21, 2015, in federal court in Massachusetts on behalf of a putative class of indirect purchasers. Complaints were also filed on behalf of a putative class of direct purchasers of Asacol^® making similar allegations to the complaints filed by the indirect purchaser plaintiffs. Those matters have been consolidated with the indirect purchaser cases. In each complaint plaintiffs allege that they paid higher prices for Warner Chilcott’s Asacol^® ~~HD and Delzicol~~^® ~~products as a result of Warner Chilcott’s alleged actions preventing or delaying generic competition in the market for Warner Chilcott’s older Asacol~~^® product in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. The Company has settled the claims brought by the direct purchaser plaintiffs. The court granted the indirect purchaser plaintiffs’ motion for class certification. The Company filed a motion for summary judgment seeking dismissal of the indirect purchaser plaintiffs’ claims which the court denied on November 9, 2017. Trial was set to being on January 22, 2018. However, on January 17, 2018, the Court of Appeals for the First Circuit issued an order granting the Company’s motion under Fed.R.Civ.P. 23(f) to appeal the district court’s decision to certify the proposed class. The appellate court thereafter issued a decision staying the trial in the district court. The appeal was fully briefed on March 26, 2018. Oral argument on the appeal was held on May 8, 2018.

~~Botox~~^® ~~Litigation~~. A class action complaint was filed in federal court in California on February 24, 2015, and amended May 29, 2015, alleging unlawful market allocation in violation of Section 1 of the Sherman Act, 15 U.S.C. §1, agreement in restraint of trade in violation of 15 U.S.C. §1 of the Sherman Act, unlawful maintenance of monopoly market power in violation of Section 2 of the Sherman Act, 15 U.S.C. §2 of the Sherman Act, violations of California’s Cartwright Act, Section 16700 et seq. of Calif. Bus. and Prof. Code, and violations of California’s unfair competition law, Section 17200 et seq. of Calif. Bus. and Prof. Code. In the complaint, plaintiffs seek an unspecified amount of treble damages. On November 30, 2017, the parties reached a tentative settlement. On March 8, 2018, the court granted plaintiffs’ motion for preliminary approval of class action settlement and set a final fairness hearing for August 24, 2018.

~~Loestrin~~^® ~~24 Litigation.~~ On April 5, 2013, two putative class actions were filed on behalf of putative classes of end-payors in the federal district court against Warner Chilcott and certain affiliates alleging that Warner Chilcott’s 2009 patent lawsuit settlements with Watson Laboratories and Lupin related to Loestrin^® ~~24 Fe were unlawful. The complaints generally allege that Watson and Lupin improperly delayed launching generic versions of Loestrin~~^® 24 in exchange for substantial payments from Warner Chilcott in violation of federal and state antitrust and consumer protection laws. The complaints each seek declaratory and injunctive relief and damages. Additional complaints making the same types of allegations have been filed by different plaintiffs, including a class of direct payors and by direct purchasers in their individual capacities. All the cases have been consolidated in the federal court for the District of Rhode Island. The parties are currently engaged in discovery.

~~Namenda~~^® ~~Litigation~~. In September 2014, the State of New York, through the Office of the Attorney General of the State of New York, filed a lawsuit in the United States District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Forest’s immediate-release product Namenda^® ~~in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda~~^® XR. The district court granted the state’s motion for a preliminary injunction which was later affirmed by the Court of Appeals for the Second Circuit. Forest and the New York Attorney General reached a settlement on November 24, 2015. On May 29, 2015, a putative class action was filed on behalf of a class of direct purchasers in the federal district court in New York. Since that time, additional complaints have been filed on behalf of putative classes of direct and indirect purchasers. The class action complaints make claims similar to those asserted by the New York Attorney General and also include claims that Namenda^® patent litigation settlements between Forest and generic companies also violated the antitrust laws. Plaintiffs moved for summary judgment on two of the counts of their complaint. The Court granted plaintiffs’ motion in part as to the collateral estoppel effect of a prior finding of anti-competitive conduct, and denied the motions on whether the Company’s obtaining pediatric exclusivity was anti-competitive conduct. On August 2, 2018, the court denied the Company’s motion for summary judgment.

~~Restasis~~^® ~~Competitor Litigation~~. On October 2,30, 2017, ~~Shire, which offers the dry-eye disease drug Xiidra~~^®~~, sued Allergan in federal district court alleging that Allergan unlawfully harmed competition by foreclosing Xiidra~~^® ~~from sales to Medicare Part D plans (and the members of such plans) through the use of discounts (a) contingent on Restasis~~^® ~~receivingpreferential formulary treatment; and/or (b) across a bundle of Allergan’s products, including Restasis~~^®~~, Lumigan~~^®~~, Combigan~~^®~~, and Alphagan P~~^®. The complaint seeks injunctive relief under federal and New Jersey antitrust law and New Jersey common law. On December 5, 2017, Allergan filed a motion to dismiss the complaint. A date for oral argument has not been set.

~~Restasis~~^® ~~Class Action Litigation~~. Between November 7, 2017, and February 26, 2018, seventeen putative class actions were filed in federal district courts against Allergan alleging that the company unlawfully harmed competition by engaging in conduct to delay the market entry of generic versions of Restasis^®. Twelve of the complaints were filed on behalf of putative classes of end-payors, and five were filed on behalf of putative classes of direct purchasers. One direct purchaser complaint and two end-payor complaints were later voluntarily dismissed. The cases have all been consolidated in a multidistrict litigation in the federal court in the Eastern District of New York. The complaints challenge Allergan’s conduct in prosecuting and obtaining patents covering Restasis^®, listing those patents in the FDA’s Orange Book, asserting those patents against potential generic competitors in patent-infringement litigation, filing citizens petitions with the FDA concerning generic companies’ drug applications for generic Restasis^®, and transferring patents to the sovereign Native American Saint Regis Mohawk Tribe. Both the end-payors and the direct purchasers allege that these actions violated federal antitrust laws, and the end-payors further allege violations of state antitrust and consumer-protection laws and unjust enrichment. All plaintiffs seek damages, declaratory relief, and injunctive relief. Plaintiffs have filed a consolidated amended complaint which the Company has since moved to dismiss.

~~Zymar~~^®~~/Zymaxid~~^® ~~Litigation~~. On February 16, 2012, Apotex Inc. and Apotex Corp. filed a complaint in the federal district court in Delaware against Senju Pharmaceuticals Co., Ltd. (“Senju”), Kyorin Pharmaceutical Co., Ltd. (“Kyorin”), and Allergan, Inc. alleging monopolization in violation of Section 2 of the Sherman Act, conspiracy to monopolize, and unreasonable restraint of trade in the market for gatifloxacin ophthalmic formulations, which includes Allergan, Inc.’s ZYMAR^® ~~gatifloxacin ophthalmic solution 0.3% and ZYMAXID~~^® ~~gatifloxacin ophthalmic solution 0.5% products. In the complaint, Plaintiffs seek an unspecified amount of treble damages and disgorgement of profits. On April 26, 2017, this matter was dismissed.~~

On June 6, 2014, a separate antitrust class action complaint was filed in the federal district court in Delaware against the same defendants as in the Apotex case. The complaint alleges that defendants unlawfully excluded or delayed generic competition in the gatifloxacin ophthalmic formulations market (generic versions of ZYMAR^® ~~and ZYMAXID~~^®~~). On October 18, 2017, the parties reached a tentative settlement. On February 27, 2018, the court granted plaintiffs’ motion for preliminary approval of class settlement.~~

~~Celexa~~^®~~/Lexapro~~^® ~~Class Actions. Forest and certain of its affiliates were named as defendants in multiple federal court actions relating to the promotion of Celexa~~^® ~~and/or Lexapro~~^® ~~all of which were consolidated in the Celexa~~^®~~/Lexapro~~^® MDL proceeding in the federal district court in Massachusetts. Actions were filed in the federal district courts in Minnesota and Washington in November 2013 and August 2014, respectively, seeking to certify a nationwide class of third-party payor entities and consumers that purchased Celexa^® ~~and Lexapro~~^® for pediatric use. The complaints each assert claims under the federal Racketeer Influenced and Corrupt Organizations (“RICO”) Act, alleging that Forest engaged in an off-label marketing scheme and paid illegal kickbacks to physicians to induce prescriptions of Celexa^® ~~and Lexapro~~^®~~. The court denied both plaintiffs’ class certification motions and entered summary judgment in favor~~subsidiaries of the Company ~~in both actions. Plaintiffs in both cases have~~ filed ~~a Notice~~an action for infringement of ~~Appeal of the summary judgment order~~U.S. Patent Number 9,770,453 (the “‘453 Patent”) against Sandoz, Inc. and ~~the order denying class certification.~~

~~Warner Chilcott Marketing Practices. On February 13, 2018, a class action complaint was filed against Warner Chilcott and certain of its affiliates~~Alcon Laboratories, Inc. (“Sandoz”) in the U.S. District Court for the District of ~~Massachusetts.~~New Jersey, in connection with the abbreviated new drug applications respectively filed with the FDA by Sandoz and Alcon, seeking approval to market a generic version of Combigan^®. On March 6, 2018, U.S. Patent Nos. 9,907,801 (the “‘801 Patent”) and 9,907,802 (the “‘802 Patent”) were added to the case. The ~~Complaint asserts~~‘453, ‘801 and ‘802 Patents are listed in the Orange Book for Combigan^® and expire on April 19, 2022. A trial date has not been set. On July 13, 2018, the district court adopted Allergan’s proposed claim construction and granted Allergan’s motion for preliminary injunction against Sandoz. On August 1, 2018, the district court entered an order setting a preliminary injunction bond in the amount of $157,300,000 under Federal Rule of Civil Procedure 65(c), which Allergan posted. Sandoz has appealed the grant of the injunction, and the appeal is ongoing.

Latisse^® IV. In December 2016, Sandoz announced the U.S. market launch of its generic copy of Latisse^®. In July 2017, subsidiaries of the Company and Duke University (collectively, “Plaintiffs”) filed a complaint for infringement of U.S. Patent Number 9,579,270 (“‘270 Patent”) against Defendants Sandoz Inc. (“Sandoz”) and Alcon Laboratories, Inc. (“Alcon”) in the U.S. District Court for the Eastern District of Texas (EDTX). The ‘270 patent expires in January 2021. In their complaint, Plaintiffs seek, among other things, a judgment that Defendants have infringed the ‘270 patent by making, selling, and offering to sell, and/or importing, their generic copy of Latisse^® within the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement. On April 3, 2018, the EDTX court issued an order, among other things, severing Plaintiff’s claims ~~under~~against Defendants and transferring Plaintiff’s claims against Alcon to the ~~federal RICO statute, violations~~District Court of ~~number~~Delaware and Plaintiff’s claims against Sandoz to the District of ~~state consumer protection statutes, common law fraud,~~Colorado. On October 5, 2018, the Delaware District Court entered an order dismissing the Delaware action against Alcon. The District of Colorado case against Sandoz is currently in fact discovery and ~~unjust enrichment~~a trial date has not yet been set.

In May and August 2018, the district court granted joint stipulations and orders to dismiss without prejudice all claims, counterclaims, and defenses in the November 2016 Action with respect to the ~~sale~~‘371 Patent and ~~marketing of certain products. The complaint seeks to certify a nationwide class of private payer entities, or their assignees, that paid Medicare benefits on behalf of their beneficiaries.~~ the ‘030 Patent, respectively, as between Plaintiffs, Teva, Mylan and Sandoz.

On ~~April 9,~~September 4, 2018, ~~the plaintiffs filed an Amended Complaint, adding certain other Allergan subsidiaries as defendants. Defendants filed a motion to dismiss the Amended Complaint on June 11, 2018.~~

~~Generic Drug Pricing Securities and ERISA Litigation~~. On November 4, 2016, a class action was filed by a putative class of Allergan shareholders in federal court in California against the Company and certain of its current and former officers alleging that the Company and certain of its current and former officers made materially false and misleading statements. Additional similar class action complaints and one complaint by an individual defendant have been filed and these cases have been consolidated in the federal district court in New Jersey. The complaints allege generally that between February 2014 and November 2016, Allergan and certain of its officers made materially false and misleading statements regarding the Company’s internal controls over its financial reporting and failed to disclose that its Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. The complaint seeks unspecified monetary damages. After the Company filed a motion to dismiss plaintiffs filed a second amended consolidated complaint on November 28, 2017. The Company’s motion to dismiss the second amended complaint, filed on January 22, 2018, is still pending. A complaint was filed in California state court, premised on the same underlying allegations, by an individual opt-out plaintiff on February 2, 2018. Two complaints were filed, one in the federal district court in California and one in the federal district court in New Jersey, that are premised on the same alleged underlying conduct that is at issue in the securities litigation but that assert claims under the Employee Retirement Income Security Act of 1974 (“ERISA”). These complaints also have been consolidated in the district court in New Jersey. The ERISA complaints assert claims on behalf of a putative class of individuals who participated in the Company’s retirement plans and seek an unspecified amount of damages and other injunctive relief. On October 23, 2017, the ERISA litigation Plaintiffs filed an amended ~~consolidated~~ complaint ~~which~~as to Mylan to assert the ‘628 patent against Mylan’s 72 mcg ANDA product.

Restasis^®. Between August 2015 and July 2016, a subsidiary of the Company ~~moved~~brought actions for infringement of U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”) and 9,248,191 (the “’191 patent”) in the U.S. District Court for the Eastern District of Texas against Akorn, Inc., Apotex, Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., InnoPharma, Inc., Famy Care Limited (“Famy Care”), TWi Pharmaceuticals, Inc. (“TWi”) and related subsidiaries and affiliates thereof.

The subsidiary entered into settlement agreements with Apotex, TWi, Famy Care and InnoPharma. As a result of certain of these settlements, Allergan will provide a license to ~~dismiss~~certain parties to launch their generic versions of Restasis^® beginning on February ~~2, 2018. Only July 3,~~27, 2024, or earlier in certain circumstances. Additionally, under certain circumstances, the Company will supply and authorize certain parties to launch an authorized generic version of Restasis® on August 28, 2024 or earlier in certain circumstances.

~~Telephone Consumer Protection Act Litigation.~~ In October 2012, Forest and certain of its affiliates were named as defendants in a putative class action in federal court in Missouri. This suit alleges that Forest and another defendant violated the Telephone Consumer Protection Act (the “TCPA”) by sending unsolicited facsimiles and facsimiles with inadequate opt-out notices. The case was stayed pending the administrative proceeding initiated by the pending FCC Petition and a separate petition Forest filed. A similar lawsuit was filed in in Missouri state court against Warner Chilcott Corporation which Warner Chilcott removed to the federal district court. In the wake of the Court of Appeals decision on the Petition discussed below, the parties reached an agreement to settle these actions.

In a related matter, on June 27, 2013, Forest filed a Petition for Declaratory Ruling with the FCC requesting that the FCC find that (1) the faxes at issue in the action complied, or substantially complied with the FCC regulation, and thus did not violate it, or (2) the FCC regulation was not properly promulgated under the TCPA. On October 30, 2014, the FCC issued a final order on the FCC Petition granting Forest and several other petitioners a retroactive waiver of the opt-out notice requirement for all faxes sent with express consent. The litigation plaintiffs appealed the final order to theU.S. Court of Appeals for the ~~District of Columbia and on March 31, 2017, the Court of Appeals~~Federal Circuit issued a decision ~~which held that~~affirming the ~~FCC regulation at issue was not properly promulgated under~~district court’s finding of invalidity of the ~~TCPA. Plaintiffs’~~asserted claims of the ‘111, ‘048, ‘930 and ‘191 Patents. On March 6, 2019, the Federal Circuit denied Allergan and the Tribe’s petition for rehearing, and a mandate issued on March 13, 2019. On April 10, 2019, Allergan and the Tribe filed a petition for a writ of certiorari ~~was denied by~~with the United States Supreme Court.

~~Prescription Opioid Drug Abuse Litigation~~On December 22, 2016, a subsidiary of the Company Allergan filed a complaint for infringement of the ’111 patent, ’162 patent, ’556 patent, ’048 patent, ’930 patent, and the ’191 patent in the U.S. District Court for the Eastern District of Texas against Deva Holding A.S. (“Deva”). On March 6, 2018, the district court granted in part and denied in part the parties’ joint motion for entry of a stipulated order, and stayed the case until such time as the Federal Circuit in the lead appeal case with Teva, Mylan and Akron issues a mandate. The parties’ stipulation provides that Deva will be bound by the outcome of that appeal.

Restasis^® IPR. ~~The~~On June 6, 2016, a subsidiary of the Company ~~has been named as a defendant, along with several other manufacturers~~received notification letters that Inter Partes Review of ~~opioid products, in approximately 1,028 matters relating to~~ the ~~promotion and sale of prescription opioid pain relievers and additional suits may be filed. The first complaints~~USPTO (“IPR”) petitions were filed by Mylan Pharmaceuticals Inc. (“Mylan”) regarding U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”), and 9,248,191 (the “‘191 patent”), which patents expire on August 27, 2024. Mylan filed the ~~California counties of Santa Clara and Orange,~~IPR petition on ~~behalf~~June 3, 2016. On June 23, 2016, a subsidiary of the ~~State~~Company received a notification letter that an IPR petition and motion for joinder was filed by Argentum Pharmaceuticals LLC (“Argentum”) regarding the ’111 patent. On December 7, 2016, the Company entered into a settlement agreement with Argentum and Argentum’s petition was withdrawn. On December 8, 2016, the USPTO granted Mylan’s petitions to institute IPRs with respect to these patents. On January 6, 2017, each of ~~California,~~Akorn and Teva filed, and on January 9, 2017 the ~~City of Chicago~~USPTO received, IPR petitions with respect to these patents and motions for joinder with the ~~State of Mississippi,~~Mylan IPR. The USPTO granted Teva’s and Akorn’s joinder motions on March 31, 2017.

On September 8, 2017, Allergan assigned all Orange Book-listed patents for Restasis^® to the Saint Regis Mohawk Tribe (“the Tribe”), a recognized sovereign tribal government, and concurrently was granted an exclusive field-of-use license to practice the patents in ~~May 2014, June 2014 and December 2015, respectively. Each~~the United States for all FDA-approved uses of the ~~lawsuits allege~~products under the Restasis^® NDAs. That same day, the Tribe filed an updated Mandatory Notice with the USPTO to reflect that the ~~manufacturer defendants engaged in a deceptive campaign~~Tribe is the patent owner, and sought permission to promote their products in violation of state laws and seek unspecified monetary damages, penalties and injunctive relief. In May 2017 the State of Ohio filed a lawsuit in state court which parallels the claims in the California, Chicago and Mississippi matters. Since the filing of the complaint by the State of Ohio, additional cases have been filed, including cases filed by others states but mainly by political subdivisions of states (i.e., counties and municipalities) in state and federal courts across the country. In addition, cases have been filed on behalf of consumers who were prescribed opioid products or were prescribed opioid products and were subsequently treated for an overdose or addiction. The federal court cases have been consolidated in an MDL in the federal court for the Northern District of Ohio. In the California case, which is pending in state court in California, the court has set a trial date of June 28, 2019.

~~The Company is aware that other states and political subdivisions are filing comparable actions against, among others, manufacturers and parties that promoted prescription opioid pain relievers.~~

~~Testosterone Replacement Therapy Class Action~~. On November 24, 2014, the Company was served with a putative class action complaint filed on behalf a class of third party payers in federal court in Illinois. The suit alleges that the Company and other named pharmaceutical defendants violated various laws including the federal RICO statute and state consumer protection laws in connection with the sale and marketing of certain testosterone replacement therapy pharmaceutical products (“TRT Products”), including the Company’s Androderm^® product. This matter was filed in the TRT Products Liability MDL, described in more detail below, notwithstanding that it is not a product liability matter. Plaintiff alleges that it reimbursed third parties for dispensing TRT Products to beneficiaries of its insurance policies. Plaintiff seeks to obtain certain equitable relief, including injunctive relief and an order requiring restitution and/or disgorgement, and to recover damages and multiple damages in an unspecified amount. Defendants jointly filedfile a motion to dismiss the third amended complaint and in its ruling the court dismissed all claims against the Company except plaintiff’s RICO conspiracy claim. Discovery in this matter is ongoing. Plaintiffs filed a motion for class certificationbased on ~~November 6, 2017.~~ tribal sovereign immunity.

On ~~March 5, 2018, Defendants filed papers in opposition to Plaintiffs’ class certification motion. On July 26,~~February 23, 2018, the ~~court entered an order~~USPTO issued orders denying ~~plaintiff’s class certification motion.~~

~~Xaleron Dispute.~~ On February 5, 2016, Xaleron Pharmaceuticals, Inc. filed a lawsuit against Allergan, Inc. and Actavis, Inc., now known as Allergan Finance, LLC, in state court in New York. The complaint, filed on February 26, 2016, alleges the defendants misappropriated Xaleron’s confidential business information and asserts claims for unfair competition, tortious interference with prospective economic advantage and unjust enrichment. The Company filed aTribe’s motion to dismiss (or terminate).

On July 20, 2018, the ~~complaint~~Federal Circuit affirmed the USPTO’s denial of the Tribe’s motion to dismiss and Allergan’s motion to withdraw. On August 20, 2018, the Tribe and Allergan filed a petition for rehearing en banc, which the Federal Circuit denied on October 22, 2018. On December 21, 2018, the Company and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court, which was denied on April 15, ~~2016.~~2019.

Saphris^®. Between September 2014 and May 2015, subsidiaries of the Company brought actions for infringement of some or all of U.S. Patent Nos. 5,763,476 (the “‘476 patent”), 7,741,358 (the “‘358 patent”) and 8,022,228 (the “‘228 patent”) against Sigmapharm Laboratories, LLC (“Sigmapharm”), Hikma Pharmaceuticals, LLC (“Hikma”), Breckenridge Pharmaceutical, Inc. (“Breckenridge”), Alembic Pharmaceuticals, Ltd. (“Alembic”) and Amneal Pharmaceuticals, LLC (“Amneal”), and related subsidiaries and affiliates thereof in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug applications respectively filed with FDA by Sigmapharm, Hikma, Breckenridge, Alembic and Amneal, each seeking approval to market a generic versions of Saphris^® and challenging each of said patents. Including a 6-month pediatric extension of regulatory exclusivity, the ‘476 patent expires in December 2020, and the ‘358 and ‘228 patents expire in October 2026. In 2016, the parties agreed to dismiss all claims related to the ‘358 and ‘228 patents, leaving only the ‘476 patent at issue. On ~~September~~October 13, 2016, the court stayed trial as to Sigmapharm and extended the 30-month stay as to Sigmapharm. On June 30, 2017, the district court issued an opinion and order finding all asserted claims of the ‘476 patent valid, that claims 1, 2, 5 and 6 were infringed by Alembic, Amneal, Breckenridge and Hikma, and that claims 4, 9 and 10 were not infringed by Alembic and Breckenridge. On July 11, 2017, the district court entered a ~~decision denying~~final judgment that ordered, among other things, that Alembic’s, Amneal’s, Breckenridge’s and Hikma’s respective ANDAs not be granted final approval by FDA earlier than the ~~Company’s motion. Defendants~~date of expiration of the ‘476 patent inclusive of any applicable adjustments, extensions or exclusivities. The case is currently on appeal.

Botulinum Neurotoxin ITC Investigation. On January 30, 2019, subsidiaries of the Company and Medytox Inc. (collectively, “Complainants”) filed a complaint with the United States International Trade Commission (“ITC”) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and Evolus Inc. (collectively, “Respondents”) requesting the ITC commence an ~~answer~~investigation with respect to the ~~complaint~~Respondents’ importation into the United States of Respondents’ botulinum neurotoxin products, including DWP-450 (also known as Jeuveau^TM), which Complainants assert were developed, made and/or imported using Medytox’s trade secrets. Complainants seek, among other things, a permanent exclusionary order and cease and desist orders covering Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. On February 28, 2019, the ~~parties are now engaged in discovery.~~ITC instituted an investigation into Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. The ~~company filed~~ITC has scheduled a ~~motion~~hearing for ~~summary judgment on April 4, 2018. The parties have reached an agreement in principle to settle~~November 5-7, 2019 and has set May 29, 2020 as the ~~litigation.~~target date for completion of the investigation.

Juvéderm^®. On April ~~26,~~5, 2017, a ~~putative class~~subsidiary of the Company brought an action ~~lawsuit was filed against Zeltiq~~for unfair competition, false advertising, dilution, conspiracy and infringement of Allergan’s Juvéderm^® trademarks in ~~state court in California alleging that Zeltiq misled customers regarding~~ the ~~promotion of its CoolSculpting product and the product’s premarket notification clearance status. On May 30, 2017, the case was removed to the United States~~U.S. District Court for the Central District of ~~California. On~~California against Dermavita Limited Partnership (“Dermavita”), Dima Corp. S.A. (“Dima Corp.”) and KBC Media Relations LLC (“KBC”). Dima Corp. had previously announced its acquisition of a license from Dermavita to develop and market in the U.S. cosmetic products under the Juvederm trademark. During June 2017, the Company entered into a settlement agreement with KBC. During July ~~20,~~ 2017, ~~Plaintiffs filed an amended complaint. In August 2017, Zeltiq filed a~~the Court preliminarily enjoined Dima Corp. from, inter alia, promoting or selling within the United States any product bearing the trademark Juvéderm^® or any other trademark confusingly similar to it. During January 2018, the Court granted Dermavita’s renewed motion to dismiss the ~~amended complaint. On June 11, 2018,~~Company’s complaint based on purported lack of personal jurisdiction. During January 2019, the Company subsidiary and Dima Corp. resolved the action and the Court ~~granted Zeltiq’s motion to dismiss~~entered a permanent injunction and final judgment in favor of the ~~amended complaint. On July 2, 2018, Plaintiffs filed~~Company subsidiary and against Dima Corp. for trademark infringement, unfair competition, dilution and false advertising.

Subsidiaries of the Company requested a ~~third amended complaint. On July 23, 2018, Zeltiq filed a motion to dismiss the third amended complaint.~~

~~In July 2012, Forest was named as a defendant in an action brought by certain former Company sales representatives~~preliminary injunction against Dermavita, Dima Corp, Aesthetic Services, Jacqueline Sillam and ~~specialty sales representatives~~Dimitri Sillam in the ~~federal district court~~High Court of Paris, France. During June 2017, the Paris Court preliminarily enjoined the defendants, inter alia, to refrain from promoting or selling in ~~New York. The action is a putative class~~France its Juvederm products, to transfer various domain names and ~~collective action, and alleges class claims under Title VII for gender discrimination with respect~~ to pay ~~and promotions, as well as discrimination~~provisional damages to Allergan, on the basis ~~of pregnancy,~~that such use would infringe Allergan’s EU and ~~a collective action claim under the Equal Pay Act. The proposed Title VII gender class includes all current~~French Juvéderm^® trademarks and ~~former female sales representatives employed by~~would amount to unfair competition. This injunction has become final. A subsidiary of the Company ~~throughout~~has also filed against Dermavita, Dima Corp. and others a full action of trademark infringement in the ~~U.S. from 2008 to~~Paris court. Dermavita has requested that the ~~date~~full action be stayed

pending the outcome of ~~judgment,~~the Nanterre action and the ~~proposed Title~~

~~VII pregnancy sub-class includes all current~~EUIPO trademark proceedings, both mentioned below. The Paris court rejected Dermavita’s stay request and ~~former female sales representatives who~~subsequently ordered the defendants to pay more than 75,000 Euros in liquidated damages for violation of the preliminary injunction mentioned above. Dermavita has filed an action against subsidiaries of the Company in the Nanterre, France court alleging that the subsidiaries have not used its Juvéderm trademark and requesting the court to revoke the Company’s trademark based on its purported lack of use or purportedly invalid license and assignment agreements. On February 21, 2019, the Nanterre Court ruled in the Company’s favor, holding that the license and assignment agreements were valid and that Allergan has used its trademark in commerce. Dermavita has appealed this decision.

Furthermore, more than 150 trademark opposition and cancellation actions between Allergan and Dermavita have been are, or will become pregnant while employed by the Company throughout the U.S. from 2008 to the date of judgment. The proposed Equal Pay Act collective action class includes current, former, and future female sales representatives who were not compensated equally to similarly-situated male employees during the applicable liability period. The second amended complaint also includes non-class claims on behalf of certainfiled in front of the ~~named Plaintiffs for sexual harassment~~USPTO, EUIPO and ~~retaliation under Title VII,~~various other national and ~~for violations~~regional trademark offices around the world. Most of the Family and Medical Leave Act. On April 3, 2017, the parties agreed to settle this matter. On February 1, 2018, the court granted preliminary approval of the settlement and set a fairness hearing for May 4, 2018. On June 29, 2018, the Court granted final approval of the settlement.these actions remain pending; however, Allergan has received favorable decisions in more than ten (10) such actions.

~~Aczone~~ ^® ~~Gel, 7.5%.~~Combigan In June and July 2017, Allergan, Inc. brought actions for infringement of U.S. Patent No. 9,517,219 (the “‘219 patent”) in the U.S. District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals, Inc. (collectively, “Taro”). Taro had notified Allergan in April and July 2017, that it filed an ANDA with the FDA seeking to obtain approval to market a generic version of Aczone^® Gel, 7.5% before the ‘219 patent expires in November 2033. These lawsuits triggered automatic stays of approval of Taro’s ANDA that expire no earlier than October 2019 and January 2020, respectively (unless there is a final court decision adverse to Plaintiff sooner). Trial has been tentatively scheduled for February 4, 2019.

~~Aczone~~^® ~~Gel, 7.5% IPR.~~ ~~Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, “Amneal”) filed a petition for~~ ~~Inter Partes~~ Review (Trial number IPR2018-00608) with the USPTO regarding U.S. Patent No. 9,161,926, which was accorded a filing date of February 12, 2018. On June 8, 2018, Allergan filed a Patent Owner Preliminary Response.

~~Bystolic~~^®. On ~~January 19, 2018, Allergan Sales, LLC, Allergan USA, Inc., and Forest Laboratories Holdings, Ltd. (collectively, “Allergan”) brought~~October 30, 2017, subsidiaries of the Company filed an action for infringement of U.S. Patent No. 6,545,040 in the United States District Court for the District of Delaware against Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd. (collectively, “Aurobindo”). Aurobindo had notified Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity) that Aurobindo had filed an ANDA with FDA seeking to obtain approval to market generic versions of Bystolic^® 2.5 mg, 5 mg, 10 mg, and 20 mg nebivolol hydrochloride tablet products before the ‘040 Patent expires in December 17, 2021. This lawsuit triggered an automatic stay of approval of Aurobindo’s ANDA that expires no earlier than June 2020 (unless there is a final court decision adverse to Plaintiffs sooner). No trial date or case schedule has been set.

Previously, the Company had asserted the ‘040 patent in actions against Actavis, Alkem, Amerigen, Glenmark, Hetero, Indchemie and Torrent, and related subsidiaries and affiliates thereof (collectively, “the Original Defendants”), and reached settlements terminating those actions. As previously announced, under the terms of the settlement agreements, the Company will provide licenses to each of the Original Defendants that will permit them to launch their generic versions of Bystolic as of the date that is the later of (a) three calendar months prior to the expiration of the ‘040 patent, including any extensions and/or pediatric exclusivities, or (b) the date each company receives final FDA approval of its ANDA, or earlier in certain circumstances.

~~Byvalson~~^®. On September 18, 2017, Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) brought an action for infringement of U.S. Patent Nos. 7,803,838Number 9,770,453 (the “‘838 patent”) and 7,838,552 (the “‘552 patent”) in the U.S. District Court for the District of New Jersey against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, “Prinston”). Prinston notified Forest that it filed an ANDA with the FDA seeking to obtain approval to market a generic version of Byvalson^® before the ‘838 and ‘552 patents expire. This lawsuit triggered an automatic stay of approval of the Prinston ANDA until February 2020 (unless a court issues a decision adverse to Forest sooner). No trial date or schedule has been set.

~~Combigan~~^® ~~II-III~~. On March 9, 2015, Allergan filed a complaint against Sandoz in the U.S. District Court for the Eastern District of Texas, Marshall Division, alleging that Sandoz’s proposed generic product infringes certain U.S. Patents including U.S. Patent Nos. 7,030,149 (the “149453 Patent”)~~, 7,320,976 (the “’976 Patent”), and 8,748,425 (the “’425 Patent”).~~

A bench trial concluded on October 27, 2016. On December 30, 2016, the court entered an opinion and final judgment in favor of Allergan and against Sandoz, that the asserted claims of the ‘149 Patent, ‘976 Patent and ‘425 Patent were not invalid, and that Sandoz infringes the asserted claims of the ‘425 Patent. The court also held in favor of Sandoz and against Allergan, that Sandoz does not infringe the asserted claims of the ‘149 and ‘976 Patents. Sandoz filed a notice of appeal and Allergan filed a notice of cross appeal. The Federal Circuit heard oral arguments on October 2, 2017 and on December 22, 2017, issued a decision affirming the district court’s finding of no invalidity of the asserted claims and non-infringement of the claims of the ‘149 and ‘976 Patents, and reversing the district court’s finding of infringement of claim 1 of the ‘425 Patent. On March 29, 2018, the Federal Circuit denied Allergan’s combined petition for panel rehearing or rehearing ~~en banc. The mandate was issued on April 4, 2018. On April 6, 2018,~~

~~Sandoz filed an unopposed motion to vacate the district court’s injunction orders. The district court vacated certain final judgments on June 6, 2018.~~

~~Combigan~~^® IV~~. On October 30, 2017, Allergan Sales, LLC and Allergan, Inc. (collectively, “Allergan”) filed a complaint~~ against Sandoz, Inc. and Alcon Laboratories, Inc. (“Sandoz”) in the U.S. District Court for the District of New Jersey, ~~alleging that their proposed~~in connection with the abbreviated new drug applications respectively filed with the FDA by Sandoz and Alcon, seeking approval to market a generic ~~versions~~version of Combigan^® ~~infringe U.S. Patent Number 9,770,453 (the “‘453 Patent”)~~. On March 6, 2018, ~~Allergan and Sandoz submitted a stipulation and proposed order to grant Allergan leave to file an amended complaint to assert additional claims of infringement of~~ U.S. Patent Nos. 9,907,801 (the “‘801 Patent”) and 9,907,802 (the “‘802 Patent”). were added to the case. The ‘453, ‘801 and ‘802 Patents are listed in the Orange Book for Combigan^®and expire on April 19, 2022. A trial date has not been set. On April 17, 2018, Sandoz filed an amended answer and counterclaims alleging non-infringement, invalidity, inequitable conduct, unclean hands and certain other antitrust counterclaims, including fraud on the U.S. Patent Office, sham litigation, abusive serial patent enforcement, and state monopolization claims. On May 22, 2018, Allergan filed a motion to dismiss Sandoz’s antitrust and inequitable conduct counterclaims (and to strike a related affirmative defense), or alternatively to bifurcate and stay Sandoz’s antitrust counterclaims. On July 13, 2018, the district court adopted Allergan’s proposed claim construction and granted Allergan’s motion for preliminary injunction against Sandoz. On ~~July 26,~~August 1, 2018, ~~Sandoz filed a notice of appeal regarding~~ the ~~claim construction and preliminary injunction.~~

~~Delzicol~~^®. On August 28, 2015, Warner Chilcott Company, LLC, Warner Chilcott (US), LLC, and Qualicaps Co., Ltd. (collectively, “Plaintiffs”) brought an action for infringement of U.S. Patent No. 6,649,180 (the “‘180 patent”) in the United States District Court for the Eastern District of Texas against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, “Teva”). Teva notified Plaintiffs that it has filed an ANDA with the FDA seeking to obtain approval to market generic versions of Delzicol^® before the ‘180 patent expires in April 2020. On November 9, 2015, Plaintiffs also brought an action for infringement of ‘180 patent in the United States District Court for the Eastern District of Texas against Mylan Pharmaceuticals, Inc., Mylan Laboratories Limited and Mylan, Inc. (collectively, “Mylan”). Mylan notified Plaintiffs that it has filed an ANDA with the FDA seeking to obtain approval to market generic versions of Delzicol^® ~~before the ‘180 patent expires in April 2020. In March 2016, the~~district court entered an order ~~consolidating~~setting a preliminary injunction bond in the ~~Mylan litigation (C.A. 2:15-cv-01740) with~~amount of $157,300,000 under Federal Rule of Civil Procedure 65(c), which Allergan posted. Sandoz has appealed the ~~Teva litigation (C.A. 2:15-cv-01471) matter as the lead case.~~

On April 1, 2016, Warner Chilcott Company, LLC, Warner Chilcott (US), LLC, Allergan Pharmaceuticals International Ltd., Allergan USA, LLC and Qualicaps Co., Ltd. (collectively, “Plaintiffs”) brought an action for infringementgrant of the ~~‘180 patent in~~injunction, and the ~~United States District Court for the Eastern District of Texas against Zydus International Pvt. Ltd., Zydus Pharmaceuticals (USA) Inc.~~appeal is ongoing.

Fetzima^®. In October and ~~Cadila Healthcare Ltd. (collectively, “Zydus”). Zydus notified the Company that it has filed an ANDA with the FDA seeking to obtain approval to market generic versions of Delzicol~~^® ~~before the ‘180 patent expires. On~~ November ~~28, 2016, Plaintiffs entered into a settlement agreement with Zydus. Under the terms~~2017, subsidiaries of the ~~settlement agreement, Zydus may launch its generic version of Delzicol~~^® ~~on March 1, 2020, or earlier under certain circumstances.~~

On April 21, 2017, Plaintiffs brought an action for infringement of the ‘180 patent in the United States District Court for the Eastern District of Texas against Teva Pharmaceuticals USA, Inc., which had notified Plaintiffs that, on or before March 9, 2017, it had amended its ANDA seeking to obtain approval to market generic versions of Delzicol^®. Teva also notified Plaintiffs that it had submitted to FDA a new paragraph IV certification for the ‘180 patent in connection with its ANDA. On August 7, 2017, Teva and Mylan filed motions for summary judgment of non-infringement, and Teva filed a motion for summary judgment for alleged improper Orange Book listing. On September 28, 2017, the Magistrate Judge issued a Report and Recommendation granting Teva’s and Mylan’s motions for summary on non-infringement and denying, as moot, Teva’s summary judgment motion concerning Orange Book listing. On October 24, 2017, the District Court adopted the Magistrate Judge’s recommendation as to non-infringement and issued final judgment on that issue. The District Court also ruled that defendants’ counterclaims be taken up after finality is achieved with respect to the non-infringement issue. On November 21, 2017, Plaintiffs filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit.

On December 18, 2017, Plaintiffs Allergan Sales, LLC and Qualicaps Co., Ltd. entered into a settlement agreement with Mylan and the actions with respect to Mylan were subsequently dismissed. Under the terms of the settlement agreement, Mylan may launch its generic version of Delzicol^® ~~on July 1, 2019, or earlier under certain circumstances.~~

~~Appeal briefing between Plaintiffs and Teva, the remaining defendant, was completed on May 8, 2018. A date for oral argument has not been set.~~

~~Fetzima~~^®. ~~In September and October 2017, certain Allergan subsidiaries~~Company and Pierre Fabre Medicament received Paragraph IV certification notice letters from Amneal Pharmaceuticals LLC, Aurobindo Pharma USA, Inc., MSN Laboratories Private Limited, Prinston Pharmaceutical Inc., Torrent Pharmaceuticals Limited, West-Ward Pharmaceuticals International Limited, and Zydus Pharmaceuticals (USA) Inc. indicating that they had submitted to FDA ANDAs seeking approval to manufacture and sell generic versionsS.A.S. brought actions for infringement of ~~FETZIMA~~^® ~~20 mg, 40 mg, 80 mg, and 120 mg extended release capsules (“FETZIMA”) before the expiration of the three patents listed in the Orange Book, including~~ U.S. Patent Nos. RE43,879 (the “‘879 Patent”); 8,481,598 (the “‘598 Patent”); and

8,865,937 (the “‘937 Patent”). against MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, “MSN”), Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC (collectively, “Prinston”), Torrent Pharmaceuticals Limited and Torrent Pharma Inc. (collectively, “Torrent”), West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp. (collectively, “West-Ward”), Zydus Pharmaceuticals (USA) Inc. (“Zydus”), Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited (collectively, “Aurobindo”), and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals Private Limited (collectively, “Amneal”), in connection with abbreviated new drug applications, respectively filed with the FDA by MSN, Prinston, Torrent, West-Ward, Zydus, Aurobindo, and Amneal, each seeking approval to market generic versions of Fetzima® and challenging said patents. The ‘879 Patent expires in June 2023 (not including a pending application for patent term extension (“PTE”)), the ‘598 patent expires in March 2031, and the ‘937 Patent expires in May 2032. ~~These generic ANDA filers claim~~The case is currently in ~~their respective notice letters that the ‘879 Patent, the ‘598 Patent~~fact discovery, and no trial date has been set. Allergan entered into a settlement agreement with Amneal on December 18, 2018, and the ~~‘937 Patent are invalid and/or would not be infringed.~~ case as against Amneal was dismissed.

~~On October 30, 2017, Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as~~In April 2019, subsidiaries of the ~~surviving entity) and Forest Laboratories Holdings Limited, Allergan USA, Inc.,~~Company and Pierre Fabre Medicament S.A.S. ~~(collectively, “Forest”)~~ brought an action for infringement of the ‘879, ~~Patent, the~~ ‘598 ~~Patent~~ and ~~the~~ ‘937 ~~Patent~~Patents against ~~MSN Laboratories Private Limited~~Micro Labs Ltd. and ~~MSN Pharmaceuticals~~Micro Labs USA, Inc. ~~(collectively, “MSN”~~(“Micro”) in connection with Micro’s abbreviated new drug application seeking approval to market a generic version of Fetzima^® and challenging said patents. No trial date has been set.

Juvéderm ^®. On ~~October 31, 2017, Forest brought actions~~February 26, 2019, subsidiaries of the Company filed a complaint for infringement of U.S. Patent Nos. 8,450,475 (the “‘475 Patent), 8,357,795 (the “‘795 Patent”), 8,822,676 (the “‘676 Patent”), 9,089,519 (the “‘519 Patent”), 9,238,013 (the “‘013 Patent”) and 9,358,322 (the “‘322 Patent”) in the ~~‘879 Patent,~~U.S. District Court for the ~~‘598 Patent, and the ‘937 Patent~~District of Delaware against ~~Prinston Pharmaceutical~~Prollenium US Inc. and ~~Solco Healthcare U.S., LLC (collectively, “Prinston”), Torrent Pharmaceuticals Limited and Torrent Pharma~~Prollenium Medical Technologies Inc. (collectively, ~~“Torrent”~~“Prollenium”)~~, West-Ward Pharmaceuticals International Limited~~. The complaint seeks, among other things, a judgment that Defendants have infringed these patents by making, selling, offering to sell, and ~~West-Ward Pharmaceuticals Corp. (collectively, “West-Ward”),~~importing Prollenium’s Revanesse® Versa+TM product within and ~~Zydus Pharmaceuticals (USA) Inc. (“Zydus”)~~into the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement. No trial date has been set.

Kybella^®. On November ~~15, 2017, Forest~~9, 2018, a subsidiary of the Company brought ~~actions~~an action for infringement of ~~the ‘879~~U.S. Patent ~~the ‘598 Patent~~Nos. 8,101,593 (the “‘593 Patent”), 8,367,649 (the “‘649 Patent”) and ~~the ‘937 Patent~~8,653,058 (the “‘058 Patent”) against ~~Aurobindo~~Slayback Pharma ~~USA, Inc. and Aurobindo Pharma Limited (collectively, “Aurobindo”), and Amneal Pharmaceuticals~~ LLC ~~and Amneal Pharmaceuticals Private Limited (collectively, “Amneal”~~(“Slayback”)~~. Each of these lawsuits were brought~~ in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with the FDA by Slayback seeking approval to market a generic version of Kybella® and ~~triggered automatic stays of approval~~challenging said patents. The ‘593, ‘649, and ‘058 Patents expire in March 2030. On April 10, 2019, a subsidiary of the ~~ANDAs until January 2021 (unless there is a final court decision adverse to Forest sooner)~~Company, together with Los Angeles Biomedical Research Institute at Harbor UCLA-Medical Center (“LA BioMed”) and The Regents of the University of California (the “Regents”) (all collectively, “Plaintiffs”), filed an amended complaint against Slayback asserting infringement of the ‘593, ‘649 and ‘058 Patents and U.S. Patent Nos. 7,622,130 (the “‘130 Patent”), 7,754,230 (the “‘230 Patent”), 8,298,556 (the “‘556 Patent”) and 8,846,066 (the “‘066 Patent”).

InThe ‘130 and ‘230 Patents expire in December ~~2017~~2027 (not including pending applications for patent term extension (“PTE”)), the ‘556 Patent expires in August 2025, and ~~January 2018 MSN, Torrent, West-Ward, Zydus, and Amneal filed answers and counterclaims, and Prinston and Aurobindo filed answers,~~the ‘066 Patent expires in ~~their respective actions. In January 2018 Forest filed answers to MSN, Torrent, West-Ward and Zydus’s counterclaims. On~~ February ~~8, 2018, the district court consolidated the MSN, Prinston, Torrent, West-Ward, Zydus, Aurobindo and Amneal actions.~~2025. No trial date has been set.

~~Juvéderm~~Latisse^® ~~XC IPRs.~~ ~~On August 2, 2017, Teoxane S.A. (“Teoxane”) filed a petition for~~ IV~~Inter Partes~~ ~~Review (Trial number IPR2017-01906) with the USPTO regarding U.S. Patent No. 8,357,795. And on August 24, 2017, Teoxane filed a petition for~~ ~~Inter Partes~~ ~~Review (Trial Number IPR2017-02002) with the USPTO regarding U.S. Patent Number 8,450,475. On March 9, 2018, the USPTO denied institution of both Teoxane IPRs.~~

~~Lastacaft~~^®. In July 2017, the Company and Vistakon Pharmaceuticals, LLC received a Paragraph IV certification notice letter from Aurobindo Pharma USA Inc. (“Aurobindo”) indicating that it had submitted to FDA an ANDA seeking approval to manufacture and sell a generic version of LASTACAFT^® (“LASTACAFT”) before the expiration of U.S. Patent No. 8,664,215 (the “‘215 Patent) listed in the Orange Book. The ‘215 Patent expires December 2027. Aurobindo claims that the patent listed in its notice letter is invalid, unenforceable and/or would not be infringed. On September 8, 2017, Allergan, Inc. and Vistakon Pharmaceuticals, LLC (collectively, “Plaintiffs”), brought an action for infringement of the ‘215 Patent in the U.S. District Court for the District of Delaware against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. and Auromedics Pharma LLC (collectively, “Defendants”). This lawsuit triggered an automatic stay of approval of the applicable ANDA that expires no earlier than January 2020 (unless there is a final court decision adverse to Plaintiffs sooner). Trial has been scheduled for July 2019.

~~Latisse~~^® IV. In December 2016, Sandoz announced the U.S. market launch of ~~Defendants’~~its generic copy of ~~LATISSE~~Latisse^®. In July 2017, ~~Plaintiffs Allergan~~subsidiaries of the Company and Duke University (collectively, “Plaintiffs”) filed a complaint for infringement of U.S. Patent Number 9,579,270 (“‘270 Patent”) against Defendants Sandoz Inc. (“Sandoz”) and Alcon Laboratories, Inc. (“Alcon”) in the U.S. District Court for the Eastern District of Texas (EDTX). ~~(The~~The ‘270 patent expires in January 2021.) In their complaint, Plaintiffs seek, among other things, a judgment that Defendants have infringed the ‘270 patent by making, selling, and offering to sell, and/or importing, their generic copy of ~~LATISSE~~Latisse^® within the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement.

On April 3, 2018, the EDTX court issued an ~~order: (i) denying Defendant’s motion to transfer the case to MDNC, and (ii)~~order, among other things, severing Plaintiff’s claims against Defendants and transferring Plaintiff’s claims against Alcon to the District Court of Delaware and Plaintiff’s claims against Sandoz to the District of Colorado. NoOn October 5, 2018, the Delaware District Court entered an order dismissing the Delaware action against Alcon. The District of Colorado case ~~schedule~~against Sandoz is currently in fact discovery and a trial date has not yet been set.

Latisse^® V. ~~In August~~On September 25, 2017, subsidiaries of the Company and Duke University received a Paragraph IV certification notice letter from Alembic Pharmaceuticals, Ltd. (“Alembic”) indicating that it had submitted to FDA an ANDA seeking approval to manufacture and sell a generic version of LATISSE^® (“LATISSE”) before the expiration of U.S. Patent Nos. 8,038,988 (the “‘988 Patent”), 8,101,161 (the “‘161 Patent”), 8,263,054 (the “‘054 Patent”), 8,541,466 (the “‘466 Patent”), 8,632,760 (the “‘760 Patent”), 8,758,733 (the “‘733 Patent”), 8,906,962 (the “‘962 Patent”), 8,986,715 (the “‘715 Patent”), 9,216,183 (the “‘183” Patent), 9,226,931 (the “‘931 Patent) and 9,579,270 (the “‘270 Patent”). (The ‘466, ‘962 and ‘270 Patents expire in January 2021; the ‘054, ‘760, ‘733, ‘715, ‘183, and ‘931 Patents expire in January 2023; the ‘988 Patent expires in August 2023; and the ‘161 Patent expires in May 2024). Alembic claims that the patents listed in its notice letter are invalid, unenforceable and/or would not be infringed. On September 25, 2017, Allergan, Inc., Allergan Sales, LLC and Duke University (collectively, “Plaintiffs”), brought an action for infringement of ~~the ‘270~~U.S. Patent ~~in the U.S. District Court for the District of New Jersey~~No. 9,579,270 (the “‘270 Patent”) against Alembic Pharmaceuticals, Ltd., Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. (collectively, “Alembic”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Alembic, seeking approval to market a generic version of Latisse^® and challenging the ‘270 patent. The Company subsidiaries and Duke entered into a settlement agreement with Alembic and the case was dismissed on April 4, 2019.

Latisse^® VI. ~~This lawsuit triggered an automatic stay of approval~~On September 19, 2018, subsidiaries of the ~~applicable ANDA that expires no earlier than February 2020 (unless there is~~Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Akorn, Inc. and Hi-Tech Pharmacal Co., Inc. (collectively, “Akorn”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Akorn seeking approval to market a ~~final court decision adverse to Plaintiffs sooner).~~generic version of Latisse® and challenging the ‘270 patent. No trial date has been set.

Linzess^®. Beginning in ~~In October and~~ November 2016 subsidiaries of the Company and Ironwood ~~received Paragraph IV certification notice letters from Teva Pharmaceuticals USA, Inc. (“Teva”) , Aurobindo Pharma Ltd., Mylan~~ Pharmaceuticals, Inc. ~~(“Mylan”~~(collectively, “Plaintiffs”), ~~and Sandoz Inc. (“Sandoz”) indicating that they had submitted to FDA ANDAs seeking approval to manufacture and sell generics version of LINZESS~~^® ~~145 mcg and 290 mcg capsules (“LINZESS”) before the expiration~~brought multiple actions for infringement of some or all of ~~the nine patents then listed in the Orange Book, including~~ U.S. Patent Nos. 7,304,036 (the “‘036 Patent”); 7,371,727 (the “‘727 Patent”); 7,704,947 (the “‘947 Patent”); 7,745,409 (the “‘409 Patent”); 8,080,526 (the “‘526 Patent”); 8,110,553 (the “‘553 Patent”); 8,748,573 (the “‘573 Patent”); 8,802,628 (the “‘628 Patent”); and 8,933,030 (the “‘030 Patent”) against Teva Pharmaceuticals USA, Inc. (“Teva”), Aurobindo Pharma Ltd. (“Aurobindo”), Mylan Pharmaceuticals Inc. (“Mylan”), Sandoz Inc. (“Sandoz”) and Sun Pharma Global FZE (“Sun”) in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva, Aurobindo, Mylan, Sandoz and Sun, each seeking approval to market generic versions of Linzess^® 145 mcg and 290 mcg capsules and challenging some or all of said patents (“November 2016 Action”). ~~(The~~The ‘727, ‘947, ‘409, ‘526 and ‘553 Patents expire in January 2024; the ‘036 Patent expires in August 2026; and the ‘573, ‘628 and ‘030 Patents expire in 2031.~~) Teva, Aurobindo Pharma Ltd., Mylan and Sandoz claim that~~ In the ~~patents discussed in their respective notice letters are invalid, unenforceable and/or would not be infringed. On~~ November ~~30,~~ 2016 Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity), Forest Laboratories Holdings, Ltd., Allergan USA, Inc. and Ironwood Pharmaceuticals, Inc. (collectively, “Plaintiffs”), brought an action for infringement of some or all of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘573, ‘628 and ‘030 Patents in the U.S. District Court for the District of Delaware against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. (collectively, “Aurobindo”), Teva, Mylan and Sandoz. This lawsuit triggered an automatic stay of approval of the applicable ANDAs that expires no earlier than February 2020 (unless there is a final court decision adverse to Plaintiffs sooner).Action, expert discovery has been completed. Trial is scheduled for June 2019. ~~On July 13, 2017, Mylan filed a motion to dismiss for improper venue. That motion is currently pending.~~

In May 2017, the Company and Ironwood also received a Paragraph IV certification notice letter from Sun Pharma Global FZE indicating that it had submitted to FDA an ANDA seeking approval to manufacture and sell a generic version of LINZESS before the expiration of the ‘573, ‘628 and ‘030 Patents. Sun Pharma Global FZE claims that the patents are invalid and/or would not be infringed. On June 30, 2017, Plaintiffs brought an action for infringement of the ‘573, ‘628 and ‘030 Patents in the U.S. District Court for the District of Delaware against Sun Pharma Global FZE and Sun Pharmaceutical Industries Inc. (collectively, “Sun”). In January 2018, Allergan and Ironwood entered into a settlement agreement with Sun and certain Sun affiliates. Under the terms of the settlement agreement, Plaintiffs will provide a license to Sun to market a generic version of LINZESS in the United States beginning on February 1, 2031 (subject to U.S. FDA approval), or earlier in certain circumstances. The Sun action was dismissed on January 18, 2018.

In July 2017, the Company and Ironwood received a second Notice Letter relating to the ANDA submitted to the FDA by Aurobindo. Aurobindo claims that the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553 Patents, as well as the ‘573, ‘628 and ‘030 Patents, are invalid and/or would not be infringed. On August 25, 2017, Plaintiffs brought an action for infringement of these patents in the U.S. District Court for the District of Delaware against Aurobindo. On September 28, 2017, this action was consolidated with the first action filed against Aurobindo. On April 30, 2018, Allergan and Ironwood entered into a settlement agreement with Aurobindo. Under the terms of the settlement agreement, Plaintiffs will provide a license to Aurobindo to market a generic version of LINZESS in the United States beginning on August 5, 2030 (subject to U.S. FDA approval), or earlier in certain circumstances. The Aurobindo actions were dismissed on May 7, 2018.

In September 2017, October 2017 and January 2018, the Company and Ironwood received second Notice Letters relating to the ANDAs submitted to the FDA by Teva, Mylan and Sandoz, respectively. Teva, Mylan and Sandoz claim that U.S. Patent No. 9,708,371 (the “‘371 Patent”) is invalid and/or would not be infringed by their respective ANDAs. (The ‘371 Patent expires in 2033.) On October 20, 2017, November 30, 2017 and January 20, 2018, Plaintiffs brought actions for infringement of ~~the ‘371 patent~~U.S. Patent No. 9,708,371 (the “‘371 Patent”) in the U.S. District Court for the District of Delaware against Teva, Mylan and Sandoz, respectively. The ~~actions filed~~‘371 Patent expires in ~~October and November 2017 against Teva and Mylan~~2033. The ‘371 patent actions have been consolidated with the ~~lawsuit filed in~~ November ~~2016.~~ 2016 Action.

In December 2017 and February 2018, the Company and Ironwood received Paragraph IV certification notice letters from Teva and Mylan, respectively indicating that they had submitted to FDA ANDAs seeking approval to manufacture and sell generic versions of LINZESS^® 72 mcg capsules (“72 mcg ANDA”) before the expiration of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘030 and ‘371 Patents. Teva and Mylan claim that these patents are invalid, unenforceable and/or would not be infringed. On February 2, 2018 and March 29, 2018, ~~Forest Laboratories Holdings, Ltd., Allergan USA, Inc., Allergan Sales, LLC and Ironwood Pharmaceuticals, Inc. (collectively, “Plaintiffs”),~~Plaintiffs brought actions for infringement of some or all of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘030 and ‘371 Patents against Teva and Mylan in the U.S. District Court for the District of Delaware ~~against~~in connection with abbreviated new drug applications respectively filed with the FDA by Teva and Mylan, ~~respectively. These lawsuits triggered automatic stays~~each seeking approval to market generic versions generic versions of ~~approval of Teva’s~~Linzess^® 72 mcg ~~ANDA and Mylan’s~~ capsules (“72 mcg ~~ANDA that expire no earlier than June 2020 and August 2020, respectively (unless there is a final court decision adverse to Plaintiffs sooner). On March 14, 2018,~~ANDA”) before the expiration said patents. The district court consolidated the ~~Teva~~ 72 mcg ANDA ~~matter~~actions with the ~~lawsuit filed in~~ November ~~2016.~~ 2016 Action.

In May and August 2018, the district court granted joint stipulations and orders to dismiss without prejudice all claims, counterclaims, and defenses in the ~~consolidated actions~~November 2016 Action with respect to the ‘371 ~~patent~~Patent and the ‘030 Patent, respectively, as between Plaintiffs, Teva, Mylan and Sandoz.

On ~~July 10,~~September 4, 2018, Plaintiffs filed ~~a motion~~an amended complaint as to ~~dismiss all claims and declaratory judgment counterclaims between Plaintiffs and~~ Mylan ~~with respect~~ to assert the ~~‘371~~‘628 patent ~~for lack of subject matter jurisdiction.~~

~~Namenda XR~~^®. Between January and October 2014, Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd. (collectively, “Forest”) and Merz Pharma and Adamas Pharmaceuticals, Forest’s licensors for Namenda XR^® (all collectively, “Plaintiffs”), brought actions for infringement of some or all of U.S. Patent Nos. 5,061,703 (the “‘703 patent”), 8,039,009 (the “‘009 patent”), 8,168,209 (the “‘209 patent”), 8,173,708 (the “‘708 patent”), 8,283,379 (the “‘379 patent”), 8,329,752 (the “‘752 patent”), 8,362,085 (the “‘085 patent”), and 8,598,233 (the “‘233 patent”) in the U.S. District Court for the District of Delaware against Wockhardt, Teva, Sun, Apotex, Anchen, Zydus, Watson, Par, Mylan, Amneal, Ranbaxy, and Amerigen, and related subsidiaries and affiliates thereof. Plaintiffs entered settlement agreements with every defendant except Teva.Mylan’s 72 mcg ANDA product.

On July 26, 2016, the district court entered a final judgment of invalidity of claim 1 of the ‘209 patent, claims 1, 6, 10 and 15 of the ‘708 patent, claim 1 of the ‘379 patent, claims 1 and 9 of the ‘752 patent, claims 1 and 7 of the ‘085 patent and claim 1 of the ‘233 patent in favor of Teva, and Plaintiffs appealed. On December 11, 2017, the Court of Appeals for the Federal Circuit issued a decision affirming the district court’s judgment of invalidity with respect to certain claims of the ‘209, ‘708, ‘379, ‘752 and ‘085 patents. On February 12, 2018, the Federal Circuit denied Plaintiffs petitions for panel rehearing and rehearing ~~en banc~~.

Previously, on September 29, 2016, the Company issued a press release following announcement of ANDA approvals, including FDA final approval by Lupin which stated that if the district court ruling is upheld on appeal to the U.S. Court of Appeals for the Federal Circuit, there is a possibility that generic entry for Namenda XR could occur following an adverse decision. The Federal Circuit issued the mandate of the court on February 20, 2018, and certain generics launched the generic products shortly thereafter.

~~Namzaric~~^®. On August 27, 2015, Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity), Forest Laboratories Holdings, Ltd. and Adamas Pharmaceuticals, Inc. (all collectively, “Plaintiffs”), brought an action for infringement of some or all of U.S. Patent Nos. 8,039,009 (the “’009 patent”), 8,058,291 (the “‘291 patent”), 8,168,209 (the “‘209 patent”), 8,173,708 (the “‘708 patent”), 8,283,379 (the “‘379 patent”), 8,293,794 (the “‘794 patent”), 8,329,752 (the “‘752 patent”), 8,338,485 (the “‘485 patent”), 8,338,486 (the “‘486 patent”), 8,362,085 (the “‘085 patent”), 8,580,858 (the “‘858 patent”) and 8,598,233 (the “‘233 patent”) in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc., and related subsidiaries and affiliates thereof. On October 23, 2015, the Company also brought an action for infringement of the ‘009, ‘291, ‘209, ‘708, ‘379, ‘794, ‘752, ‘485, ‘486, ‘085, ‘858 and ‘233 patents in the U.S. District Court for the District of Delaware against Amerigen Pharmaceuticals, Inc. and Amerigen Pharmaceuticals Ltd. (collectively, “Amerigen”). The Company entered into a settlement agreement with Par on April 29, 2016. On August 30, 2016, Plaintiffs entered into a settlement agreement with ~~Amneal, who is believed to be a first applicant with respect to~~Sun and certain ~~dosage strengths (memantine hydrochloride extended-release~~Sun affiliates and ~~donepezil hydrochloride, 14 mg/10 mg and 28 mg/10 mg) of Namzaric~~^®~~. Under~~ the terms of the agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Plaintiffs will provide a license to Amneal that will permit it to launch its generic version of Namzaric^® ~~as of January 1, 2025, or earlier in certain circumstances. Alternatively, under certain circumstances, Amneal has an option to launch an authorized generic version of Namzaric beginning~~case against Sun was dismissed on January ~~1, 2026. On October 21, 2016,~~18, 2018. Plaintiffs entered into a settlement agreement with ~~Amerigen,~~Aurobindo and the case against Aurobindo was ~~dismissed.~~

On November 10, 2016, the Company also brought an action for infringement of the ‘009, ‘291, ‘485, ‘486, and ‘858 patents in the U.S. District Court for the District of Delaware against Apotex Corp and Apotex Inc. (“Apotex”). On April 10, 2017,dismissed on May 7, 2018. Plaintiffs entered into a settlement agreement with ~~Apotex,~~Mylan and the case against Mylan was ~~dismissed.~~

~~On June 2, 2017,~~dismissed on December 27, 2018. Under the ~~Company and Adamas Pharma, LLC brought an action for infringement~~terms of the ‘009, ‘291, ‘485, ‘486, and ‘858 patents in the U.S. District Court for the District of Delaware against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (collectively, “Macleods”). On March 9, 2018, the Company entered into a settlement agreement, ~~with Macleods with respect~~Plaintiffs will provide a license to ~~Macleods’ proposed~~Mylan to market its generic versions of ~~Namzaric~~Linzess^® 145 mcg and ~~the case was dismissed.~~

~~Rapaflo~~^®. On June 17, 2013, Actavis, Inc., now known as Allergan Finance, LLC., Watson Laboratories, Inc., (collectively, “Actavis”) and Kissei Pharmaceutical Co., Ltd. (“Kissei”) sued Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited, Unit 3 (collectively, “Hetero”)290 mcg in the United States ~~District Court for the District of Delaware, alleging that sales of silodosin tablets, a~~beginning on February 5, 2030 (subject to FDA approval), and its generic version of ~~Actavis’ Rapaflo~~Linzess^® ~~tablets, would infringe U.S. Patent No. 5,387,603 (the “‘603 patent”). On June 17, 2013 Actavis and Kissei sued Sandoz Inc. (“Sandoz”)~~72 mcg in the United States ~~District Court for the District of Delaware, alleging that sales of Sandoz’s generic version of Rapaflo~~^®would infringe the ‘603 patent. On December 22, 2014, the Parties completed a settlement agreement with Hetero. On April 13, 2017, the Sandoz action was dismissed pursuant to a settlement agreement.

Onbeginning on August ~~18, 2017, Allergan Finance, LLC, Allergan Sales, LLC and Kissei Pharmaceutical Co., Ltd. (collectively, “Plaintiffs”), brought an action for infringement of the ‘603 Patent~~5, 2030, or earlier in the U.S. District Court for the District of Delaware against Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., and Aurobindo Pharma USA LLC (collectively, “Aurobindo”). This lawsuit triggered an automatic stay of approval of the applicable ANDA through to patent expiration (unless there is a final court decision adverse to Plaintiffs sooner). On April 20, 2018, this matter was dismissed without prejudice. certain circumstances.

Restasis^®. Between August 2015 and July 2016, ~~Allergan~~a subsidiary of the Company brought actions for infringement of U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”) and 9,248,191 (the “’191 patent”) in the U.S. District Court for the Eastern District of Texas against Akorn, Inc., Apotex, Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., InnoPharma, Inc., Famy Care Limited (“Famy Care”), TWi Pharmaceuticals, Inc. (“TWi”) and related subsidiaries and affiliates thereof.

~~Allergan~~The subsidiary entered into settlement agreements with Apotex, TWi, Famy Care and InnoPharma. As a result of certain of these settlements, Allergan will provide a license to certain parties to launch their generic versions of Restasis^® beginning on February 27, 2024, or earlier in certain circumstances. Additionally, under certain circumstances, ~~Allergan~~the Company will supply and authorize certain parties to launch an authorized generic version of ~~Restasis~~^®Restasis® on August 28, ~~2024.~~2024 or earlier in certain circumstances.

On September 8, 2017, ~~Allergan~~the Company assigned all Orange Book-listed patents for Restasis^®to the Saint Regis Mohawk Tribe (“the Tribe”), a recognized sovereign tribal government, and concurrently was granted an exclusive field-of-use license to practice the patents in the United States for all FDA-approved uses of the products under the ~~Restasis~~^®Restasis® NDAs. ~~On October 13, 2017, Allergan filed an opposed motion to join the Tribe as a co-plaintiff in the pending action against Teva, Mylan and Akorn.~~

On October 16, 2017, the District Court issued a decision and final judgment finding that the asserted claims of the ‘111 patent, the ‘048 patent, the ‘930 patent and the ‘191 patent were infringed, but invalid on the ground of obviousness. The District Court also held that the asserted claims were not invalid as anticipated, for lack of enablement, or for improper inventorship. ~~In a separate Order, the District Court joined the Tribe as a co-plaintiff under Federal Rule of Civil Procedure 25(c) and declined to rule on the validity of the patent assignment to the Tribe.~~ On ~~October 27, 2017, Plaintiffs filed a notice of appeal to~~November 13, 2018, the U.S. Court of Appeals for the Federal ~~Circuit. No oral argument date has been set.~~Circuit issued a decision affirming the district court’s finding of invalidity of the asserted claims of the ‘111, ‘048, ‘930 and ‘191 Patents. On March 6, 2019, the Federal Circuit denied Allergan and the Tribe’s petition for rehearing, and a mandate issued on March 13, 2019. On April 10, 2019, Allergan and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court.

On December 22, 2016, a subsidiary of the Company Allergan filed a complaint for infringement of the ~~ʼ111~~’111 patent, ~~ʼ162~~’162 patent, ~~ʼ556~~’556 patent, ~~ʼ048~~’048 patent, ~~ʼ930~~’930 patent, and the ~~ʼ191~~’191 patent in the U.S. District Court for the Eastern District of Texas against Deva Holding A.S. (“Deva”). On March 6, 2018, the district court granted in part and denied in part the parties’ joint motion for entry of a stipulated order, and stayed the case until such time as the Federal Circuit in the lead appeal case with Teva, Mylan and Akron issues a mandate. The parties’ stipulation provides that Deva will be bound by the outcome of that appeal.

Restasis^® ~~IPR.~~IPR. On June 6, 2016, ~~Allergan, Inc.~~a subsidiary of the Company received notification letters that Inter Partes Review of the USPTO (“IPR”) petitions were filed by Mylan Pharmaceuticals Inc. (“Mylan”) regarding U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”), and 9,248,191 (the “‘191 patent”), which patents expire on August 27, 2024. Mylan filed the IPR petition on June 3, 2016. On June 23, 2016, ~~Allergan~~a subsidiary of the Company received a notification letter that aan IPR petition and motion for joinder was filed by Argentum Pharmaceuticals LLC (“Argentum”) regarding the ’111 patent. On December 7, 2016, ~~Allergan~~the Company entered into a settlement agreement with Argentum and Argentum’s petition was withdrawn. On December 8, 2016, the USPTO granted Mylan’s petitions to institute IPRs with respect to these patents. On January 6, 2017, each of Akorn ~~Famy Care~~ and Teva filed, and on January 9, 2017 the USPTO received, IPR petitions with respect to these patents and motions for joinder with the Mylan IPR. The USPTO granted Teva’s and Akorn’s joinder motions on March 31, 2017. On April 27, 2017, the USPTO decided not to join Famy Care as a petitioner to the earlier-filed IPR petitions. On July 10, 2017, the USPTO denied Famy Care’s motion for joinder with the IPRs instituted in December 2016, and on July 10 and 12, 2017, granted Famy Care’s petitions to institute IPRs with respect to these same patents. On July 28, 2017, the USPTO rescheduled the hearing for September 13, 2017.

On September 8, 2017, Allergan assigned all Orange Book-listed patents for Restasis^®to the Saint Regis Mohawk Tribe (“the Tribe”), a recognized sovereign tribal government, and concurrently was granted an exclusive field-of-use license to practice the patents in the United States for all FDA-approved uses of the products under the Restasis^® NDAs. That same day, the Tribe filed an updated Mandatory Notice with the USPTO to reflect that the Tribe is the patent owner, and sought permission to file a motion to dismiss based on tribal sovereign immunity. During a September 11, 2017 teleconference, the USPTO postponed the September 13, 2017 hearing and set a briefing schedule on the Tribe’s motion to dismiss. The Tribe filed its opening brief on September 22, 2017, Petitioners filed their opposition brief on October 13, 2017, and the Tribe filed its reply brief on October 20, 2017. On October 4, 2017, the USPTO denied Mylan’s request for authorization to file a motion for additional discovery, and denied without prejudice Allergan’s counsel’s request to withdraw from the IPR proceedings. On November 3, 2017, the USPTO issued an order that (a) granted a motion by High Tech Inventors Alliance requesting authorization to file a brief as ~~amicus curiae~~ ~~on the issues presented in the Tribe’s motion to terminate, (b) permitted any other~~ ~~amicus curiae~~ wishing to file a brief related to the Tribe’s motion to terminate to do so, (c) permitted the parties to file a single response to any amicus briefs, (d) denied without prejudice Allergan’s counsel’s renewed request for authorization to file a motion to withdraw as counsel, and (e) adjusted the time to enter a final written decision in these proceedings to April 6, 2018. On November 29, 2017, the USPTO granted Patent Owner’s motions to seal certain portions of certain exhibits. Between December 1 and December 4, 2017, amicus briefs were submitted on behalf of Petitioners and Patent Owner, which both filed responses on December 15, 2017.

On December 21, 2017, Allergan’s counsel renewed its request to file a motion to withdraw on the ground that, as of September 8, 2017, Allergan ceased to be an owner of the six patents involved in the IPR proceedings. On January 2, 2018, the USPTO authorized Allergan to file a motion to withdraw. Allergan filed its motion on January 9, 2018, and Petitioners filed its opposition on January 17, 2018. On December 22, 2017, the USPTO granted Petitioners’ request to file supplemental briefing limited to addressing the issue of litigation waiver discussed in the USPTO’s recent ~~LSI~~ ~~and~~ ~~Ericsson~~ ~~decisions. Petitioners and Patent Owner filed their supplemental briefs on January 5, and January 12, 2018, respectively.~~

On January 2, 2018, the Tribe filed a Request for Oral Hearing pursuant to 37 C.F.R. § 42.70(a) seeking certain discovery concerning the identity and impartiality of the merits panel assigned to this IPR. On January 4, 2018, the USPTO issued an order (a) denying the Tribe’s request for oral hearing, (b) denying the Tribe’s request for authorization to file a motion for additional discovery, (c) ordering the Tribe not to make any further requests for additional discovery directed to the Board in the IPR proceedings, and (d) ordering the Tribe not to file any further papers in the IPR proceedings without prior authorization from the Board. On January 9, 2018, Allergan filed a motion to withdraw from the IPRs on the ground that Allergan ceased to be the patent owner.

On February 23, 2018, the USPTO issued orders denying the Tribe’s motion to dismiss (or terminate), denying Allergan’s motion to withdraw, setting a rescheduled hearing date for April 3, 2018, and setting a deadline to issue final written decisions by June 8, 2018. On February 28, 2018, the Tribe and Allergan filed a combined notice of appeal..

On March 8, 2018, the Tribe and Allergan filed a motion concerning the PTAB’s divested jurisdiction or, in the alternative, for a stay pending the appeal. On March 22, 2018, the USPTO issued an order denying the motion.

~~On March 16, 2018, the Tribe and Allergan filed with the Federal Circuit a motion to stay the IPR proceedings pending review of their February 28, 2018 appeal.~~

~~On March 26, 2018, the Federal Circuit issued an order~~ ~~sua sponte~~ expediting the briefing and argument schedule on the merits of the appeal. On March 28, 2018, the Federal Circuit granted the Tribe and Allergan’s motion to stay the IPR proceedings. The stay remains in effect until the day after oral argument in the appeals in June 2018, at which time the Federal Circuit will address whether the stay shall remain in effect or whether it will be lifted. The parties’ appeal briefing was completed on May 18, 2018. Oral argument was held on June 4, 2018. On July 20, 2018, the Federal Circuit affirmed the USPTO’s denial of the Tribe’s motion to dismiss and Allergan’s motion to withdraw. On August 20, 2018, the Tribe and Allergan filed a petition for rehearing en banc, which the Federal Circuit denied on October 22, 2018. On December 21, 2018, the Company and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court, which was denied on April 15, 2019.

Saphris^®. Between September 2014 and May 2015, ~~Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as~~subsidiaries of the ~~surviving entity), and Forest Laboratories Holdings Ltd. (collectively, “Forest”)~~Company brought actions for infringement of some or all of U.S. Patent Nos. 5,763,476 (the “‘476 patent”), 7,741,358 (the “‘358 patent”) and 8,022,228 (the “‘228 patent”) against Sigmapharm Laboratories, LLC (“Sigmapharm”), Hikma Pharmaceuticals, LLC (“Hikma”), Breckenridge Pharmaceutical, Inc. (“Breckenridge”), Alembic Pharmaceuticals, Ltd. (“Alembic”) and Amneal Pharmaceuticals, LLC (“Amneal”), and related subsidiaries and affiliates thereof in the U.S. District Court for the District of Delaware ~~against~~in connection with an abbreviated new drug applications respectively filed with FDA by Sigmapharm, ~~Laboratories, LLC,~~ Hikma, ~~Pharmaceuticals, LLC,~~ Breckenridge, ~~Pharmaceutical, Inc.,~~ Alembic ~~Pharmaceuticals, Ltd.~~ and Amneal, ~~Pharmaceuticals, LLC,~~each seeking approval to market a generic versions of Saphris^® and ~~related subsidiaries and affiliates thereof.~~challenging each of said patents. Including a 6-month pediatric extension of regulatory exclusivity, the ‘476 patent expires in December 2020, and the ‘358 and ‘228 patents expire in October 2026. ~~On September 30, 2015, the District Court consolidated all pending actions. On March 28,~~In 2016, the ~~court entered Forest and Hikma’s proposed joint stipulation and order of adverse judgment and dismissal of~~parties agreed to dismiss all claims related to the ‘358 and ‘228 ~~patents. In April 2016, the court granted the proposed consent judgment of non-infringement and order of dismissal of counterclaims related to the ‘358 and ‘228~~ patents, as well as a stipulation and order with respect to infringement of Claims 1, 2, and 6 of the ʼ476 patent, between Plaintiffs and Breckenridge. The Court also granted the proposed stipulation of entry and proposed order of adverse judgment and dismissal of counterclaims related to the ʼ358 and ʼ228 patents between Plaintiffs and Sigmapharm. In April, May and July 2016, the court granted the proposed stipulations and orders of infringement of certain claims ofleaving only the ‘476 patent ~~as to Hikma, Breckenridge and Alembic.~~at issue. On October 13, 2016, the court stayed trial as to Sigmapharm and extended the 30-month stay as to Sigmapharm. ~~Trial with respect to the ‘476 patent, the only remaining patent-in-suit, concluded on November 3, 2016.~~ On June 30, 2017, the district court issued an opinion and order finding all asserted claims of the ‘476 patent valid, that claims 1, 2, 5 and 6 were infringed by Alembic, Amneal, Breckenridge and Hikma, and that claims 4, 9 and 10 were not infringed by Alembic and Breckenridge. On July 11, 2017, the district court entered a final judgment that ordered, among other things, that Alembic’s, Amneal’s, Breckenridge’s and Hikma’s respective ANDAs not be granted final approval by FDA earlier than the date of expiration of the ‘476 patent inclusive of any applicable adjustments, extensions or exclusivities. The case is currently on appeal.

On March 14, 2019, the Federal Circuit vacated the district court’s July ~~28,~~ 2017 ~~Alembic, Amneal, Breckenridge~~judgment that claims 1 and ~~Hikma (the “Appeal Defendants”) filed notices of appeal.~~4 are not invalid and remanded for the district court to consider a fact question and its impact on the obviousness analysis. On ~~August 9, 2017,~~April 15, 2019, Plaintiffs filed a ~~notice~~combined petition for panel rehearing and rehearing en banc with respect to this issue. In its March 14, 2019 order, the Federal Circuit also vacated the judgment of ~~cross appeal. Briefing was completed on April~~non-infringement of claims 4, ~~2018. A date~~9 and 10 as to Alembic and Breckenridge and remanded for ~~oral argument has not been set.~~

~~On July 25, 2017, the District Court actions were reassigned to Judge Mitchel S. Goldberg of the U.S. District Court for the Eastern District of Pennsylvania. On February 9, 2018,~~ the district court ~~lifted the stay on the issue of~~to consider their infringement ~~as to Sigmapharm. On March 14, 2018, the district court issued~~under a ~~scheduling order setting~~revised claim construction.

A separate bench trial ~~to begin on June 18, 2018 with respect to~~concerning Sigmapharm’s infringement of claim 1 of the ‘476 ~~patent. The district~~patent began on June 20, 2018, and on November 16, 2018, the court ~~also acknowledged~~held that ~~(a) the 30 month stay as to Sigmapharm is set to expire June 21, 2018, (b) Sigmapharm agreed not to launch its~~Sigmapharms’ proposed ~~generic~~ANDA product ~~until FDA approval and after the district court issues its decision, and (c) Plaintiffs and Sigmapharm agreed to be bound by the outcome~~would infringe claim 1 of the ~~pending appeal~~‘476 patent On November 26, 2018, Sigmapharm sought relief from the November 16, 2018 decision. On November 30, 2018, the Company moved for entry of final judgment. Both motions are currently pending.

Botulinum Neurotoxin ITC Investigation. On January 30, 2019, subsidiaries of the Company and Medytox Inc. (collectively, “Complainants”) filed a complaint with the ~~Appeal~~

~~Defendants~~United States International Trade Commission (“ITC”) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and ~~any proceedings on remand, if necessary,~~Evolus Inc. (collectively, “Respondents”) requesting the ITC commence an investigation with respect to ~~infringement~~the Respondents’ importation into the United States of ~~claims 4, 9~~Respondents’ botulinum neurotoxin products, including DWP-450 (also known as Jeuveau^TM), which Complainants assert were developed, made and/or imported using Medytox’s trade secrets. Complainants seek, among other things, a permanent exclusionary order and 10cease and desist orders covering Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. On February 28, 2019, the ITC instituted an investigation into Respondents’ botulinum neurotoxin products, including DWP-450/Jeuveau^TM. The ITC has scheduled a hearing for November 5-7, 2019 and has set May 29, 2020 as the target date for completion of the ~~‘476 patent. A bench trial concluded on June 20, 2018. The parties filed their opening post-trial briefs on July 19, 2018.~~

~~Savella~~^®. On October 5 and 6, 2017, Forest Laboratories Holdings, Ltd., Allergan Sales, LLC and Allergan USA, Inc. (collectively, “Allergan and Forest”) brought actions for infringement of U.S. Patent Nos. 6,602,911 (the “‘911 patent”), 7,888,342 (the “‘342 patent”), and 7,994,220 (the “‘220 patent”) in the U.S. District Court for the District of Delaware and the District of New Jersey, respectively, against Strides Pharma Global Pte Limited and Strides Pharma Inc. (collectively, Strides”). On April 20, 2018, the Company entered into a settlement agreement with Strides and the case was dismissed.investigation.

~~Viibryd~~^® ~~IPR.~~ On January 5, 2018, Argentum Pharmaceuticals LLC submitted to the USPTO a petition for Inter Partes Review (“IPR”) seeking cancellation of certain claims of U.S. Patent No. 8,673,921 (the “‘921 patent”). The ‘921 patent is listed in the Orange Book for Viibryd^® ~~and expires in June 2022. On July 23, 2018, the USPTO denied institution of the IPR.~~

Juvéderm^®. On April 5, 2017, ~~Allergan, Inc. (“Allergan”)~~a subsidiary of the Company brought an action for unfair competition, false advertising, dilution, conspiracy and infringement of Allergan’s ~~JUVÉDERM~~Juvéderm^® trademarks in the U.S. District Court for the Central District of California against Dermavita Limited Partnership (“Dermavita”), Dima Corp. S.A. (“Dima Corp.”) and KBC Media Relations LLC (“KBC”). Dima Corp. had previously announced its acquisition of a license from Dermavita to develop and market in the U.S. cosmetic products under the Juvederm trademark. During June 2017, ~~Allergan~~the Company entered into a settlement agreement with KBC. During July 2017, the Court preliminarily enjoined Dima Corp. from, inter alia,, promoting or selling within the United States any product bearing the trademark ~~JUVEDERM~~Juvéderm^® or any other trademark confusingly similar to it. During January 2018, the Court granted Dermavita’s renewed motion to dismiss ~~Allergan’s~~the Company’s complaint based on purported lack of personal jurisdiction. During January 2019, the Company subsidiary and Dima Corp. resolved the action and the Court entered a permanent injunction and final judgment in favor of the Company subsidiary and against Dima Corp. for trademark infringement, unfair competition, dilution and false advertising.

~~Allergan Holdings France SAS and Allergan France SAS~~Subsidiaries of the Company requested a preliminary injunction against Dermavita, Dima Corp, Aesthetic Services, Jacqueline Sillam and Dimitri Sillam in the High Court of Paris, France. During June 2017, the Paris Court preliminarily enjoined the defendants, ~~from~~, inter alia,, to refrain from promoting or selling in France its Juvederm products, ~~requiring the~~to transfer of various domain names and ~~payment of~~to pay provisional damages to Allergan, on the basis that such use would infringe Allergan’s EU and French ~~JUVÉDERM~~Juvéderm^® trademarks and would amount to unfair competition. This injunction has ~~been appealed. Allergan France~~become final. A subsidiary of the Company has also filed against Dermavita, Dima Corp. and others a full action of trademark infringement in the Paris court. Dermavita has requested that the full action be stayed

pending the outcome of the Nanterre action and the EUIPO trademark proceedings, both mentioned below. ~~On March 13, 2018, the~~The Paris court ~~will hear arguments on~~rejected Dermavita’s stay ~~request.~~request and subsequently ordered the defendants to pay more than 75,000 Euros in liquidated damages for violation of the preliminary injunction mentioned above. Dermavita has filed an action against ~~Allergan~~subsidiaries of the Company in the Nanterre, France court alleging that ~~Allergan has~~the subsidiaries have not used its ~~JUVÉDERM~~Juvéderm trademark and requesting the court to revoke ~~Allergan’s~~the Company’s trademark based on its purported lack of ~~use.~~ use or purportedly invalid license and assignment agreements. On February 21, 2019, the Nanterre Court ruled in the Company’s favor, holding that the license and assignment agreements were valid and that Allergan has used its trademark in commerce. Dermavita has appealed this decision.

Asacol^® Litigation. Class action complaints have been filed against certain subsidiaries of the Company on behalf of putative classes of direct and indirect purchasers. The lawsuits have been consolidated in the U.S. District Court for the District of Massachusetts. The complaints allege that plaintiffs paid higher prices for Asacol^® HD and Delzicol^® as a result of alleged actions preventing or delaying generic competition in the market for an older Asacol^® product in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. The Company has settled the claims brought by the direct purchaser plaintiffs. While the district court granted the indirect purchaser plaintiffs’ motion for class certification, the Court of Appeals for the First Circuit later issued a decision reversing the lower court’s decision on class certification. The appellate court recently denied plaintiffs’ motion for rehearing en banc and remanded the case back to the District Court where the court recently denied plaintiffs’ renewed motion for class certification.

Loestrin^® 24 Litigation. Putative classes of direct and indirect purchasers as well as opt-out direct purchasers have filed complaints that have been consolidated in the U.S. District Court for the District of Rhode Island. The lawsuits allege that subsidiaries of the Company engaged in anticompetitive conduct, including when settling patent lawsuits related to Loestrin^® 24 Fe, in violation of federal and state antitrust and consumer protection laws. The complaints each seek declaratory and injunctive relief and damages. The court recently conducted hearings on the class plaintiffs’ class certification motions and on the parties’ motions for summary judgement on the issue of market power.

Namenda^® Litigation. In 2014, the State of New York filed a lawsuit in the U.S. District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Namenda® in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda^® XR. The district court granted the state’s motion for a preliminary injunction which was later affirmed by the Court of Appeals for the Second Circuit. The parties in that case then reached a settlement to resolve the dispute. Following the conclusion of the New York Attorney General Matter, putative class actions were filed on behalf of direct and indirect purchasers in the same federal court. The class action complaints make claims similar to those asserted by the New York Attorney General and also include claims that Namenda® patent litigation settlements between a Company subsidiary and generic companies also violated the antitrust laws. Plaintiffs seek unspecified injunctive relief, treble damages and attorneys’ fees. The court has denied defendants’ motion for summary judgement in the direct purchaser action, certified the direct purchaser class of plaintiffs and set a trial date for October 2019.

Restasis^® Competitor Litigation. Shire, which offers the dry-eye disease drug Xiidra^®, sued subsidiaries of the Company in U.S. District Court for the District of New Jersey alleging that defendants unlawfully harmed competition by foreclosing Xiidra^® from sales to Medicare Part D plans (and the members of such plans) through the use of discounts (a) contingent on Restasis® receiving preferential formulary treatment; and/or (b) across a bundle of Allergan’s products, including Restasis^®. The complaint seeks injunctive relief and damages under federal and state law. The court issued a decision on March 22, 2019 granting the defendants’ motion to dismiss the complaint. On April 25, 2019, Shire filed an amended complaint.

Restasis^® Class Action Litigation. Several class actions were filed on behalf of putative classes of direct and indirect purchasers of Restasis^® alleging that subsidiaries of the company harmed competition by engaging in conduct to delay the market entry of generic versions of Restasis^® in violation of the federal antitrust laws as well as state antitrust and consumer-protection laws and unjust enrichment. The cases have been consolidated in the U.S. District Court for the District of New Jersey. All plaintiffs seek damages, declaratory relief, and injunctive relief. The parties are currently engaged in discovery.

Celexa^®/Lexapro^® Class Actions. Certain subsidiaries of the Company were named in federal court actions relating to the promotion of Celexa^® and/or Lexapro^® all of which were consolidated in an MDL proceeding in the U.S. District Court for the District of Massachusetts. Most of these claims were resolved through a settlement in September 2014. However, two lawsuits remain which assert claims under the federal Racketeer Influenced and Corrupt Organizations (“RICO”) Act. The court has entered summary judgment in favor of the defendants in both actions and denied plaintiffs’ class certification motions. Plaintiffs in both cases appealed the dismissal of their claims and denial of class certification to the United States Court of Appeals for the First Circuit and the appeals court issued a decision in January 2019 affirming the denial of the class certification motions but reversing the lower court’s decision granting the defendants’ summary judgment motions.

Warner Chilcott Marketing Practices. A putative nationwide class of private payer entities, or their assignees, that paid Medicare benefits on behalf of their beneficiaries filed a complaint against certain subsidiaries of the Company in the U.S. District Court for the District of Massachusetts. The Complaint asserts claims under the federal RICO statute, state consumer protection statutes, common law fraud, and unjust enrichment with respect to the sale and marketing of certain products. Defendants’ motion to dismiss the Amended Complaint is still pending.

Generic Drug Pricing Securities and ERISA Litigation. Putative classes of shareholders and two individual opt-out plaintiffs filed class action lawsuits against the Company and certain of its current and former officers alleging that defendants made materially false and misleading statements between February 2014 and November 2016 regarding the Company’s internal controls over its financial reporting and that it failed to disclose that its former Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. These lawsuits have been consolidated in the U.S. District Court for the District of New Jersey. The complaints seek unspecified monetary damages. On April 11, 2019, the court heard oral arguments on the Company’s motion to dismiss the complaint. In addition, class action complaints have been filed premised on the same alleged underlying conduct that is at issue in the securities litigation but that assert claims under the Employee Retirement Income Security Act of 1974 (“ERISA”). These complaints have been consolidated in the district court in New Jersey. The court granted the Company’s motion to dismiss this complaint. The ERISA plaintiffs have appealed this decision to the Third Circuit Court of Appeals.

Prescription Opioid Drug Abuse Litigation. The Company has been named as a defendant, along with several other manufacturers and distributors of opioid products, in over 1,850 matters relating to the promotion and sale of prescription opioid pain relievers and additional suits have been filed. The lawsuits allege generally that the manufacturer defendants engaged in a deceptive campaign to promote their products in violation of state laws and seek unspecified monetary damages, penalties and injunctive relief. Plaintiffs in these suits include states, political subdivisions of states (i.e., counties and municipalities), Native American tribes and other private litigants such as insurance plans, hospital systems and consumers who were prescribed opioid products and were subsequently treated for an overdose or addiction. Cases are pending in both federal and state courts. The federal court cases have been consolidated in an MDL in the U.S. District Court for the Northern District of Ohio, with a first set of cases set for trial in October 2019.

Testosterone Replacement Therapy Class Action. Subsidiaries of the Company were named in a class action complaint filed on behalf a putative class of third-party payers in the U.S. District Court for the Northern District of Illinois. The suit alleges that the Company’s subsidiaries violated various laws including the federal RICO statute and state consumer protection laws in connection with the sale and marketing of Androderm^®. The class plaintiffs seek to obtain certain equitable relief, including injunctive relief and an order requiring restitution and/or disgorgement, and to recover damages and multiple damages in an unspecified amount. While the lawsuit is ongoing, the court has denied plaintiff’s class certification motion. On February 14, 2019, the court granted Defendants’ motion for summary judgment, dismissing the case in its entirety. On March 19, 2019, plaintiffs filed a Notice of Appeal to the Seventh Circuit.

Oculeve Shareholder Dispute. On February 26, 2019, Fortis Advisors LLC, as a representative of the former stockholders of Oculeve, Inc., filed a lawsuit against a subsidiary of the Company in state court in Delaware. The lawsuit centers on a claim that the Company breached the terms of a July 2015 merger agreement. The Company subsidiary has moved to dismiss the complaint.

Actonel^® Litigation. ~~Warner Chilcott~~A subsidiary of the Company is a defendant in ~~approximately 168~~over 500 filed cases in federal and ~~a potential defendant with respect to approximately 383 unfiled claims involving a total of approximately 553 claimants~~various state courts, relating to ~~Warner Chilcott’s~~the bisphosphonate prescription drug Actonel^®. In addition, there are three cases pending in provincial courts in Canada, two involving single plaintiffs, and a third on behalf of a purported class of injured plaintiffs. The ~~claimants~~complaints allege, among other things, that Actonel^® caused them to suffer osteonecrosis of the jaw (“ONJ”)~~, a rare but serious condition that involves severe loss or destruction of the jawbone,~~ and/or atypical fractures of the ~~femur (“AFF”). Warner Chilcott is in the initial stages of discovery in these litigations. All of the filed cases~~femur. Plaintiffs are in either federal or state courts in the United States, with the exception of three cases filed in provincial courts in Canada. Two Canadian cases involve a single plaintiff, and the other is a purported product liability class action involving two named plaintiffs. The Canadian action alleges, among other things, that Actonel^® ~~caused the plaintiffs and the proposed class members who ingested Actonel~~^® ~~to suffer ONJ or other side effects. It is expected that the plaintiffs in the purported class action will seek class certification. Plaintiffs have typically asked for~~seeking unspecified monetary and injunctive relief, as well as attorneys’ fees. ~~Warner Chilcott~~The Company subsidiary is being indemnified by Sanofi for certain ~~Actonel~~ claims pursuant to ~~a collaboration~~an agreement ~~relating to the two parties’ co-promotion of the product in the United States~~with Sanofi and ~~other countries. In addition, Warner Chilcott~~ is ~~also~~being partially indemnified by the Procter & Gamble Company

(“P&G”) for ONJ claims that were pending at the time ~~Warner Chilcott~~the Company subsidiary acquired P&G’s global pharmaceutical business in ~~October~~ 2009. ~~In May and September 2013, Warner Chilcott entered into two settlement agreements~~Settlements have been reached that have resolved ~~a majority~~most of the ~~then-existing~~pending ONJ-related claims. Recently, all pending Actonel cases in New Jersey state court were dismissed without prejudice subject to refilling after the U.S. Supreme Court issues a decision in Merck Sharp & Dohme Corp. v. Albrecht, Doc. No. 17-290.

~~AlloDerm Litigation.~~ Breast Implant Litigation~~LifeCell Corporation is named as~~. Certain Company subsidiaries are defendants in more than a ~~defendant in approximately 370 lawsuits~~dozen cases alleging that ~~its biologic mesh product AlloDerm did not perform~~Allergan’s textured breast implants caused women to develop a rare condition known as ~~intended~~anaplastic large cell lymphoma (“ALCL”), and ~~caused various injuries. Plaintiffs allege~~that the ~~product was defectively designed or manufactured and/or did not have proper warnings. These cases are consolidated in Superior Court of New Jersey, Middlesex County. Prior~~defendants failed to properly warn against this risk and failed to promptly and properly report the ~~close of its sale to Allergan, LifeCell mediated the New Jersey cases in December 2016 and~~

~~negotiated a settlement of its pending New Jersey cases, which was paid by LifeCell on April 19, 2017. Approximately 369~~results of the post-marketing studies relating to these products. These cases have been ~~dismissed, with the balance anticipated to be dismissed pending estate filings. LifeCell’s insurers participated~~filed in both federal and state courts in the ~~settlement.~~United States and well as provincial courts in Canada. One ~~other case is pending in Oklahoma but~~of the Canadian cases has been asserted on behalf a putative class of consumers.

Benicar^® Litigation. A subsidiary of the Company has ~~not yet~~ been ~~served.~~

~~Benicar~~^® ~~Litigation.~~ ~~Forest is~~ named in ~~approximately 1,759 actions~~a number of lawsuits involving allegations that Benicar^®~~, a treatment for hypertension that Forest co-promoted with Daiichi Sankyo between 2002 and 2008,~~ caused certain gastrointestinal injuries. Under ~~Forest’s Co-Promotion Agreement,~~a co-promotion agreement, Daiichi Sankyo is defending ~~Forest~~the Company subsidiary in these ~~lawsuits. On August 1, 2017, Daiichi~~lawsuits and has announced that it has agreed to enter into a program to settle all of the pending cases on behalf of all defendants, including ~~Forest.~~the Company subsidiary.

Celexa^®/Lexapro^® Litigation. Certain ~~Forest entities~~Company subsidiaries are defendants in ~~approximately 166~~over 150 actions alleging that ~~Celexa~~^®Celexa® or Lexapro^® caused various birth defects. Several of the cases involve multiple minor-plaintiffs. The majority of these actions have been consolidated in state court in Missouri; none of the actions are set for trial.

RepliForm ~~Litigation.~~ ^® Litigation~~LifeCell Corporation~~. A Company subsidiary has been named as a defendant in ~~approximately 325~~over 300 cases alleging that its biologic mesh product RepliForm^® did not perform as intended and caused various injuries. ~~In all~~The majority of those cases Boston Scientific Corporation, LifeCell’s distributor, has been named as a co-defendant. In addition, a significant portion of those cases also name another manufacturer as a defendant whose product was implanted at the same time. All but a few of thethese cases have been consolidated ~~for centralized management~~ in ~~the Superior Court of Massachusetts, Middlesex County. The other cases are venued in federal~~state court in ~~West Virginia, and~~Massachusetts, with the rest pending in state courts in Delaware and ~~Minnesota.~~Minnesota and the federal court in West Virginia. Approximately 200 of these cases have been settled or dismissed.

Testosterone Litigation. ~~Beginning in 2014, a~~A number of product liability suits were filed against ~~Actavis, Inc., now known as Allergan Finance, LLC, and one or more of its former~~certain Company subsidiaries as well as other manufacturers and distributors of testosterone products, for personal injuries including but not limited to cardiovascular events allegedly arising out of the use of Androderm^®. ~~There are approximately 525 currently pending actions which~~The cases have been consolidated in an MDL in ~~federal court in~~the U.S. District Court for Northern District of Illinois. ~~The defendants have responded to~~In mid-2018, the ~~plaintiffs’ master complaint in the MDL and discovery is ongoing. The~~ parties ~~have~~ reached an agreement ~~in principle~~ to settle all of the ~~remaining~~pending cases.

The Company and its ~~affiliates~~subsidiaries are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings that could result in litigation, and other litigation matters that arise from time to time.

~~Forest.~~ ~~Forest~~Company subsidiaries have received ~~a subpoena, dated April 29, 2015,~~subpoenas and/or Civil Investigative Demands (“CID”) from the ~~U.S.~~United States Department of Justice, the United States Health and Human Services, Office of Inspector General, ~~(“OIG”). The subpoena requests~~United States Congressional Committees as well as various state regulatory and enforcement authorities. Each of the subpoenas and CIDs seek documents and information relating to discrete topics, including but not limited to: the calculation and reporting by certain Company subsidiaries of their Average Manufacturer ~~(“AMP”)~~Prices, Average Wholesale Prices and Best ~~Price calculations~~Prices for several of ~~its products. Subsequently, Forest received a Civil Investigative Demand (“CID”) from~~their products; sales and marketing practices of Botox to urology practices; the ~~OIG, dated August 16, 2016, primarily related~~promotion and sale of two gastroenterology products; the Saint Regis Mohawk Tribe’s acquisition of six Restasis patents and the granting of exclusive licenses to the ~~calculation~~Restasis product to the Company; and, the promotion and sale of ~~Best Price. The~~opioid products. In each case, the Company isand its subsidiaries are cooperating fully with the ~~OIG’s~~governmental authority’s requests.

~~Forest~~Certain states have initiated lawsuits and ~~certain~~qui tam lawsuits have been filed by private parties, also known as relators, on behalf of ~~its affiliates are~~the federal or state governments. Certain Company subsidiaries have been named as defendants in ~~three state court actions pending in Illinois, Utah and Wisconsin involving~~ ~~qui tam~~ ~~actions alleging~~lawsuits that allege generally that ~~the plaintiffs (all government agencies)~~state Medicaid agencies were overcharged for their share of Medicaid drug reimbursement ~~costs. Forest and the other defendants filed a motion~~costs due to ~~dismiss Utah’s amended complaint. This motion to dismiss was denied in part. On October 30, 2017,~~inflated Average Wholesale Prices (“AWP”) reported by the Company ~~reached an agreement to settle the~~subsidiaries. AWP lawsuits are currently pending in Illinois, Utah ~~action. On February 17, 2014, the Wisconsin state court granted defendants’ motion to dismiss plaintiff’s second amended complaint. However, the~~and Wisconsin.

Namenda XR^®/Namzaric^® Qui Tam. A relator filed a ~~separate action making~~qui tam lawsuit on behalf of the ~~same basic allegations as in~~United States government and several individual states against the Company and certain of its ~~amended complaint~~subsidiaries along with Adamas Pharma LLC and Adamas Pharmaceuticals, Inc. (collectively, “Adamas”). The lawsuit, filed in the ~~original~~U.S. District Court for the Northern District of California, was unsealed on February 6, 2019. The federal and state governments have declined to intervene in this action. ~~On May 17, 2017,~~The complaint alleges generally that the ~~Wisconsin state court granted defendants’ motion~~Adamas and Allergan defendants each engaged in conduct that delayed generic versions of Namenda XR^® and/or Namzaric^® from entering the market and that such conduct resulted in the submission of false claims to ~~dismiss~~ the ~~amended~~government. The Allergan defendants have not yet responded to the complaint.

~~On December 28, 2015,~~Medical Aesthetics Qui Tam. A subsidiary of the Company was recently served with a ~~putative class action complaint~~qui tam lawsuit that was filed in ~~state court in Pennsylvania~~the U.S. District Court for the Central District of California on behalf of ~~a putative class of private payers. Defendants removed~~ the ~~complaint~~United States and several individual states. The federal and state

governments have declined to ~~the federal court~~intervene in ~~Pennsylvania.~~this action. The complaint alleges that manufacturers of generic drugs, including a subsidiary of Forest Laboratories, Inc. that in the past had marketed generic products, caused plaintiffs to overpay for prescription drug products through the use of inflated AWPs. The complaint alleges violationscertain promotional programs and sampling practices of the ~~Pennsylvania Unfair Trade Practices~~Company’s Medical Aesthetics business result in price reporting violations and Consumer Protection Law, negligent misrepresentation/fraud, unjust enrichment, civil conspiracy and aiding and abetting. On July 24, 2017, the state court issued a decision on the Company’s individual motion to dismiss, granting it in part and denying it in part.

~~Allergan~~. On April 18, 2017, the Company received a CID, dated April 12, 2017, from the Department of Justice. The CID seeks information relating to the Company’s sales and marketing practices of Botox to urology practices.violate anti-kickback statutes. The Company ~~is cooperating fully with DOJ requests.~~

~~On October 3, 2017, the Company received a letter from the House of Representatives Committee on Oversight and Government Reform. The letter seeks information relating~~subsidiary has not yet responded to ~~the Saint Regis Mohawk Tribe’s acquisition of six Restasis~~^® ~~patents and~~

~~the granting of exclusive licenses to the Restasis~~^® ~~product to the Company. The Company has received other information requests from regulatory agencies concerning the transaction and is cooperating fully with these requests.~~

In June 2018, the Company received CID from the Department of Justice and a subpoena from the California Department of Insurance, Office of Insurance Commissioner, requesting information related to the Company’s promotion and sale of two gastroenterology products. The Company is cooperating fully with these requests.

~~Actavis/Watson~~. On October 16, 2017, the Company received a CID from the State of North Carolina Department of Justice. The CID seeks information relating to the legacy Watson company’s reporting of AMP calculations. The Company is cooperating fully with the state’s requests. On January 26, 2018, a ~~qui tam~~ complaint that was filed in federal district court in Illinois was unsealed which includes claims against Actavis LLC, a former subsidiary of the Company. The State of North Carolina reserved its right to intervene in this ~~proceeding pending an ongoing investigation. The complaint asserts claims that Actavis LLC violated the federal and state false claims acts based on its reporting of AMP prices.~~

The Company has received subpoenas from multiple states relating to the legacy Actavis and Watson companies’ promotional efforts relating to opioid products, none of which are currently promoted and many of which the Company no longer sells. The Company is cooperating fully with the states’ requests.complaint.

The following matters relate to the former generics business of the Company or the transaction pursuant to which that business was sold to Teva, effective August 2, 2016. Teva has agreed to indemnify and defend the Company against all matters asserted in litigation against the Company arising out of the former generics business, including litigations and investigations relating to generic opioid products including, without limitation, the actions described below.

Lidoderm^® Litigation. ~~On March 30, 2016, the~~The U.S. Federal Trade Commission filed a lawsuit in federal district court in the Eastern District of Pennsylvania against the Company and one of its former global generics business subsidiaries ~~Watson Laboratories, Inc., Endo Pharmaceuticals Inc.~~ and others ~~arising out of~~alleging that patent litigation settlements relating to ~~Lidoderm.~~Lidoderm were anticompetitive. The ~~Lidoderm settlement was reached by Endo Pharmaceuticals Inc. and Watson Laboratories, Inc. in May 2012, prior to Watson’s being affiliated with the Company. On October 25, 2016, the~~ FTC voluntarily withdrew its complaint in ~~federal court in~~ Pennsylvania and ~~then in January 2017~~ filed a similar complaint in the ~~federal district court in~~U.S. District Court for the Northern District California where similar lawsuits filed by private plaintiffs were already pending and where the State of California filed a similar complaint against the same defendants. ~~On January 27, 2017, Allergan Finance LLC~~Defendants in the Pennsylvania action filed a declaratory judgment action against the FTC in the ~~same~~Pennsylvania federal ~~district~~ court inbut the ~~Eastern District of Pennsylvania where~~court granted the FTC’s ~~original action had been pending. In April 2017, the~~motion to dismiss this lawsuit. The FTC and State of California’s actions were stayed pending the declaratory judgment action in the Eastern District of Pennsylvania. ~~On May 9, 2017, plaintiffs filed~~The federal court in California has not yet issued a ~~motion for summary judgment~~ruling or lifted the stay in these cases since the court’s ruling in the Eastern District of Pennsylvania.

Hydrocortisone Investigation. ~~On November 10,~~In 2016, the Company received notice from the UK Competition and Markets Authority (“CMA”) that it would be included within the scope of the CMA’s formal investigation under Section 25 of the Competition Act of 1998 (“CA98”) into suspected abuse of dominance by a former generics business subsidiary of the Company in relation to the supply of 10mg and 20mg hydrocortisone tablets. The CMA is ~~investigating~~investigating: (i) alleged excessive and unfair prices with respect to hydrocortisone tablets and (ii) whether the former generics business subsidiary entered into anti-competitive agreements with a potential competitor ~~relating to the hydrocortisone~~for this product. The CMA ~~is investigating whether the conduct infringes the Chapter II prohibition of the CA98 and/or Article 102 of the Treaty on the Functioning of the European Union. The CMA~~has issued ~~a statement~~statements of objection with respect to ~~the alleged excessive and unfair pricing in December 2016 and a separate statement~~both parts of objection with respect to the alleged anti-competitive agreements in March 2017. The CMA may pursue additional similar investigations relating to this former generic subsidiary of the Company in relation to the hydrocortisone tablet products.its investigation. The Company intends to cooperate fully with the investigation.

Teva Shareholder Derivative Litigation. ~~On or about February 26,~~In 2017, ~~Allergan plc~~the Company was named as defendant in a proposed Teva shareholder derivative litigation filed in the Economic Division of the Tel Aviv District Court in Israel. ~~In order to proceed with the lawsuit, plaintiffs have to secure court approval and have filed a motion seeking such approval.~~ The lawsuit contains allegations ~~directed at~~that the Company aided and abetted Teva’s board of directors ~~and the approval process needed by Teva to approve the Master Purchase Agreement and also includes claims regarding the amount and form~~violations of ~~consideration Teva paid in connection with the Master Purchase Agreement. Pursuant to the court’s order, plaintiffs have filed a consolidated motion seeking approval from~~Israeli securities laws. To date, the court has not determined whether it will allow plaintiffs to ~~commence the shareholder derivative suit. The Company submitted a written response to plaintiffs’ motion on December 5, 2017.~~

~~Florida Subpoena Related to Oxymorphone Products~~. In January 2018, the Company received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of Florida seeking information related to oxymorphone products which were sold by

the divested generics business. This subpoena appears to be related to a similar inquiry disclosed by Endo International plc on January 11, 2018. The subpoena was directed to the Company as a source of information, not as a target, alongproceed with ~~others.~~

NOTE 2021 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information

The following financial information is presented to segregate the financial results of WCL, Allergan Funding SCS, and Allergan Finance, LLC (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes.

The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions.

WCL, Allergan Capital S.à.r.l. and Allergan Finance, LLC are guarantors of the long-term notes. The Company anticipates future legal entity structure changes which may impact the presentation of this footnote in the future.

WCL has revised its consolidating balance sheets as previously presented in Footnote 2526 of the December 31, ~~2017~~2018 Annual Report on Form 10-K and its consolidating financial statements as previously presented in Footnote 2120 of the ~~June 30, 2017~~March 31, 2018 Quarterly Report on Form 10-Q due to a change in the Company’s legal entity structure and other reclassifications that occurred during the ~~six~~three months ended ~~June 30, 2018.~~March 31, 2019. As a result, prior period information has been recast to conform to the current period presentation.

The following financial information presents the consolidating balance sheets as of ~~June 30, 2018~~March 31, 2019 and December 31, ~~2017,~~2018, the related ~~statement~~statements of operations for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ and the statements of cash flows for the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 and ~~2017.~~2018.

	Warner Chilcott Limited (Parent Guarantor)		Allergan Capital S.a.r.l. (Guarantor)		Allergan Funding SCS (Issuer)		Allergan Finance, LLC (Issuer and Guarantor)		Non- guarantors		Eliminations			Consolidated Warner Chilcott Limited		Warner Chilcott Limited (Parent Guarantor)		Allergan Capital S.a.r.l. (Guarantor)		Allergan Funding SCS (Issuer)		Allergan Finance, LLC (Issuer and Guarantor)		Non- guarantors		Eliminations			Consolidated Warner Chilcott Limited
ASSETS
Current assets:
Cash and cash equivalents	$	0.1	$	294.5	$	-	$	-	$	1,378.9	$	-		$	1,673.5	$	0.1	$	60.4	$	1.3	$	-	$	724.9	$	-		$	786.7
Marketable securities		-		-		-		-		21.5		-			21.5		-		200.5		-		-		794.7		-			995.2
Accounts receivable, net		-		-		-		-		2,760.8		-			2,760.8		-		-		-		-		2,731.2		-			2,731.2
Receivables from Parents		-		4,223.5		-		-		1,609.9		-			5,833.4		-		-		-		-		814.1		-			814.1
Inventories		-		-		-		-		922.5		-			922.5		-		-		-		-		943.2		-			943.2
Intercompany receivables		-		1,984.4		1,459.8		75.6		21,603.4		(25,123.2	)		-		-		4,089.7		597.5		33.7		27,471.6		(32,192.5	)		-
Current assets held for sale																	-		-		-		-		45.7		-			45.7
Prepaid expenses and other current assets		-		-		1.4		88.3		633.2		-			722.9		-		-		-		33.3		747.6		-			780.9
Total current assets		0.1		6,502.4		1,461.2		163.9		28,930.2		(25,123.2	)		11,934.6		0.1		4,350.6		598.8		67.0		34,273.0		(32,192.5	)		7,097.0
Property, plant and equipment, net		-		-		-		-		1,761.4		-			1,761.4		-		-		-		-		1,781.1		-			1,781.1
Right of use asset - operating leases																	-		-		-		-		455.4		-			455.4
Investments and other assets		-		-		-		-		297.9		-			297.9		-		-		-		-		1,979.5		-			1,979.5
Investment in subsidiaries		78,676.1		85,953.6		-		109,103.2		-		(273,732.9	)		-		59,338.6		67,744.4		25,425.0		96,294.5		-		(248,802.5	)		-
Non current intercompany receivables		-		31,524.5		19,123.8		-		29,253.5		(79,901.8	)		-		-		15,603.7		-		-		1,082.9		(16,686.6	)		-
Non current receivables from Parents		-		-		-		-		3,964.0		-			3,964.0
Non current assets held for sale		-		-		-		-		180.4		-			180.4		-		-		-		-		897.2		-			897.2
Deferred tax assets		-		-		-		-		896.8		-			896.8		-		51.4		-		-		981.2		-			1,032.6
Product rights and other intangibles		-		-		-		-		49,928.3		-			49,928.3		-		-		-		-		42,264.6		-			42,264.6
Goodwill		-		-		-		-		49,687.2		-			49,687.2		-		-		-		-		43,336.6		-			43,336.6
Total assets	$	78,676.2	$	123,980.5	$	20,585.0	$	109,267.1	$	164,899.7	$	(378,757.9	)	$	118,650.6	$	59,338.7	$	87,750.1	$	26,023.8	$	96,361.5	$	127,051.5	$	(297,681.6	)	$	98,844.0
LIABILITIES AND EQUITY													��
Current liabilities:
Accounts payable and accrued expenses		-		-		163.3		93.9		4,424.4		-			4,681.6		-		0.1		103.0		118.9		4,412.3		-			4,634.3
Intercompany payables		-		11,010.6		0.6		10,592.2		3,519.8		(25,123.2	)		-		-		17,016.3		12.2		10,443.1		4,720.9		(32,192.5	)		-
Payables to Parents		-		-		-		-		2,379.7		-			2,379.7		-		-		-		-		3,034.9		-			3,034.9
Income taxes payable		-		-		-		-		92.5		-			92.5		-		-		3.9		-		123.0		-			126.9
Current portion of long-term debt and capital leases		-		-		1,296.4		0.5		51.6		-			1,348.5
Current portion of long-term debt																	-		-		3,887.2		-		84.6		-			3,971.8
Current portion of lease liability - operating																	-		-		-		-		116.1		-			116.1
Total current liabilities		-		11,010.6		1,460.3		10,686.6		10,468.0		(25,123.2	)		8,502.3		-		17,016.4		4,006.3		10,562.0		12,491.8		(32,192.5	)		11,884.0
Long-term debt and capital leases		-		-		19,123.8		2,132.7		2,745.5		-			24,002.0
Long-term debt																	-		-		14,738.2		2,140.2		2,675.7		-			19,554.1
Lease liability - operating																	-		-		-		-		415.2		-			415.2
Other long-term liabilities		-		0.2		-		-		753.2		-			753.4		-		-		-		-		804.4		-			804.4
Long-term intercompany payables		-		28,217.5		-		1,036.0		50,648.3		(79,901.8	)		-		-		-		-		1,082.9		15,603.7		(16,686.6	)		-
Other taxes payable		-		-		-		-		1,576.2		-			1,576.2		-		-		-		-		1,612.0		-			1,612.0
Deferred tax liabilities		-		0.2		-		-		5,140.3		-			5,140.5		-		-		-		-		5,235.6		-			5,235.6
Total liabilities		-		39,228.5		20,584.1		13,855.3		71,331.5		(105,025.0	)		39,974.4		-		17,016.4		18,744.5		13,785.1		38,838.4		(48,879.1	)		39,505.3
Total equity / (deficit)		78,676.2		84,752.0		0.9		95,411.8		93,568.2		(273,732.9	)		78,676.2		59,338.7		70,733.7		7,279.3		82,576.4		88,213.1		(248,802.5	)		59,338.7
Total liabilities and equity	$	78,676.2	$	123,980.5	$	20,585.0	$	109,267.1	$	164,899.7	$	(378,757.9	)	$	118,650.6	$	59,338.7	$	87,750.1	$	26,023.8	$	96,361.5	$	127,051.5	$	(297,681.6	)	$	98,844.0

	Warner Chilcott Limited (Parent Guarantor)		Allergan Capital S.a.r.l. (Guarantor)		Allergan Funding SCS (Issuer)		Allergan Finance, LLC (Issuer and Guarantor)		Non- guarantors		Eliminations			Consolidated Warner Chilcott Limited		Warner Chilcott Limited (Parent Guarantor)		Allergan Capital S.a.r.l. (Guarantor)		Allergan Funding SCS (Issuer)		Allergan Finance, LLC (Issuer and Guarantor)		Non- guarantors		Eliminations			Consolidated Warner Chilcott Limited
ASSETS
Current assets:
Cash and cash equivalents	$	0.1	$	593.1	$	0.1	$	-	$	1,223.0	$	-		$	1,816.3	$	0.1	$	1.8	$	0.8	$	-	$	875.9	$	-		$	878.6
Marketable securities		-		400.2		-		-		4,231.9		-			4,632.1		-		489.9		-		-		537.0		-			1,026.9
Accounts receivable, net		-		-		-		-		2,899.0		-			2,899.0		-		-		-		-		2,868.1		-			2,868.1
Receivables from Parents		-		4,223.5		-		-		1,573.9		-			5,797.4		-				-		-		640.9		-			640.9
Inventories		-		-		-		-		904.5		-			904.5		-		-		-		-		846.9		-			846.9
Intercompany receivables		-		8,118.7		5,507.6		19.6		25,417.0		(39,062.9	)		-		-		3,534.7		961.0		16.7		24,779.3		(29,291.7	)		-
Current assets held for sale																	-		-		-		-		34.0		-			34.0
Prepaid expenses and other current assets		-		-		-		85.0		1,038.0		-			1,123.0		-		-		-		33.3		785.4		-			818.7
Total current assets		0.1		13,335.5		5,507.7		104.6		37,287.3		(39,062.9	)		17,172.3		0.1		4,026.4		961.8		50.0		31,367.5		(29,291.7	)		7,114.1
Property, plant and equipment, net		-		-		-		-		1,785.4		-			1,785.4		-		-		-		-		1,787.0		-			1,787.0
Investments and other assets		-		-		-		-		267.9		-			267.9		-		-		-		-		1,970.6		-			1,970.6
Investment in subsidiaries		81,282.1		87,583.9		-		109,169.8		-		(278,035.8	)		-		62,940.2		73,846.0		26,406.9		99,255.9		-		(262,449.0	)		-
Non current intercompany receivables		-		27,518.7		20,985.0		-		30,544.0		(79,047.7	)		-		-		28,239.4		18,090.2		-		19,674.2		(66,003.8	)		-
Non current receivables from Parents		-		-		-		-		3,964.0		-			3,964.0
Non current assets held for sale		-		-		-		-		81.6		-			81.6		-		-		-		-		882.2		-			882.2
Deferred tax assets		-		-		-		-		316.0		-			316.0		-		43.6		-		-		1,020.1		-			1,063.7
Product rights and other intangibles		-		-		-		-		54,648.3		-			54,648.3		-		-		-		-		43,695.4		-			43,695.4
Goodwill		-		-		-		-		49,862.9		-			49,862.9		-		-		-		-		45,913.3		-			45,913.3
Total assets	$	81,282.2	$	128,438.1	$	26,492.7	$	109,274.4	$	178,757.4	$	(396,146.4	)	$	128,098.4	$	62,940.3	$	106,155.4	$	45,458.9	$	99,305.9	$	146,310.3	$	(357,744.5	)	$	102,426.3
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses		-		0.6		202.9		89.3		5,222.8		-			5,515.6		-		0.1		156.3		92.9		4,538.1		-			4,787.4
Intercompany payables		-		12,186.2		1,828.5		11,402.3		13,645.9		(39,062.9	)		-		-		14,315.0		21.7		10,442.6		4,512.4		(29,291.7	)		-
Payables to Parents		-		-		-		-		2,340.6		-			2,340.6		-		-		-		-		2,829.2		-			2,829.2
Income taxes payable		-		-		-		-		74.9		-			74.9		-		-		-		-		72.4		-			72.4
Current portion of long-term debt and capital leases		-		-		3,475.4		-		756.4		-			4,231.8
Current portion of long-term debt																	-		-		779.6		-		88.7		-			868.3
Total current liabilities		-		12,186.8		5,506.8		11,491.6		22,040.6		(39,062.9	)		12,162.9		-		14,315.1		957.6		10,535.5		12,040.8		(29,291.7	)		8,557.3
Long-term debt and capital leases		-		-		20,985.0		2,130.1		2,728.4		-			25,843.5
Long-term debt																	-		-		18,090.2		2,135.9		2,703.3		-			22,929.4
Other long-term liabilities		-		0.2		-		-		886.7		-			886.9		-		-		-		-		882.0		-			882.0
Long-term intercompany payables		-		30,395.0		-		149.0		48,503.7		(79,047.7	)		-		-		18,597.4		-		1,076.8		46,329.6		(66,003.8	)		-
Other taxes payable		-		-		-		-		1,573.5		-			1,573.5		-		-		-		-		1,615.5		-			1,615.5
Deferred tax liabilities		-		0.2		-		-		6,349.2		-			6,349.4		-		-		-		-		5,501.8		-			5,501.8
Total liabilities		-		42,582.2		26,491.8		13,770.7		82,082.1		(118,110.6	)		46,816.2		-		32,912.5		19,047.8		13,748.2		69,073.0		(95,295.5	)		39,486.0
Total equity / (deficit)		81,282.2		85,855.9		0.9		95,503.7		96,675.3		(278,035.8	)		81,282.2		62,940.3		73,242.9		26,411.1		85,557.7		77,237.3		(262,449.0	)		62,940.3
Total liabilities and equity	$	81,282.2	$	128,438.1	$	26,492.7	$	109,274.4	$	178,757.4	$	(396,146.4	)	$	128,098.4	$	62,940.3	$	106,155.4	$	45,458.9	$	99,305.9	$	146,310.3	$	(357,744.5	)	$	102,426.3

	Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited			Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited
Net revenues	$	-		$	-		$	-		$	-		$	4,124.2		$	-		$	4,124.2		$	-		$	-		$	-		$	-		$	3,597.1		$	-		$	3,597.1

Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		-			-			-			-			481.8			-			481.8			-			-			-			-			497.8			-			497.8
Research and development		-			-			-			-			689.2			-			689.2			-			-			-			-			435.0			-			435.0
Selling and marketing		-			-			-			-			853.4			-			853.4			-			-			-			-			804.0			-			804.0
General and administrative		-			-			1.2			-			298.3			-			299.5			-			-			-			-			306.1			-			306.1
Amortization		-			-			-			-			1,697.1			-			1,697.1			-			-			-			-			1,399.4			-			1,399.4
In-process research and development impairments		-			-			-			-			276.0			-			276.0
Goodwill impairments																							-			-			-			-			2,467.0			-			2,467.0
Asset sales and impairments, net		-			-			-			-			259.6			-			259.6			-			-			-			-			(5.2	)		-			(5.2	)
Total operating expenses		-			-			1.2			-			4,555.4			-			4,556.6			-			-			-			-			5,904.1			-			5,904.1
Operating (loss)		-			-			(1.2	)		-			(431.2	)		-			(432.4	)		-			-			-			-			(2,307.0	)		-			(2,307.0	)

Interest income / (expense), net		-			267.4			(5.1	)		(20.7	)		(399.8	)		-			(158.2	)
Other income, net		-			-			9.2			-			206.2			-			215.4
Total other income / (expense), net		-			267.4			4.1			(20.7	)		(193.6	)		-			57.2
Income / (loss) before income taxes and noncontrolling interest		-			267.4			2.9			(20.7	)		(624.8	)		-			(375.2	)
Interest (expense), net																							-			(23.4	)		(59.6	)		(19.9	)		(77.6	)		-			(180.5	)
Other (expense) / income, net																							-			-			(0.1	)		-			13.9			-			13.8
Total other (expense), net																							-			(23.4	)		(59.7	)		(19.9	)		(63.7	)		-			(166.7	)
(Loss) before income taxes and noncontrolling interest																							-			(23.4	)		(59.7	)		(19.9	)		(2,370.7	)		-			(2,473.7	)
(Benefit) for income taxes		-			-			-			(4.4	)		(0.8	)		-			(5.2	)		-			-			-			-			(68.7	)		-			(68.7	)
Losses / (earnings) of equity interest subsidiaries		372.4			656.0			-			(76.0	)		-			(952.4	)		-			2,405.7			2,345.0			809.3			2,377.4			-			(7,937.4	)		-
Net (loss) / income from continuing operations, net of tax	$	(372.4	)	$	(388.6	)	$	2.9		$	59.7		$	(624.0	)	$	952.4		$	(370.0	)
(Loss) from discontinued operations, net of tax		-			-			-			-			-			-			-
Net (loss) / income	$	(372.4	)	$	(388.6	)	$	2.9		$	59.7		$	(624.0	)	$	952.4		$	(370.0	)	$	(2,405.7	)	$	(2,368.4	)	$	(869.0	)	$	(2,397.3	)	$	(2,302.0	)	$	7,937.4		$	(2,405.0	)
(Income) attributable to noncontrolling interest		-			-			-			-			(2.4	)		-			(2.4	)		-			-			-			-			(0.7	)		-			(0.7	)
Net (loss) / income attributable to members	$	(372.4	)	$	(388.6	)	$	2.9		$	59.7		$	(626.4	)	$	952.4		$	(372.4	)	$	(2,405.7	)	$	(2,368.4	)	$	(869.0	)	$	(2,397.3	)	$	(2,302.7	)	$	7,937.4		$	(2,405.7	)
Other comprehensive (loss) / income, net of tax		(448.6	)		(646.0	)		-			(748.7	)		(448.6	)		1,843.3			(448.6	)		(128.8	)		(140.8	)		(172.6	)		(584.0	)		(128.8	)		1,026.2			(128.8	)
Comprehensive (loss) / income attributable to members	$	(821.0	)	$	(1,034.6	)	$	2.9		$	(689.0	)	$	(1,075.0	)	$	2,795.7		$	(821.0	)	$	(2,534.5	)	$	(2,509.2	)	$	(1,041.6	)	$	(2,981.3	)	$	(2,431.5	)	$	8,963.6		$	(2,534.5	)

Warner
Chilcott
Limited
(Parent
Guarantor)

Allergan
Capital
S.a.r.l.
(Guarantor)

Allergan
Funding
SCS
(Issuer)

Allergan
Finance,
LLC
(Issuer and
Guarantor)

Non-
guarantors

Eliminations

Consolidated
Warner
Chilcott
Limited

Net revenues

$
-

$
-

$
-

$
-

$
7,796.3

$
-

$
7,796.3

Operating expenses:

Cost of sales (excludes amortization and
   impairment of acquired intangibles including
   product rights)

-

-

-

-

1,004.6

-

1,004.6

Research and development

-

-

-

-

1,163.9

-

1,163.9

Selling and marketing

-

-

-

-

1,653.4

-

1,653.4

General and administrative

-

-

0.5

-

593.1

-

593.6

Amortization

-

-

-

-

3,394.7

-

3,394.7

In-process research and development
   impairments

-

-

-

-

798.0

-

798.0

Asset sales and impairments, net

-

-

-

-

272.7

-

272.7

Total operating expenses

-

-

0.5

-

8,880.4

-

8,880.9

Operating (loss)

-

-

(0.5
)

-

(1,084.1
)

-

(1,084.6
)

Interest income / (expense), net

-

526.4

(8.4
)

(41.9
)

(814.6
)

-

(338.5
)
Other income, net

-

-

9.2

-

127.4

-

136.6

Total other income / (expense), net

-

526.4

0.8

(41.9
)

(687.2
)

-

(201.9
)
Income / (loss) before income taxes and
   noncontrolling interest

-

526.4

0.3

(41.9
)

(1,771.3
)

-

(1,286.5
)
Provision / (benefit) for income taxes

-

-

0.3

(16.6
)

(671.1
)

-

(687.4
)
Losses / (earnings) of equity interest subsidiaries

603.7

1,201.5

-

(505.6
)

-

(1,299.6
)

-

Net (loss) / income from continuing operations,
   net of tax

$
(603.7
)

$
(675.1
)

$
-

$
480.3

$
(1,100.2
)

$
1,299.6

$
(599.1
)
(Loss) from discontinued operations, net of tax

-

-

-

-

-

-

-

Net (loss) / income

$
(603.7
)

$
(675.1
)

$
-

$
480.3

$
(1,100.2
)

$
1,299.6

$
(599.1
)
(Income) attributable to noncontrolling interest

-

-

-

-

(4.6
)

-

(4.6
)
Net (loss) / income attributable to members

$
(603.7
)

$
(675.1
)

$
-

$
480.3

$
(1,104.8
)

$
1,299.6

$
(603.7
)
Other comprehensive (loss) / income, net of tax

(327.8
)

(428.8
)

-

(572.2
)

(327.8
)

1,328.8

(327.8
)
Comprehensive (loss) / income attributable to
   members

$
(931.5
)

$
(1,103.9
)

$
-

$
(91.9
)

$
(1,432.6
)

$
2,628.4

$
(931.5
)

	Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited			Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited
Net revenues	$	-		$	-		$	-		$	-		$	4,007.4		$	-		$	4,007.4		$	-		$	-		$	-		$	-		$	3,672.1		$	-		$	3,672.1

Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		-			-			-			-			550.2			-			550.2			-			-			-			-			522.8			-			522.8
Research and development		-			-			-			-			489.4			-			489.4			-			-			-			-			474.7			-			474.7
Selling and marketing		-			-			-			-			935.2			-			935.2			-			-			-			-			800.0			-			800.0
General and administrative		-			-			10.1			-			437.6			-			447.7			-			-			(0.7	)		-			294.8			-			294.1
Amortization		-			-			-			-			1,757.9			-			1,757.9			-			-			-			-			1,697.6			-			1,697.6
In-process research and development impairments		-			-			-			-			703.3			-			703.3			-			-			-			-			522.0			-			522.0
Asset sales and impairments, net		-			-			-			-			14.0			-			14.0			-			-			-			-			13.1			-			13.1
Total operating expenses		-			-			10.1			-			4,887.6			-			4,897.7			-			-			(0.7	)		-			4,325.0			-			4,324.3
Operating (loss)		-			-			(10.1	)		-			(880.2	)		-			(890.3	)
Operating income / (loss)																							-			-			0.7			-			(652.9	)		-			(652.2	)

Interest income / (expense), net		-			256.3			61.1			(38.4	)		(519.2	)		-			(240.2	)		-			259.0			(3.3	)		(21.2	)		(414.8	)		-			(180.3	)
Other (expense) / income, net		-			-			(110.4	)		(39.9	)		16.8			-			(133.5	)
Other (expense), net																							-			-			-			-			(78.8	)		-			(78.8	)
Total other income / (expense), net		-			256.3			(49.3	)		(78.3	)		(502.4	)		-			(373.7	)		-			259.0			(3.3	)		(21.2	)		(493.6	)		-			(259.1	)
Income / (loss) before income taxes and noncontrolling interest		-			256.3			(59.4	)		(78.3	)		(1,382.6	)		-			(1,264.0	)		-			259.0			(2.6	)		(21.2	)		(1,146.5	)		-			(911.3	)
(Benefit) for income taxes		-			-			(0.9	)		(73.9	)		(506.4	)		-			(581.2	)
Provision / (benefit) for income taxes																							-			-			0.3			(12.2	)		(670.3	)		-			(682.2	)
Losses / (earnings) of equity interest subsidiaries		693.2			982.1			-			84.9			-			(1,760.2	)		-			231.3			506.0			331.7			645.3			-			(1,714.3	)		-
Net (loss) / income from continuing operations, net of tax	$	(693.2	)	$	(725.8	)	$	(58.5	)	$	(89.3	)	$	(876.2	)	$	1,760.2		$	(682.8	)
(Loss) from discontinued operations, net of tax		-			-			-			-			(8.4	)		-			(8.4	)
Net (loss) / income	$	(693.2	)	$	(725.8	)	$	(58.5	)	$	(89.3	)	$	(884.6	)	$	1,760.2		$	(691.2	)	$	(231.3	)	$	(247.0	)	$	(334.6	)	$	(654.3	)	$	(476.2	)	$	1,714.3		$	(229.1	)
(Income) attributable to noncontrolling interest		-			-			-			-			(2.0	)		-			(2.0	)		-			-			-			-			(2.2	)		-			(2.2	)
Net (loss) / income attributable to members	$	(693.2	)	$	(725.8	)	$	(58.5	)	$	(89.3	)	$	(886.6	)	$	1,760.2		$	(693.2	)	$	(231.3	)	$	(247.0	)	$	(334.6	)	$	(654.3	)	$	(478.4	)	$	1,714.3		$	(231.3	)
Other comprehensive income / (loss), net of tax		903.3			960.5			-			2,152.7			903.3			(4,016.5	)		903.3			183.8			270.6			118.5			358.5			183.8			(931.4	)		183.8
Comprehensive income / (loss) attributable to members	$	210.1		$	234.7		$	(58.5	)	$	2,063.4		$	16.7		$	(2,256.3	)	$	210.1
Comprehensive (loss) / income attributable to members																						$	(47.5	)	$	23.6		$	(216.1	)	$	(295.8	)	$	(294.6	)	$	782.9		$	(47.5	)

Warner
Chilcott
Limited
(Parent
Guarantor)

Allergan
Capital
S.a.r.l.
(Guarantor)

Allergan
Funding
SCS
(Issuer)

Allergan
Finance,
LLC
(Issuer and
Guarantor)

Non-
guarantors

Eliminations

Consolidated
Warner
Chilcott
Limited

Net revenues

$
-

$
-

$
-

$
-

$
7,580.3

$
-

$
7,580.3

Operating expenses:

Cost of sales (excludes amortization and
   impairment of acquired intangibles including
   product rights)

-

-

-

-

1,000.6

-

1,000.6

Research and development

-

-

-

-

1,249.3

-

1,249.3

Selling and marketing

-

-

-

-

1,804.3

-

1,804.3

General and administrative

-

-

10.1

1.1

750.8

-

762.0

Amortization

-

-

-

-

3,493.9

-

3,493.9

In-process research and development
   impairments

-

-

-

-

1,043.3

-

1,043.3

Asset sales and impairments, net

-

-

-

-

21.4

-

21.4

Total operating expenses

-

-

10.1

1.1

9,363.6

-

9,374.8

Operating (loss)

-

-

(10.1
)

(1.1
)

(1,783.3
)

-

(1,794.5
)

Interest income / (expense), net

-

528.1

64.8

(78.0
)

(993.4
)

-

(478.5
)
Other (expense), net

-

-

(110.4
)

(39.9
)

(1,906.0
)

-

(2,056.3
)
Total other income / (expense), net

-

528.1

(45.6
)

(117.9
)

(2,899.4
)

-

(2,534.8
)
Income / (loss) before income taxes and
   noncontrolling interest

-

528.1

(55.7
)

(119.0
)

(4,682.7
)

-

(4,329.3
)
(Benefit) for income taxes

-

(0.2
)

-

(59.0
)

(1,054.1
)

-

(1,113.3
)
Losses / (earnings) of equity interest subsidiaries

3,230.5

3,782.4

-

2,225.8

-

(9,238.7
)

-

Net (loss) / income from continuing operations,
   net of tax

$
(3,230.5
)

$
(3,254.1
)

$
(55.7
)

$
(2,285.8
)

$
(3,628.6
)

$
9,238.7

$
(3,216.0
)
(Loss) from discontinued operations, net of tax

-

-

-

-

(11.5
)

-

(11.5
)
Net (loss) / income

$
(3,230.5
)

$
(3,254.1
)

$
(55.7
)

$
(2,285.8
)

$
(3,640.1
)

$
9,238.7

$
(3,227.5
)
(Income) attributable to noncontrolling interest

-

-

-

-

(3.0
)

-

(3.0
)
Net (loss) / income attributable to members

$
(3,230.5
)

$
(3,254.1
)

$
(55.7
)

$
(2,285.8
)

$
(3,643.1
)

$
9,238.7

$
(3,230.5
)
Other comprehensive income / (loss), net of tax

2,663.4

2,720.6

-

3,793.6

2,663.4

(9,177.6
)

2,663.4

Comprehensive (loss) / income attributable to
   members

$
(567.1
)

$
(533.5
)

$
(55.7
)

$
1,507.8

$
(979.7
)

$
61.1

$
(567.1
)

	Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited			Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations				Consolidated Warner Chilcott Limited
Cash Flows From Operating Activities:
Net (loss) / income	$	(603.7	)	$	(675.1	)	$	-		$	480.3		$	(1,100.2	)	$	1,299.6		$	(599.1	)	$	(2,405.7	)	$	(2,368.4	)	$	(869.0	)	$	(2,397.3	)	$	(2,302.0	)	$	7,937.4			$	(2,405.0	)
Reconciliation to net cash provided by / (used in) operating activities:
Losses / (earnings) of equity interest subsidiaries		603.7			1,201.5			-			(505.6	)		-			(1,299.6	)		-			2,405.7			2,345.0			809.3			2,377.4			-			(7,937.4	)			-
Depreciation		-			-			-			-			105.2			-			105.2			-			-			-			-			47.5			-				47.5
Amortization		-			-			-			-			3,394.7			-			3,394.7			-			-			-			-			1,399.4			-				1,399.4
Provision for inventory reserve		-			-			-			-			45.4			-			45.4			-			-			-			-			18.8			-				18.8
Share-based compensation		-			-			-			-			127.4			-			127.4			-			-			-			-			52.3			-				52.3
Deferred income tax benefit		-			-			-			-			(1,359.6	)		-			(1,359.6	)		-			-			-			-			(229.7	)		-				(229.7	)
In-process research and development impairments		-			-			-			-			798.0			-			798.0
Loss on asset sales and impairments, net		-			-			-			-			272.7			-			272.7
Gain on sale of Teva securities, net		-			-			-			-			(60.9	)		-			(60.9	)
Gain on sale of business		-			-			-			-			(53.0	)		-			(53.0	)
Goodwill impairments																							-			-			-			-			2,467.0							2,467.0
(Gain) on asset sales and impairments, net																							-			-			-			-			(5.2	)		-				(5.2	)
Non-cash extinguishment of debt		-			-			4.0			-			-			-			4.0			-			-			-			-			0.3			-				0.3
Cash charge related to extinguishment of debt		-			-			(13.1	)		-			-			-			(13.1	)
Amortization of deferred financing costs		-			-			11.1			0.8			-			-			11.9			-			-			4.1			0.4			0.1			-				4.6
Non-cash lease expense																							-			-			-			-			30.1			-				30.1
Contingent consideration adjustments, including accretion		-			-			-			-			(101.8	)		-			(101.8	)		-			-			-			-			18.7			-				18.7
Dividends from subsidiaries		2,103.7			-			-			-			-			(2,103.7	)		-			1,045.8			-			-			-			-			(1,045.8	)			-
Other, net		-			-			(1.5	)		(0.4	)		1.6			-			(0.3	)		-			-			(1.3	)		(0.4	)		(8.6	)		-				(10.3	)
Changes in assets and liabilities (net of effects of acquisitions)		-			(1,225.0	)		3,942.3			24.9			(2,578.4	)		-			163.8			-			(207.4	)		209.4			19.9			(196.2	)		-				(174.3	)
Net cash provided by / (used in) operating activities		2,103.7			(698.6	)		3,942.8			-			(508.9	)		(2,103.7	)		2,735.3			1,045.8			(230.8	)		152.5			-			1,292.5			(1,045.8	)			1,214.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment		-			-			-			-			(106.5	)		-			(106.5	)		-			-			-			-			(64.8	)		-				(64.8	)
Additions to product rights and other intangibles																							-			-			-			-			(7.5	)		-				(7.5	)
Additions to investments		-			(400.0	)		-			-			(1,055.9	)		-			(1,455.9	)		-			-			-			-			(538.2	)		-				(538.2	)
Proceeds from sale of investments and other assets		-			800.0			-			-			4,851.3			-			5,651.3			-			289.4			-			-			279.7			-				569.1
Payments to settle Teva related matters		-			-			-			-			(466.0	)		-			(466.0	)
Proceeds from sales of property, plant and equipment		-			-			-			-			11.5			-			11.5			-			-			-			-			17.2			-				17.2
Net cash provided by investing activities		-			400.0			-			-			3,234.4			-			3,634.4
Acquisitions of businesses, net of cash acquired																							-			-			-			-			(80.6	)		-				(80.6	)
Net cash provided by / (used in) investing activities																							-			289.4			-			-			(394.2	)		-				(104.8	)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		-			700.0			-			-			9.0			-			709.0
Proceeds from forward sale of Teva securities		-			-			-			-			465.5			-			465.5
Payments on debt, including capital lease obligations and credit facility		-			(700.0	)		(3,956.0	)		-			(710.8	)		-			(5,366.8	)
Cash charge related to extinguishment of debt		-			-			13.1			-			-			-			13.1
Payments on debt, including finance lease obligations and credit facility																							-			-			(152.0	)		-			(7.4	)		-		��		(159.4	)
Payments of contingent consideration and other financing		-			-			-			-			(10.6	)		-			(10.6	)		-			-			-			-			(2.0	)		-				(2.0	)
Payments to settle Teva related matters		-			-			-			-			(234.0	)		-			(234.0	)
Dividends to Parents		(2,103.7	)		-			-			-			(2,103.7	)		2,103.7			(2,103.7	)		(1,045.8	)		-			-			-			(1,045.8	)		1,045.8				(1,045.8	)
Net cash (used in) / provided by financing activities		(2,103.7	)		-			(3,942.9	)		-			(2,584.6	)		2,103.7			(6,527.5	)		(1,045.8	)		-			(152.0	)		-			(1,055.2	)		1,045.8				(1,207.2	)
Effect of currency exchange rate changes on cash and cash equivalents		-			-			-			-			15.0			-			15.0			-			-			-			-			5.9			-				5.9
Net (decrease) / increase in cash and cash equivalents		-			(298.6	)		(0.1	)		-			155.9			-			(142.8	)
Net increase / (decrease) in cash and cash equivalents																							-			58.6			0.5			-			(151.0	)		-				(91.9	)
Cash and cash equivalents at beginning of period		0.1			593.1			0.1			-			1,223.0			-			1,816.3			0.1			1.8			0.8			-			875.9			-				878.6
Cash and cash equivalents at end of period	$	0.1		$	294.5		$	0.0		$	-		$	1,378.9		$	-		$	1,673.5		$	0.1		$	60.4		$	1.3		$	-		$	724.9		$	-			$	786.7

	Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited			Warner Chilcott Limited (Parent Guarantor)			Allergan Capital S.a.r.l. (Guarantor)			Allergan Funding SCS (Issuer)			Allergan Finance, LLC (Issuer and Guarantor)			Non- guarantors			Eliminations			Consolidated Warner Chilcott Limited
Cash Flows From Operating Activities:
Net (loss) / income	$	(3,230.5	)	$	(3,254.1	)	$	(55.7	)	$	(2,285.8	)	$	(3,640.1	)	$	9,238.7		$	(3,227.5	)	$	(231.3	)	$	(247.0	)	$	(334.6	)	$	(654.3	)	$	(476.2	)	$	1,714.3		$	(229.1	)
Reconciliation to net cash provided by / (used in) operating activities:
Losses / (earnings) of equity interest subsidiaries		3,230.5			3,782.4			-			2,225.8			-			(9,238.7	)		-			231.3			506.0			331.7			645.3			-			(1,714.3	)		-
Depreciation		-			-			-			-			81.2			-			81.2			-			-			-			-			56.1			-			56.1
Amortization		-			-			-			-			3,493.9			-			3,493.9			-			-			-			-			1,697.6			-			1,697.6
Provision for inventory reserve		-			-			-			-			48.7			-			48.7			-			-			-			-			14.2			-			14.2
Share-based compensation		-			-			-			-			148.5			-			148.5			-			-			-			-			72.5			-			72.5
Deferred income tax benefit		-			-			-			-			(1,478.8	)		-			(1,478.8	)		-			-			-			-			(1,026.4	)		-			(1,026.4	)
In-process research and development impairments		-			-			-			-			1,043.3			-			1,043.3			-			-			-			-			522.0			-			522.0
Loss on asset sales and impairments, net		-			-			-			-			21.4			-			21.4			-			-			-			-			13.1			-			13.1
Net income impact of other-than-temporary loss on investment in Teva securities		-			-			-			-			1,978.0			-			1,978.0
Amortization of inventory step up		-			-			-			-			87.8			-			87.8
Non-cash extinguishment of debt		-			-			17.6			12.2			(38.0	)		-			(8.2	)
Cash charge related to extinguishment of debt		-			-			91.6			26.1			52.8			-			170.5
Loss on sale of Teva securities, net																							-			-			-			-			77.7			-			77.7
Amortization of deferred financing costs		-			-			11.1			2.1			-			-			13.2			-			-			5.9			0.4			-			-			6.3
Contingent consideration adjustments, including accretion		-			-			-			-			15.2			-			15.2			-			-			-			-			5.3			-			5.3
Dividends from subsidiaries		611.9			-			-			-			-			(611.9	)		-			1,859.5			-			-			-			-			(1,859.5	)		-
Other, net		-			(10.0	)		-			-			(12.6	)		-			(22.6	)		-			-			(1.5	)		(0.4	)		8.4			-			6.5
Changes in assets and liabilities (net of effects of acquisitions)		-			(4,901.7	)		(176.4	)		1,789.0			3,519.1			-			230.0			-			(1,675.2	)		3,498.5			9.0			(1,453.5	)		-			378.8
Net cash provided by / (used in) operating activities		611.9			(4,383.4	)		(111.8	)		1,769.4			5,320.4			(611.9	)		2,594.6			1,859.5			(1,416.2	)		3,500.0			-			(489.2	)		(1,859.5	)		1,594.6
Cash Flows From Investing Activities:
Additions to property, plant and equipment		-			-			-			-			(137.2	)		-			(137.2	)		-			-			-			-			(46.4	)		-			(46.4	)
Additions to product rights and other intangibles		-			-			-			-			(586.3	)		-			(586.3	)
Additions to investments		-			(3,989.6	)		-			-			(2,798.3	)		-			(6,787.9	)		-			(400.0	)		-			-			(1,055.9	)		-			(1,455.9	)
Proceeds from sale of investments and other assets		-			7,866.4			-			-			5,331.1			-			13,197.5			-			800.0			-			-			4,089.5			-			4,889.5
Payments to settle Teva related matters																							-			-			-			-			(466.0	)		-			(466.0	)
Proceeds from sales of property, plant and equipment		-			-			-			-			4.3			-			4.3			-			-			-			-			11.1			-			11.1
Acquisitions of business, net of cash acquired		-			-			-			-			(5,290.4	)		-			(5,290.4	)
Net cash provided by / (used in) investing activities		-			3,876.8			-			-			(3,476.8	)		-			400.0
Net cash provided by investing activities																							-			400.0			-			-			2,532.3			-			2,932.3
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		-			-			3,020.9			-			2.1			-			3,023.0			-			700.0			-			-			9.0			-			709.0
Debt issuance and other financing costs		-			-			(17.5	)		-			-			-			(17.5	)
Payments on debt, including capital lease obligations and credit facility		-			-			(2,800.0	)		(1,743.3	)		(1,035.9	)		-			(5,579.2	)
Cash charge related to extinguishment of debt		-			-			(91.6	)		(26.1	)		(52.8	)		-			(170.5	)
Payments on debt, including finance lease obligations and credit facility																							-			(200.0	)		(3,500.0	)		-			(622.1	)		-			(4,322.1	)
Payments of contingent consideration and other financing		-			-			-			-			(505.1	)		-			(505.1	)		-			-			-			-			(9.3	)		-			(9.3	)
Proceeds from forward sale of Teva securities																							-			-			-			-			372.3			-			372.3
Payments to settle Teva related matters																							-			-			-			-			(234.0	)		-			(234.0	)
Dividends to Parents		(611.9	)		-			-			-			(611.9	)		611.9			(611.9	)		(1,859.5	)		-			-			-			(1,859.5	)		1,859.5			(1,859.5	)
Net cash (used in) / provided by financing activities		(611.9	)		-			111.8			(1,769.4	)		(2,203.6	)		611.9			(3,861.2	)		(1,859.5	)		500.0			(3,500.0	)		-			(2,343.6	)		1,859.5			(5,343.6	)
Effect of currency exchange rate changes on cash and cash equivalents		-			-			-			-			11.5			-			11.5			-			-			-			-			(5.3	)		-			(5.3	)
Net (decrease) in cash and cash equivalents		-			(506.6	)		-			-			(348.5	)		-			(855.1	)		-			(516.2	)		-			-			(305.8	)		-			(822.0	)
Cash and cash equivalents at beginning of period		0.1			513.9			-			-			1,199.2			-			1,713.2			0.1			593.1			0.1			-			1,223.0			-			1,816.3
Cash and cash equivalents at end of period	$	0.1		$	7.3		$	-		$	-		$	850.7		$	-		$	858.1		$	0.1		$	76.9		$	0.1		$	-		$	917.2		$	-		$	994.3

The following discussion of our financial condition and the results of operations should be read in conjunction with the “Consolidated Financial Statements” and notes thereto included elsewhere in this Quarterly Report on Form 10-Q (“Quarterly Report”) and our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2017~~2018 (the “Annual Report”). This discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, among others, those identified under “Risk Factors” in our Annual Report, and elsewhere in this Quarterly Report.

References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group (together with other direct or indirect parents of Warner Chilcott Limited, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited disclosures relate only to itself and not to any other company.

The following are the significant transactions that were completed or announced in the ~~six~~three months ended ~~June 30, 2018.~~March 31, 2019.

On April 6, 2018, the Company completed the acquisition of Elastagen Pty Ltd, which was accounted for as an asset acquisition as the purchase primarily related to one asset. An upfront expense of $96.1 million was expensed as a component of research and development (“R&D”) during the three and six months ended June 30, 2018. Under the terms of the agreement, Elastagen Pty Ltd is eligible to receive additional consideration of up to $165.0 million.

On ~~January 31, 2018,~~March 26, 2019, the Company ~~completed the~~acquired Envy Medical, Inc. (“Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of ~~Repros Therapeutics, Inc.,~~$81.4 million, which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities. The transaction was ~~accounted for as an asset acquisition as the purchase primarily related to one asset. A net charge of $33.2 million was expensed~~treated as a ~~component of R&D during~~business combination. The acquisition combines Envy’s skin care product portfolio with the ~~six months ended June 30, 2018.~~Company’s leading medical aesthetics business.

Results for the Three Months Ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~

Results of operations, including segment net revenues, segment operating expenses and segment contribution consisted of the following for the three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30, 2018													Three Months Ended March 31, 2019
		US Specialized Therapeutics			US General Medicine			International			Total				US Specialized Therapeutics			US General Medicine			International			Total
Net revenues		$	1,826.7		$	1,320.0		$	948.9		$	4,095.6			$	1,542.9		$	1,249.9		$	801.5		$	3,594.3

Operating expenses:
Cost of sales⁽¹⁾			148.7			201.8			139.4			489.9				120.1			190.5			109.7			420.3
Selling and marketing			343.3			254.8			246.2			844.3				356.8			210.5			237.6			804.9
General and administrative			48.1			34.7			33.9			116.7				54.6			43.8			25.7			124.1
Segment contribution		$	1,286.6		$	828.7		$	529.4		$	2,644.7			$	1,011.4		$	805.1		$	428.5		$	2,245.0
Contribution margin			70.4	%		62.8	%		55.8	%		64.6	%			65.6	%		64.4	%		53.5	%		62.5	%
Corporate⁽²⁾												189.8													258.0
Research and development												689.2													435.0
Amortization												1,697.1													1,399.4
In-process research and development impairments												276.0
Goodwill impairments																									2,467.0
Asset sales and impairments, net												259.6													(5.2	)
Operating (loss)											$	(467.0	)											$	(2,309.2	)
Segment operating margin												(11.4	)%
Operating margin																									(64.2	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $28.6 million.
⁽²⁾Corporate includes net revenues of $2.8 million.														⁽²⁾Corporate includes net revenues of $2.8 million.

		Three Months Ended June 30, 2017													Three Months Ended March 31, 2018
		US Specialized Therapeutics			US General Medicine			International			Total				US Specialized Therapeutics			US General Medicine			International			Total
Net revenues		$	1,715.0		$	1,427.7		$	858.5		$	4,001.2			$	1,578.6		$	1,223.7		$	864.0		$	3,666.3

Operating expenses:
Cost of sales⁽¹⁾			128.8			203.2			125.0			457.0				134.2			182.6			120.9			437.7
Selling and marketing			356.8			288.1			238.9			883.8				313.2			225.5			245.7			784.4
General and administrative			49.8			41.3			28.3			119.4				50.2			38.9			31.4			120.5
Segment contribution		$	1,179.6		$	895.1		$	466.3		$	2,541.0			$	1,081.0		$	776.7		$	466.0		$	2,323.7
Contribution margin			68.8	%		62.7	%		54.3	%		63.5	%			68.5	%		63.5	%		53.9	%		63.4	%
Corporate⁽²⁾												478.8													270.3
Research and development												489.4													474.7
Amortization												1,757.9													1,697.6
In-process research and development impairments												703.3													522.0
Asset sales and impairments, net												14.0													13.1
Operating (loss)											$	(902.4	)											$	(654.0	)
Segment operating margin												(22.6	)%
Operating margin																									(17.8	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $6.2 million.
⁽²⁾Corporate includes net revenues of $5.8 million.														⁽²⁾Corporate includes net revenues of $5.8 million.

The following table presents top product sales and net contribution for the US Specialized Therapeutics segment for the three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30,						Change							Three Months Ended March 31,						Change
		2018			2017			Dollars			%				2019			2018			Dollars			%
Total Eye Care		$	587.0		$	600.1		$	(13.1	)		(2.2	)%		$	465.1		$	491.1		$	(26.0	)		(5.3	)%
Restasis^®			318.2			336.4			(18.2	)		(5.4	)%			231.7			255.8			(24.1	)		(9.4	)%
Alphagan^®/Combigan^®			98.1			96.4			1.7			1.8	%			83.0			84.2			(1.2	)		(1.4	)%
Lumigan^®/Ganfort^®			73.0			79.0			(6.0	)		(7.6	)%			57.7			66.8			(9.1	)		(13.6	)%
Eye Drops			53.8			50.7			3.1			6.1	%			49.4			46.2			3.2			6.9	%
Ozurdex^®			27.6			24.9			2.7			10.8	%			30.3			25.5			4.8			18.8	%
Other Eye Care			16.3			12.7			3.6			28.3	%			13.0			12.6			0.4			3.2	%
Total Medical Aesthetics			743.6			643.9			99.7			15.5	%			648.2			635.6			12.6			2.0	%
Facial Aesthetics			387.5			349.2			38.3			11.0	%			366.5			327.7			38.8			11.8	%
Botox^® Cosmetics			236.5			210.3			26.2			12.5	%			229.5			196.7			32.8			16.7	%
Juvederm^® Collection			139.8			126.2			13.6			10.8	%			129.7			122.8			6.9			5.6	%
Kybella^®			11.2			12.7			(1.5	)		(11.8	)%			7.3			8.2			(0.9	)		(11.0	)%
Plastic Surgery			75.9			61.3			14.6			23.8	%			61.2			60.7			0.5			0.8	%
Breast Implants			75.9			61.3			14.6			23.8	%			61.2			60.7			0.5			0.8	%
Regenerative Medicine			137.6			115.8			21.8			18.8	%			122.9			128.2			(5.3	)		(4.1	)%
Alloderm^®			107.1			84.6			22.5			26.6	%			95.0			99.5			(4.5	)		(4.5	)%
Other Regenerative Medicine			30.5			31.2			(0.7	)		(2.2	)%			27.9			28.7			(0.8	)		(2.8	)%
Body Contouring			108.3			78.9			29.4			37.3	%			62.9			87.1			(24.2	)		(27.8	)%
Coolsculpting^® Consumables			71.9			47.9			24.0			50.1	%			47.8			53.4			(5.6	)		(10.5	)%
Coolsculpting^® Systems & Add On Applicators			36.4			31.0			5.4			17.4	%			15.1			33.7			(18.6	)		(55.2	)%
Skin Care(3)			34.3			38.7			(4.4	)		(11.4	)%			34.7			31.9			2.8			8.8	%
SkinMedica^®			20.8			25.4			(4.6	)		(18.1	)%
Latisse^®			13.5			13.3			0.2			1.5	%
Total Medical Dermatology			56.5			81.8			(25.3	)		(30.9	)%			6.1			36.7			(30.6	)		(83.4	)%
Aczone^®			21.1			41.0			(19.9	)		(48.5	)%			1.6			16.0			(14.4	)		(90.0	)%
Botox^® Hyperhidrosis			17.3			16.8			0.5			3.0	%
Tazorac^®			6.4			12.8			(6.4	)		(50.0	)%
Other Medical Dermatology			11.7			11.2			0.5			4.5	%
Other Medical Dermatology⁽⁴⁾																4.5			20.7			(16.2	)		(78.3	)%
Total Neuroscience and Urology			424.4			372.6			51.8			13.9	%			409.4			398.6			10.8			2.7	%
Botox^® Therapeutics			404.7			346.9			57.8			16.7	%
Botox^® Therapeutics⁽⁵⁾																397.6			375.8			21.8			5.8	%
Rapaflo^®			19.7			25.7			(6.0	)		(23.3	)%			11.8			22.8			(11.0	)		(48.2	)%
Other Revenues			15.2			16.6			(1.4	)		(8.4	)%
Other revenues																14.1			16.6			(2.5	)		(15.1	)%
Net revenues		$	1,826.7		$	1,715.0		$	111.7			6.5	%		$	1,542.9		$	1,578.6		$	(35.7	)		(2.3	)%
Operating expenses:
Cost of sales⁽¹⁾			148.7			128.8			19.9			15.5	%			120.1			134.2			(14.1	)		(10.5	)%
Selling and marketing			343.3			356.8			(13.5	)		(3.8	)%			356.8			313.2			43.6			13.9	%
General and administrative			48.1			49.8			(1.7	)		(3.4	)%			54.6			50.2			4.4			8.8	%
Segment contribution		$	1,286.6		$	1,179.6		$	107.0			9.1	%		$	1,011.4		$	1,081.0		$	(69.6	)		(6.4	)%
Segment margin			70.4	%		68.8	%					1.6	%			65.6	%		68.5	%					(2.9	)%
Segment gross margin⁽²⁾			91.9	%		92.5	%					(0.6	)%			92.2	%		91.5	%					0.7	%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.	⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.													⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.
⁽³⁾ Includes SkinMedica^® and Latisse^®.														⁽³⁾ Includes SkinMedica^® and Latisse^®.
⁽⁴⁾ Includes Tazorac^® sales of $9.4 million which were previously disclosed separately in the three months ended March 31, 2018.														⁽⁴⁾ Includes Tazorac^® sales of $9.4 million which were previously disclosed separately in the three months ended March 31, 2018.
⁽⁵⁾ Includes Botox^® Hyperhidrosis of $17.3 million which was previously disclosed under Medical Dermatology in the three months ended March 31, 2018.														⁽⁵⁾ Includes Botox^® Hyperhidrosis of $17.3 million which was previously disclosed under Medical Dermatology in the three months ended March 31, 2018.

The ~~Zeltiq~~^® ~~Aesthetics, Inc. (“Zeltiq”) acquisition (the “Zeltiq Acquisition”) contributed the following to the segment~~decrease in net revenues in the three months ended ~~June 30,~~March 31, 2019 was primarily driven by decreases in Restasis^®, Body Contouring and the third quarter 2018 ~~and 2017 ($ in millions):~~

~~The increase in net revenues was impacted~~divestiture of our Medical Dermatology business, partially offset by ~~the Zeltiq Acquisition which contributed three months of revenue in the current quarter compared to two months of revenue in the prior year period and~~ growth in Botox^® ~~Therapeutics,~~Cosmetics and Botox^® ~~Cosmetics and Alloderm~~^® ~~partially offset by decreases in Restasis~~^® ~~and Aczone~~^®.

~~Botox~~^® ~~Therapeutics, Botox~~^® ~~Cosmetics and Alloderm~~^®~~increased $57.8 million, or 16.7%, $26.2 million, or 12.5%, and $22.5 million, or 26.6%, respectively, versus the prior year period primarily driven by demand growth.~~

~~The decline in Aczone~~^® ~~revenues of $19.9 million, or 48.5%, was due to genericization of the branded acne market, increased discounts to maintain formulary access and a generic launch of Aczone 5%.~~

Therapeutics. The decline in Restasis^® revenues ~~of $18.2 million, or 5.4%,~~ was primarily due to price declines. ~~As a result of the U.S. District Court for the Eastern District of Texas issuing an adverse trial decision finding that the four asserted patents covering Restasis~~^® ~~(Cyclosporine Ophthalmic Emulsion) 0.05% are invalid, there is a potential for future declines in Restasis~~^® ~~revenues due to generic competition.~~

~~The increase in cost of sales was due in part to the Zeltiq Acquisition and an increase in net revenues. Excluding the Zeltiq Acquisition in both periods, segment gross margin~~Body Contouring decreased ~~to 92.9% in the three months ended June 30, 2018~~ versus ~~93.5% in~~ the prior year period primarily due to lower volumes of systems. Botox^® Cosmetics and Botox^® Therapeutics increased versus the prior year period primarily due to demand growth.

The decrease in cost of sales in the three months ended March 31, 2019 was primarily due to the decrease in net revenues and product mix.

The ~~decrease~~increase in selling and marketing expenses in the three months ended March 31, 2019 was primarily ~~due~~related to ~~lower headcount in the Eye Care and Medical Dermatology field forces due to the Company’s restructuring initiatives, lower~~increased promotional costs ~~and a decrease in the charge~~ for ~~the non-tax deductible Branded Prescription Drug Fee offset in part by the impact of the Zeltiq Acquisition.~~Facial Aesthetics products.

General and administrative expenses ~~are consistent period-over-period.~~remained stable period over period.

The following table presents top product sales and net contribution for the US General Medicine segment for the three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30,						Change							Three Months Ended March 31,						Change
		2018			2017			Dollars			%				2019			2018			Dollars			%
Total Central Nervous System (CNS)		$	269.9		$	346.6		$	(76.7	)		(22.1	)%		$	293.5		$	262.8		$	30.7			11.7	%
Vraylar^™			114.2			66.3			47.9			72.2	%
Vraylar^®																143.7			84.4			59.3			70.3	%
Viibryd^®/Fetzima^®			86.7			85.2			1.5			1.8	%			85.0			71.7			13.3			18.5	%
Saphris^®			33.8			43.0			(9.2	)		(21.4	)%			31.9			32.7			(0.8	)		(2.4	)%
Namzaric^®			31.8			33.4			(1.6	)		(4.8	)%			23.4			33.4			(10.0	)		(29.9	)%
Namenda XR^®			3.4			118.7			(115.3	)		(97.1	)%
Namenda^®(3)																9.5			40.6			(31.1	)		(76.6	)%
Total Gastrointestinal (GI)			431.9			410.8			21.1			5.1	%			358.2			388.7			(30.5	)		(7.8	)%
Linzess^®			191.8			167.8			24.0			14.3	%			161.3			159.3			2.0			1.3	%
Zenpep^®			55.5			50.5			5.0			9.9	%			63.0			52.9			10.1			19.1	%
Carafate^®/Sulcrate^®			54.3			59.2			(4.9	)		(8.3	)%			54.3			56.0			(1.7	)		(3.0	)%
Canasa^®/Salofalk^®			45.0			38.4			6.6			17.2	%
Viberzi^®			44.9			41.3			3.6			8.7	%			37.2			35.9			1.3			3.6	%
Asacol^®/Delzicol^®			32.6			45.6			(13.0	)		(28.5	)%			24.7			38.2			(13.5	)		(35.3	)%
Canasa^®/Salofalk^®																10.2			38.6			(28.4	)		(73.6	)%
Other GI			7.8			8.0			(0.2	)		(2.5	)%			7.5			7.8			(0.3	)		(3.8	)%
Total Women's Health			196.5			248.0			(51.5	)		(20.8	)%			201.0			163.3			37.7			23.1	%
Lo Loestrin^®			127.8			113.0			14.8			13.1	%			125.8			114.6			11.2			9.8	%
Liletta^®			15.5			6.6			8.9			134.8	%			14.8			8.1			6.7			82.7	%
Estrace^® Cream			13.1			90.1			(77.0	)		(85.5	)%
Minastrin^® 24			0.8			11.4			(10.6	)		(93.0	)%
Other Women's Health			39.3			26.9			12.4			46.1	%
Other Women's Health⁽⁴⁾⁽⁵⁾																60.4			40.6			19.8			48.8	%
Total Anti-Infectives			79.8			67.8			12.0			17.7	%			81.6			71.6			10.0			14.0	%
Teflaro^®			32.4			33.0			(0.6	)		(1.8	)%			33.5			32.2			1.3			4.0	%
Avycaz^®			23.5			14.5			9.0			62.1	%			29.7			21.8			7.9			36.2	%
Dalvance^®			17.7			15.2			2.5			16.4	%			12.0			11.9			0.1			0.8	%
Other Anti-Infectives			6.2			5.1			1.1			21.6	%			6.4			5.7			0.7			12.3	%
Diversified Brands			284.9			305.5			(20.6	)		(6.7	)%			270.9			274.9			(4.0	)		(1.5	)%
Bystolic^®/ Byvalson^®			148.1			150.7			(2.6	)		(1.7	)%			128.3			132.8			(4.5	)		(3.4	)%
Armour Thyroid			49.2			42.0			7.2			17.1	%			50.0			48.2			1.8			3.7	%
Savella^®			19.1			26.0			(6.9	)		(26.5	)%			20.7			19.9			0.8			4.0	%
Lexapro^®			14.5			13.1			1.4			10.7	%
PacPharma			3.7			3.7			-			0.0	%
Other Diversified Brands			50.3			70.0			(19.7	)		(28.1	)%
Other Diversified Brands⁽⁶⁾⁽⁷⁾																71.9			74.0			(2.1	)		(2.8	)%
Other revenues			57.0			49.0			8.0			16.3	%			44.7			62.4			(17.7	)		(28.4	)%
Net revenues		$	1,320.0		$	1,427.7		$	(107.7	)		(7.5	)%		$	1,249.9		$	1,223.7		$	26.2			2.1	%
Operating expenses:
Cost of sales⁽¹⁾			201.8			203.2			(1.4	)		(0.7	)%			190.5			182.6			7.9			4.3	%
Selling and marketing			254.8			288.1			(33.3	)		(11.6	)%			210.5			225.5			(15.0	)		(6.7	)%
General and administrative			34.7			41.3			(6.6	)		(16.0	)%			43.8			38.9			4.9			12.6	%
Segment contribution		$	828.7		$	895.1		$	(66.4	)		(7.4	)%		$	805.1		$	776.7		$	28.4			3.7	%
Segment margin			62.8	%		62.7	%					0.1	%			64.4	%		63.5	%					0.9	%
Segment gross margin⁽²⁾			84.7	%		85.8	%					(1.1	)%			84.8	%		85.1	%					(0.3	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.													⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.	⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.													⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.
⁽³⁾Includes Namenda XR^® and Namenda^® IR.														⁽³⁾Includes Namenda XR^® and Namenda^® IR.
⁽⁴⁾Includes Estrace^® Cream sales of $6.4 million which were previously disclosed separately in the three months ended March 31, 2018.														⁽⁴⁾Includes Estrace^® Cream sales of $6.4 million which were previously disclosed separately in the three months ended March 31, 2018.
⁽⁵⁾Includes Minastrin^® 24 sales of $5.2 million which were previously disclosed separately in the three months ended March 31, 2018.														⁽⁵⁾Includes Minastrin^® 24 sales of $5.2 million which were previously disclosed separately in the three months ended March 31, 2018.
⁽⁶⁾Includes Lexapro^® sales of $14.7 million which were previously disclosed separately in the three months ended March 31, 2018.														⁽⁶⁾Includes Lexapro^® sales of $14.7 million which were previously disclosed separately in the three months ended March 31, 2018.
⁽⁷⁾Includes PacPharma sales of $4.4 million which were previously disclosed separately in the three months ended March 31, 2018.														⁽⁷⁾Includes PacPharma sales of $4.4 million which were previously disclosed separately in the three months ended March 31, 2018.

The ~~decrease~~increase in net revenues in the three months ended March 31, 2019 was primarily due to growth in CNS and Women’s Health, offset, in part, by a decline in ~~products that lost exclusivity including Namenda XR~~GI revenues. CNS revenues increased primarily due to strong demand growth for Vraylar^®and Viibryd^® ~~($115.3 million) and Estrace~~^® ~~Cream ($77.0 million)~~, offset, in part by ~~growth in Vraylar~~^™~~, Linzess~~^®~~, and Lo Loestrin~~^®.

~~CNS revenues declined $76.7 million, or 22.1%, primarily due to~~ the decline in Namenda XR^® as a result of loss of ~~exclusivity~~exclusivity. Women’s Health revenues increased primarily due to an increase in demand for Lo Loestrin^®. GI was negatively affected by the generic impact on Canasa^®/Salofalk^®and Asacol^®, offset, in part by ~~strong~~an increase in demand growth for ~~Vraylar~~^™.

~~Women’s Health revenues declined $51.5 million, or 20.8%, primarily due to the loss of exclusivity on Estrace~~^® ~~Cream and Minastrin~~^® ~~24 offset, in part, by growth for Lo Loestrin~~^® ~~driven by higher average selling prices and increased demand.~~

~~GI revenues increased $21.1 million, or 5.1%, primarily due to growth for Linzess~~^® ~~resulting from increased demand, offset, in part, by the continued generic erosion of the market for Asacol~~Zenpep^®.

The ~~decrease~~increase in cost of sales ~~was primarily due to lower product sales and product mix, including loss of exclusivity on higher margin products. Segment gross margin was 84.7%~~ in the three months ended ~~June 30, 2018 compared~~March 31, 2019 was primarily due to ~~85.8%~~an increase in ~~the prior year period.~~net revenues.

The decrease in selling and marketing expenses in the three months ended March 31, 2019 was related to ~~headcount reductions from the Company’s restructuring initiatives,~~ lower promotional ~~costs, and a decrease in the charge for the non-tax deductible Branded Prescription Drug Fee.~~costs.

General and administrative expenses ~~decreased period-over-period due to cost savings initiatives.~~increased $4.9 million period over period.

The following table presents top product sales and net contribution for the International segment for the three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30,						Change																			Three Months Ended March 31,						Change
		2018			2017			$ Overall Change			$ Operational Change ⁽³⁾			$ Currency Change			% Overall Change			% Operational Change⁽³⁾			% Currency Change				2019			2018			$ Overall Change			$ Operational Change ⁽³⁾			$ Currency Change			% Overall Change			% Operational Change⁽³⁾			% Currency Change
Total Eye Care		$	353.7		$	322.0		$	31.7		$	25.2		$	6.5			9.8	%		7.8	%		2.0	%		$	291.8		$	343.7		$	(51.9	)	$	(22.3	)	$	(29.6	)		(15.1	)%		(6.5	)%		(8.6	)%
Lumigan^®/Ganfort^®			100.5			94.4			6.1			1.5			4.6			6.5	%		1.6	%		4.9	%			85.1			100.4			(15.3	)		(7.8	)		(7.5	)		(15.2	)%		(7.8	)%		(7.4	)%
Ozurdex^®			67.9			51.2			16.7			14.1			2.6			32.6	%		27.5	%		5.1	%			63.1			64.4			(1.3	)		4.3			(5.6	)		(2.0	)%		6.7	%		(8.7	)%
Eye Drops⁽⁴⁾																												55.4			68.8			(13.4	)		(7.3	)		(6.1	)		(19.5	)%		(10.6	)%		(8.9	)%
Alphagan^®/Combigan^®			44.6			42.7			1.9			2.2			(0.3	)		4.4	%		5.2	%		(0.8	)%			37.6			44.2			(6.6	)		(2.4	)		(4.2	)		(14.9	)%		(5.4	)%		(9.5	)%
Optive^®			30.7			27.6			3.1			2.8			0.3			11.2	%		10.1	%		1.1	%
Restasis^®			16.0			17.3			(1.3	)		(1.1	)		(0.2	)		(7.5	)%		(6.4	)%		(1.1	)%			10.4			18.3			(7.9	)		(6.5	)		(1.4	)		(43.2	)%		(35.5	)%		(7.7	)%
Other Eye Drops			41.7			43.1			(1.4	)		(1.7	)		0.3			(3.2	)%		(3.9	)%		0.7	%
Other Eye Care			52.3			45.7			6.6			7.4			(0.8	)		14.4	%		16.2	%		(1.8	)%			40.2			47.6			(7.4	)		(2.6	)		(4.8	)		(15.5	)%		(5.5	)%		(10.0	)%
Total Medical Aesthetics			409.8			358.1			51.7			44.4			7.3			14.4	%		12.4	%		2.0	%			352.8			358.5			(5.7	)		26.0			(31.7	)		(1.6	)%		7.3	%		(8.9	)%
Facial Aesthetics			329.8			287.6			42.2			36.5			5.7			14.7	%		12.7	%		2.0	%			306.8			296.1			10.7			39.6			(28.9	)		3.6	%		13.4	%		(9.8	)%
Juvederm^® Collection																												157.8			146.1			11.7			26.7			(15.0	)		8.0	%		18.3	%		(10.3	)%
Botox^® Cosmetics			171.4			148.3			23.1			20.9			2.2			15.6	%		14.1	%		1.5	%			147.4			148.6			(1.2	)		12.6			(13.8	)		(0.8	)%		8.5	%		(9.3	)%
Juvederm^® Collection			156.1			137.3			18.8			15.4			3.4			13.7	%		11.2	%		2.5	%
Belkyra^® (Kybella^®)			2.3			2.0			0.3			0.2			0.1			15.0	%		10.0	%		5.0	%			1.6			1.4			0.2			0.3			(0.1	)		14.3	%		21.4	%		(7.1	)%
Plastic Surgery			40.3			41.5			(1.2	)		(2.0	)		0.8			(2.9	)%		(4.8	)%		1.9	%			11.6			44.5			(32.9	)		(31.8	)		(1.1	)		(73.9	)%		(71.5	)%		(2.4	)%
Breast Implants			39.9			41.1			(1.2	)		(2.0	)		0.8			(2.9	)%		(4.9	)%		2.0	%			11.2			44.1			(32.9	)		(31.8	)		(1.1	)		(74.6	)%		(72.1	)%		(2.5	)%
Earfold^™			0.4			0.4			-			-			-			0.0	%		0.0	%		0.0	%
Other Plastic Surgery																												0.4			0.4			-			-			-			0.0	%		0.0	%		0.0	%
Regenerative Medicine			4.7			3.6			1.1			0.9			0.2			30.6	%		25.0	%		5.6	%			3.3			4.9			(1.6	)		(1.4	)		(0.2	)		(32.7	)%		(28.6	)%		(4.1	)%
Alloderm^®			2.3			2.3			-			(0.1	)		0.1			0.0	%		(4.3	)%		4.3	%			1.6			2.2			(0.6	)		(0.6	)		-			(27.3	)%		(27.3	)%		0.0	%
Other Regenerative Medicine			2.4			1.3			1.1			1.0			0.1			84.6	%		76.9	%		7.7	%			1.7			2.7			(1.0	)		(0.8	)		(0.2	)		(37.0	)%		(29.6	)%		(7.4	)%
Body Contouring			30.9			22.7			8.2			7.6			0.6			36.1	%		33.5	%		2.6	%			28.4			9.2			19.2			20.5			(1.3	)	n.m.			n.m.			n.m.
Coolsculpting^® Consumables			18.5			12.5			6.0			5.5			0.5			48.0	%		44.0	%		4.0	%			17.8			8.1			9.7			10.5			(0.8	)	n.m.			n.m.			n.m.
Coolsculpting^® Systems & Add On Applicators			12.4			10.2			2.2			2.1			0.1			21.6	%		20.6	%		1.0	%			10.6			1.1			9.5			10.0			(0.5	)	n.m.			n.m.			n.m.
Skin Care			4.1			2.7			1.4			1.4			-			51.9	%		51.9	%		0.0	%			2.7			3.8			(1.1	)		(0.9	)		(0.2	)		(28.9	)%		(23.7	)%		(5.2	)%
Botox^® Therapeutics and Other			166.6			151.1			15.5			8.9			6.6			10.3	%		5.9	%		4.4	%			138.8			149.7			(10.9	)		0.8			(11.7	)		(7.3	)%		0.5	%		(7.8	)%
Botox^® Therapeutics			104.6			93.8			10.8			7.6			3.2			11.5	%		8.1	%		3.4	%			93.9			96.2			(2.3	)		6.4			(8.7	)		(2.4	)%		6.7	%		(9.1	)%
Asacol^®/Delzicol^®			12.4			12.8			(0.4	)		(1.1	)		0.7			(3.1	)%		(8.6	)%		5.5	%			10.3			11.7			(1.4	)		(0.7	)		(0.7	)		(12.0	)%		(6.0	)%		(6.0	)%
Constella^®			6.4			5.5			0.9			0.6			0.3			16.4	%		10.9	%		5.5	%			5.5			5.6			(0.1	)		0.3			(0.4	)		(1.8	)%		5.4	%		(7.2	)%
Other Products			43.2			39.0			4.2			1.8			2.4			10.8	%		4.6	%		6.2	%			29.1			36.2			(7.1	)		(5.2	)		(1.9	)		(19.6	)%		(14.4	)%		(5.2	)%
Other revenues			18.8			27.3			(8.5	)		(8.6	)		0.1			(31.1	)%		(31.5	)%		0.4	%			18.1			12.1			6.0			6.3			(0.3	)		49.6	%		52.1	%		(2.5	)%
Net revenues		$	948.9		$	858.5		$	90.4		$	69.9		$	20.5			10.5	%		8.1	%		2.4	%		$	801.5		$	864.0		$	(62.5	)	$	10.8		$	(73.3	)		(7.2	)%		1.3	%		(8.5	)%
Operating expenses:
Cost of sales⁽¹⁾			139.4			125.0			14.4			12.7			1.7			11.5	%		10.2	%		1.3	%			109.7			120.9			(11.2	)		(1.9	)		(9.3	)		(9.3	)%		(1.6	)%		(7.7	)%
Selling and marketing			246.2			238.9			7.3			1.1			6.2			3.1	%		0.5	%		2.6	%			237.6			245.7			(8.1	)		12.2			(20.3	)		(3.3	)%		5.0	%		(8.3	)%
General and administrative			33.9			28.3			5.6			5.3			0.3			19.8	%		18.7	%		1.1	%			25.7			31.4			(5.7	)		(3.4	)		(2.3	)		(18.2	)%		(10.8	)%		(7.4	)%
Segment contribution		$	529.4		$	466.3		$	63.1		$	50.8		$	12.3			13.5	%		10.9	%		2.6	%		$	428.5		$	466.0		$	(37.5	)	$	3.9		$	(41.4	)		(8.0	)%		0.8	%		(8.8	)%
Segment margin			55.8	%		54.3	%											1.5	%									53.5	%		53.9	%											(0.4	)%
Segment gross margin⁽²⁾			85.3	%		85.4	%											(0.1	)%									86.3	%		86.0	%											0.3	%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.																									⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.	⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.																									⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.
⁽³⁾Defined as overall change excluding foreign exchange impact.	⁽³⁾Defined as overall change excluding foreign exchange impact.																									⁽³⁾Defined as overall change excluding foreign exchange impact.
⁽⁴⁾Includes Optive^® sales of $27.8 million which were previously disclosed separately in the three months ended March 31, 2018.																										⁽⁴⁾Includes Optive^® sales of $27.8 million which were previously disclosed separately in the three months ended March 31, 2018.

The following table presents our revenue disaggregated by geography for our International segment ($in millions):

		Three Months Ended June 30,																	Three Months Ended March 31,
		2018		2017		Overall Change ($)			Overall Change (%)			Operational Change ($)			Operational Change (%)				2019		2018		$ Overall Change			$ Operational Change			% Overall Change			% Operational Change
Europe		$	413.3	$	378.1	$	35.2			9.3	%	$	18.4			4.9	%		$	354.4	$	398.4	$	(44.0	)	$	(6.5	)		(11.0	)%		(1.6	)%
Asia Pacific, Middle East and Africa			283.6		236.3		47.3			20.0	%		37.8			16.0	%			250.7		240.8		9.9			25.9			4.1	%		10.8	%
Latin America and Canada			230.8		215.6		15.2			7.1	%		21.2			9.8	%			178.2		212.1		(33.9	)		(14.7	)		(16.0	)%		(6.9	)%
Other*			21.2		28.5		(7.3	)		(25.6	)%		(7.5	)		(26.3	)%			18.2		12.7		5.5			6.1			43.3	%		48.0	%
Total International		$	948.9	$	858.5	$	90.4			10.5	%	$	69.9			8.1	%		$	801.5	$	864.0	$	(62.5	)	$	10.8			(7.2	)%		1.3	%
*Includes royalty and other revenue	*Includes royalty and other revenue																	*Includes royalty and other revenue

The ~~increase~~decrease in net revenues isin the three months ended March 31, 2019 was primarily due to the negative impact of foreign currency as well as declines in Eye Care and Plastic Surgery, offset, in part, by operational growth ~~of total~~in Facial Aesthetics and Body Contouring. Within Eye Care, the decrease in sales is due to trade buying patterns, the generic impact of Restasis in Canada and price erosion in Europe as well as ~~the Zeltiq Acquisition. Within total Eye Care, Ozurdex~~^® ~~increased $16.7 million, or 32.6%~~a loss from foreign currency. Plastic Surgery decreased versus the prior year period, primarily driven by ~~demand~~a fourth quarter 2018 suspension of sales and withdrawal of the remaining textured breast implants from the market in Europe. The operational growth ~~and a benefit from foreign currency. Within~~in Facial Aesthetics ~~Botox~~^® ~~Cosmetics sales grew $23.1 million, or 15.6% driven primarily by~~and Body Contouring was due to an increase in demand ~~growth and a benefit from foreign currency. Juvederm~~^® ~~Collection revenues increased $18.8 million, or 13.7% versus the prior year period, primarily resulting from demand growth and a benefit from foreign currency.~~growth.

The ~~increase~~decrease in cost of sales in the three months ended March 31, 2019 was primarily due to the ~~increase~~decrease in net ~~revenues and the Zeltiq Acquisition. Excluding the Zeltiq Acquisition in both periods, segment gross margin was 85.8% in the three months ended June 30, 2018 and 2017.~~revenues.

The ~~increase~~decrease in selling and marketing expenses ~~is consistent with~~in the ~~increase~~three months ended March 31, 2019 was primarily due to the impact from foreign currency, offset, in ~~net revenues.~~part, by an expansion of the sales force in certain markets.

General and administrative expenses ~~increased period-over-period due to the expansion of our International segment.~~remained stable period over period.

Corporate represents the results of corporate initiatives as well as the impact of select revenues and shared costs. The following represents the Corporate amounts for the three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

		Three Months Ended June 30, 2018																						Three Months Ended March 31, 2019
		Integration			Non- Acquisition Related Restructuring			Fair Value Adjustments			Effect of Purchase Accounting			Other			Revenues and Shared Costs			Total				Integration / Divestiture			Non- Acquisition Related Restructuring			Fair Value Adjustments			Effect of Purchase Accounting			Other			Revenues and Shared Costs			Total
Net revenues		$	-		$	-		$	-		$	-		$	-		$	28.6		$	28.6			$	-		$	-		$	-		$	-		$	-		$	2.8		$	2.8
Operating expenses:
Cost of sales⁽¹⁾			1.0			9.3			(128.8	)		0.4			(0.1	)		110.1			(8.1	)			-			4.6			16.2			0.3			-			56.4			77.5
Selling and marketing			0.5			6.9			-			1.7			-			-			9.1				-			(1.8	)		-			0.9			-			-			(0.9	)
General and administrative			14.9			(3.0	)		-			0.5			31.6			173.4			217.4				5.4			0.1			-			0.3			11.2			167.2			184.2
Contribution		$	(16.4	)	$	(13.2	)	$	128.8		$	(2.6	)	$	(31.5	)	$	(254.9	)	$	(189.8	)		$	(5.4	)	$	(2.9	)	$	(16.2	)	$	(1.5	)	$	(11.2	)	$	(220.8	)	$	(258.0	)

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.																						⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.

		Three Months Ended June 30, 2017																						Three Months Ended March 31, 2018
		Integration			Non- Acquisition Related Restructuring			Fair Value Adjustments			Effect of Purchase Accounting			Other			Revenues and Shared Costs			Total				Integration / Divestiture			Non- Acquisition Related Restructuring			Fair Value Adjustments			Effect of Purchase Accounting			Other			Revenues and Shared Costs			Total
Net revenues		$	-		$	-		$	-		$	-		$	-		$	6.2		$	6.2			$	-		$	-		$	-		$	-		$	-		$	5.8		$	5.8
Operating expenses:
Cost of sales⁽¹⁾			1.3			5.4			(24.8	)		61.0			(0.2	)		50.5			93.2				0.5			12.6			3.4			1.1			-			67.5			85.1
Selling and marketing			11.0			29.9			-			8.9			(0.5	)		2.1			51.4				0.9			10.3			-			4.3			-			0.1			15.6
General and administrative			40.2			3.5			-			36.4			49.1			211.2			340.4				13.8			7.3			-			1.6			9.0			143.7			175.4
Contribution		$	(52.5	)	$	(38.8	)	$	24.8		$	(106.3	)	$	(48.4	)	$	(257.6	)	$	(478.8	)		$	(15.2	)	$	(30.2	)	$	(3.4	)	$	(7.0	)	$	(9.0	)	$	(205.5	)	$	(270.3	)

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.	⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.																						⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights.

In the three months ended ~~June 30,~~March 31, 2019 and 2018, ~~and 2017, integration and restructuring charges primarily included costs related to the integration of LifeCell Corporation (“LifeCell”) and Zeltiq.~~

In the three months ended June 30, 2018, the Company incurred charges related to the restructuring of its internal infrastructure. The restructuring programs included charges associated with scaling our manufacturing plants.

In the three months ended June 30, 2017, the Company recorded an estimate for severance and other restructuring costs relating to the commercial organization of $29.9 million as the Company intended to eliminate approximately 400 positions.

Fair value adjustments primarily relate to changes in estimated contingent liabilities which are based on future amounts to be paid based on achievement of sales levels for the respective products. In the three months ended June 30, 2018, the income in cost of sales primarily relates to the Company’s True Tear product not achieving a milestone event, as well as a corresponding decrease in commercial forecasts.

In the three months ended June 30, 2018 and 2017, the Company incurred charges related to the purchase accounting impact on share-based compensation related to the Zeltiq Acquisition, the acquisition of Allergan, Inc. (the “Allergan Acquisition”), and the acquisition of Forest Laboratories, Inc. (the “Forest Acquisition”), which increased cost of sales, selling and marketing and general and administrative expenses.

In the three months ended June 30, 2017, the Company incurred purchase accounting effects of $59.9 million in cost of sales related to the fair value inventory step-up from the acquisition of LifeCell (the “LifeCell Acquisition”) and the Zeltiq Acquisition as products were sold to the Company’s third-party customers. A cash share-based compensation charge of $31.5 million associated with the Zeltiq Acquisition was also included in the three months ended June 30, 2017.

In the three months ended June 30, 2018, the Company recorded milestone revenue related to an on-going intellectual property agreement of $25.0 million. In the three months ended June 30, 2018 and 2017, general and administrative costs included legal settlement charges of $29.0 million and $42.5 million, respectively.

Shared costs primarily include above site and unallocated costs associated with running our global manufacturing facilities and corporate general and administrative expenses. In the three months ended June 30, 2018, the Company incurred transactional foreign exchange losses of $11.2 million, compared with transactional foreign exchange losses of $71.0 million in the three months ended June 30, 2017.

R&D expenses consist predominantly of personnel-related costs, active pharmaceutical ingredient costs, contract research, license and milestone fees, and biostudy and facility costs associated with product development.

~~R&D expenses consisted of the following components in the three months ended June 30, 2018 and 2017 ($ in millions):~~

~~The following represents milestone payments, asset acquisitions and upfront license payments in the three months ended June 30, 2018 and 2017, respectively ($ in millions):~~

Acquisition, integration and restructuring charges in the three months ended June 30, 2017 included $26.8 million of severance and restructuring costs related to a then-planned internal reduction of approximately 200 R&D positions.

~~Amortization in the three months ended June 30, 2018 and 2017 was as follows ($ in millions):~~

~~IPR&D impairments and Asset sales and impairments, net consisted of the following components in the three months ended June 30, 2018 and 2017 ($ in millions):~~

~~In the three months ended June 30, 2018, the Company recorded the following IPR&D impairments:~~

~~In the three months ended June 30, 2017, the Company recorded the following IPR&D impairments:~~

~~Interest income in the three months ended June 30, 2018 and 2017 was as follows ($ in millions):~~

~~Interest expense consisted of the following components in the three months ended June 30, 2018 and 2017 ($ in millions):~~

Interest expense in the three months ended June 30, 2018 decreased versus the three months ended June 30, 2017 due to scheduled maturities and early debt extinguishment of senior secured notes period-over-period, as well as the impact from debt refinancing.

~~Other income / (expense), net consisted of the following components in the three months ended June 30, 2018 and 2017 ($ in millions):~~

~~Refer to the Teva Share Activity in the Six Months Ended June 30, 2018 and 2017 section of Management’s Discussion and Analysis on page 91 for further details.~~

During the three and six months ended June 30, 2018, the Company repurchased $455.9 million of senior notes in the open market. As a result of the debt extinguishment, the Company recognized a gain net of $9.1 million, within “Other income / (expense)” ~~for the cash discount received of $13.1 million, including the non-cash write-off of premiums and debt fees related to the repaid notes of $4.0 million~~.

~~During the three and six months ended June 30, 2018, the Company redeemed and retired the following senior notes ($ in millions):~~

On May 30, 2017, the Company completed the repurchase of certain debt securities issued for cash under a previously announced tender offer. During the three months ended June 30, 2017, as a result of the debt extinguishment, the Company recognized a loss of $161.5 million, within “Other income / (expense)” for the early tender payment and non-cash write-off of premiums and debt fees related to the repurchased notes, including $170.5 million of a make-whole premium.

During the three months ended June 30, 2017, the Company received dividend income of $34.1 million from its equity stake in Teva. On February 8, 2018, Teva suspended all dividends on ordinary shares.

~~(Benefit) for income taxes in the three months ended June 30, 2018 and 2017 was as follows: ($ in millions):~~

The Company’s effective tax rate for the three months ended June 30, 2018 was 1.1% compared to 44.8% for the three months ended June 30, 2017. The effective tax rate for the three months ended June 30, 2018 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by the ~~additional U.S. tax on the earnings of certain non-U.S. subsidiaries which are considered Global Intangible Low Taxed Income (“GILTI”) and the~~ tax impact of amortization of intangible assets at rates less than the Irish statutory rate. Additionally, the tax benefit for the three months ended June 30, 2018 included tax benefits due to the impairment of certain intangible assets offset by tax detriments related to the integration of acquired assets and investments sold and held for sale.

The effective tax rate for the three months ended June 30, 2017 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. Additionally, the tax benefit for the three months ended June 30, 2017 included tax benefits related to the impairment of certain intangible assets and an excess tax over book basis in a U.S. subsidiary expected to reverse in the foreseeable future.

The effective tax rate for the three months ended June 30, 2018 was lower compared to the three months ended June 30, 2017 primarily due to the unfavorable tax impacts of U.S. Tax Reform, gains on the sale of certain assets and the absence of a one-time tax benefit for the tax over book basis in a U.S. subsidiary recorded in the period ended June 30, 2017.

~~Results of operations, including segment net revenues, segment operating expenses and segment contribution consisted of the following for the six months ended June 30, 2018 and 2017 ($ in millions):~~

~~The following table presents top product sales and net contribution for the US Specialized Therapeutics segment for the six months ended June 30, 2018 and 2017 ($ in millions):~~

Six Months Ended June 30,

Change

2018

2017

Dollars

%

Total Eye Care

$
1,078.1

$
1,153.2

$
(75.1
)

(6.5
)%
Restasis^®

574.0

645.2

(71.2
)

(11.0
)%
Alphagan^®/Combigan^®

182.3

182.8

(0.5
)

(0.3
)%
Lumigan^®/Ganfort^®

139.8

153.3

(13.5
)

(8.8
)%
Eye Drops

100.0

98.5

1.5

1.5
%
Ozurdex^®

53.1

47.4

5.7

12.0
%
Other Eye Care

28.9

26.0

2.9

11.2
%
Total Medical Aesthetics

1,379.2

1,134.0

245.2

21.6
%
Facial Aesthetics

715.2

667.9

47.3

7.1
%
Botox^® Cosmetics

433.2

394.1

39.1

9.9
%
Juvederm^® Collection

262.6

246.0

16.6

6.7
%
Kybella^®

19.4

27.8

(8.4
)

(30.2
)%
Plastic Surgery

136.6

115.6

21.0

18.2
%
Breast Implants

136.6

115.6

21.0

18.2
%
Regenerative Medicine

265.8

191.3

74.5

38.9
%
Alloderm^®

206.6

138.7

67.9

49.0
%
Other Regenerative Medicine

59.2

52.6

6.6

12.5
%
Body Contouring

195.4

78.9

116.5

147.7
%
Coolsculpting^® Consumables

125.3

47.9

77.4

161.6
%
Coolsculpting^® Systems & Add On Applicators

70.1

31.0

39.1

126.1
%
Skin Care

66.2

80.3

(14.1
)

(17.6
)%
SkinMedica^®

38.9

53.4

(14.5
)

(27.2
)%
Latisse^®

27.3

26.9

0.4

1.5
%
Total Medical Dermatology

110.5

168.4

(57.9
)

(34.4
)%
Aczone^®

37.1

81.6

(44.5
)

(54.5
)%
Botox^® Hyperhidrosis

34.6

33.6

1.0

3.0
%
Tazorac^®

15.8

36.2

(20.4
)

(56.4
)%
Other Medical Dermatology

23.0

17.0

6.0

35.3
%
Total Neuroscience and Urology

805.7

707.3

98.4

13.9
%
Botox^® Therapeutics

763.2

655.7

107.5

16.4
%
Rapaflo^®

42.5

51.6

(9.1
)

(17.6
)%
Other Revenues

31.8

34.1

(2.3
)

(6.7
)%
Net revenues

$
3,405.3

$
3,197.0

$
208.3

6.5
%
Operating expenses:

Cost of sales⁽¹⁾

282.9

218.0

64.9

29.8
%
Selling and marketing

656.5

687.2

(30.7
)

(4.5
)%
General and administrative

98.3

94.6

3.7

3.9
%
Segment contribution

$
2,367.6

$
2,197.2

$
170.4

7.8
%
Segment margin

69.5
%

68.7
%

0.8
%
Segment gross margin⁽²⁾

91.7
%

93.2
%

(1.5
)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.

⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.

~~The Zeltiq and LifeCell acquisitions contributed the following to the segment in the six months ended June 30, 2018 ($ in millions):~~

~~The Zeltiq and LifeCell acquisitions contributed the following to the segment in the six months ended June 30, 2017 ($ in millions):~~

~~The increase in net revenues was primarily driven by the Zeltiq and LifeCell acquisitions and growth in Botox~~^® ~~Therapeutics and Botox~~^® ~~Cosmetics, partially offset by decreases in Restasis~~^® ~~and Aczone~~^®.

~~Botox~~^® ~~Therapeutics and Botox~~^® ~~Cosmetics increased $107.5 million, or 16.4% and $39.1 million, or 9.9%, respectively, versus the prior year period primarily driven by demand growth.~~

~~The decline in Aczone~~^® ~~revenues of $44.5 million, or 54.5%, was due to genericization of the branded acne market, increased discounts to maintain formulary access and a generic launch of Aczone 5%.~~

~~The decline in Restasis~~^® ~~revenues of $71.2 million, or 11.0% was due to both price declines and volume declines due to trade buying patterns.~~

The increase in cost of sales was primarily due to the LifeCell and Zeltiq acquisitions. Excluding the LifeCell and Zeltiq acquisitions in both periods, segment gross margin decreased to 94.0% in the six months ended June 30, 2018 versus 94.9% in the prior year period primarily due to product mix.

The decrease in selling and marketing expenses primarily relates to lower headcount in the Eye Care and Medical Dermatology field forces due to the Company’s restructuring initiatives, lower promotional costs and a decrease in the charge for the non-tax deductible Branded Prescription Drug Fee, offset in part by the impact of the Zeltiq and LifeCell acquisitions.

~~The following table presents top product sales and net contribution for the US General Medicine segment for the six months ended June 30, 2018 and 2017 ($ in millions):~~

Six Months Ended June 30,

Change

2018

2017

Dollars

%

Total Central Nervous System (CNS)

$
532.7

$
655.7

$
(123.0
)

(18.8
)%
Vraylar^™

198.6

119.9

78.7

65.6
%
Viibryd^®/Fetzima^®

158.4

157.7

0.7

0.4
%
Saphris^®

66.5

80.3

(13.8
)

(17.2
)%
Namzaric^®

65.2

57.0

8.2

14.4
%
Namenda XR^®

43.9

240.7

(196.8
)

(81.8
)%
Namenda^® IR

0.1

0.1

-

0.0
%
Total Gastrointestinal (GI)

820.6

798.3

22.3

2.8
%
Linzess^®

351.1

315.4

35.7

11.3
%
Carafate^®/Sulcrate^®

110.3

117.9

(7.6
)

(6.4
)%
Zenpep^®

108.4

97.0

11.4

11.8
%
Canasa^®/Salofalk^®

83.6

76.7

6.9

9.0
%
Viberzi^®

80.8

72.8

8.0

11.0
%
Asacol^®/Delzicol^®

70.8

103.2

(32.4
)

(31.4
)%
Other GI

15.6

15.3

0.3

2.0
%
Total Women's Health

359.8

492.7

(132.9
)

(27.0
)%
Lo Loestrin^®

242.4

212.8

29.6

13.9
%
Liletta^®

23.6

13.8

9.8

71.0
%
Estrace^® Cream

19.5

163.5

(144.0
)

(88.1
)%
Minastrin^® 24

6.0

52.5

(46.5
)

(88.6
)%
Other Women's Health

68.3

50.1

18.2

36.3
%
Total Anti-Infectives

151.4

123.5

27.9

22.6
%
Teflaro^®

64.6

63.6

1.0

1.6
%
Avycaz^®

45.3

25.8

19.5

75.6
%
Dalvance^®

29.6

24.8

4.8

19.4
%
Other Anti-Infectives

11.9

9.3

2.6

28.0
%
Diversified Brands

559.8

604.5

(44.7
)

(7.4
)%
Bystolic^®/ Byvalson^®

280.9

290.5

(9.6
)

(3.3
)%
Armour Thyroid

97.4

79.3

18.1

22.8
%
Savella^®

39.0

50.3

(11.3
)

(22.5
)%
Lexapro^®

29.2

26.5

2.7

10.2
%
PacPharma

8.1

6.7

1.4

20.9
%
Other Diversified Brands

105.2

151.2

(46.0
)

(30.4
)%
Other revenues

119.4

98.8

20.6

20.9
%
Net revenues

$
2,543.7

$
2,773.5

$
(229.8
)

(8.3
)%
Operating expenses:

Cost of sales⁽¹⁾

384.4

397.7

(13.3
)

(3.3
)%
Selling and marketing

480.3

590.6

(110.3
)

(18.7
)%
General and administrative

73.6

82.0

(8.4
)

(10.2
)%
Segment contribution

$
1,605.4

$
1,703.2

$
(97.8
)

(5.7
)%
Segment margin

63.1
%

61.4
%

1.7
%
Segment gross margin⁽²⁾

84.9
%

85.7
%

(0.8
)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.

⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.

~~The decrease in net revenues was primarily due to a decline in products that lost exclusivity including Namenda XR~~^® ~~($196.8 million), Estrace~~^® ~~Cream ($144.0 million), and Minastrin~~^® ~~24 ($46.5 million), offset, in part, by growth in Vraylar~~^™~~, Linzess~~^®~~, and Lo Loestrin~~^®.

~~CNS revenues declined $123.0 million, or 18.8%, primarily due to the decline in Namenda XR~~^® ~~as a result of loss of exclusivity, offset, in part, by strong demand growth for Vraylar~~^™.

~~Women’s Health revenues declined $132.9 million, or 27.0%, primarily due to the loss of exclusivity on Estrace~~^® ~~Cream and Minastrin~~^® ~~24, offset, in part, by growth for Lo Loestrin~~^® ~~driven by higher average selling prices and increased demand.~~

~~GI revenues increased $22.3 million, or 2.8%, primarily due to growth for Linzess~~^® ~~resulting from increased demand, offset, in part, by the loss of exclusivity of Asacol~~^®.

The decrease in cost of sales was primarily due to lower product sales and product mix, including loss of exclusivity on higher margin products. Segment gross margin was 84.9% in the six months ended June 30, 2018 compared to 85.7% in the prior year period.

The decrease in selling and marketing expenses related to headcount reductions from the Company’s restructuring initiatives, lower promotional costs, and a decrease in the charge for the non-tax deductible Branded Prescription Drug Fee.

~~General and administrative expenses decreased period-over-period due to cost savings initiatives.~~

~~The following table presents top product sales and net contribution for the International segment for the six months ended June 30, 2018 and 2017 ($ in millions):~~

Six Months Ended June 30,

Change

2018

2017

$
Overall
Change

$
Operational
Change ⁽³⁾

$
Currency
Change

%
Overall
Change

%
Operational
Change⁽³⁾

%
Currency
Change

Total Eye Care

$
697.4

$
621.5

$
75.9

$
42.7

$
33.2

12.2
%

6.9
%

5.3
%
Lumigan^®/Ganfort^®

200.9

180.3

20.6

6.2

14.4

11.4
%

3.4
%

8.0
%
Ozurdex^®

132.3

102.3

30.0

20.5

9.5

29.3
%

20.0
%

9.3
%
Alphagan^®/Combigan^®

88.8

85.0

3.8

1.6

2.2

4.5
%

1.9
%

2.6
%
Optive^®

58.5

55.1

3.4

1.2

2.2

6.2
%

2.2
%

4.0
%
Restasis^®

34.3

31.2

3.1

2.7

0.4

9.9
%

8.7
%

1.2
%
Other Eye Drops

82.7

80.9

1.8

(1.1
)

2.9

2.2
%

(1.4
)%

3.6
%
Other Eye Care

99.9

86.7

13.2

11.6

1.6

15.2
%

13.4
%

1.8
%
Total Medical Aesthetics

768.3

646.2

122.1

92.2

29.9

18.9
%

14.3
%

4.6
%
Facial Aesthetics

625.9

533.5

92.4

68.6

23.8

17.3
%

12.9
%

4.4
%
Botox^® Cosmetics

320.0

270.5

49.5

39.6

9.9

18.3
%

14.6
%

3.7
%
Juvederm^® Collection

302.2

259.5

42.7

28.9

13.8

16.5
%

11.1
%

5.4
%
Belkyra^® (Kybella^®)

3.7

3.5

0.2

0.1

0.1

5.7
%

2.9
%

2.8
%
Plastic Surgery

84.8

79.5

5.3

1.6

3.7

6.7
%

2.0
%

4.7
%
Breast Implants

84.0

78.7

5.3

1.6

3.7

6.7
%

2.0
%

4.7
%
Earfold^™

0.8

0.8

-

-

-

0.0
%

0.0
%

0.0
%
Regenerative Medicine

9.6

5.6

4.0

3.4

0.6

71.4
%

60.7
%

10.7
%
Alloderm^®

4.5

3.5

1.0

0.8

0.2

28.6
%

22.9
%

5.7
%
Other Regenerative Medicine

5.1

2.1

3.0

2.6

0.4

142.9
%

123.8
%

19.1
%
Body Contouring

40.1

22.7

17.4

16.8

0.6

76.7
%

74.0
%

2.7
%
Coolsculpting^® Consumables

26.6

12.5

14.1

13.6

0.5

112.8
%

108.8
%

4.0
%
Coolsculpting^® Systems & Add On Applicators

13.5

10.2

3.3

3.2

0.1

32.4
%

31.4
%

1.0
%
Skin Care

7.9

4.9

3.0

1.8

1.2

61.2
%

36.7
%

24.5
%
Botox^® Therapeutics and Other

316.3

285.0

31.3

14.4

16.9

11.0
%

5.1
%

5.9
%
Botox^® Therapeutics

200.8

176.2

24.6

14.6

10.0

14.0
%

8.3
%

5.7
%
Asacol^®/Delzicol^®

24.1

24.9

(0.8
)

(2.5
)

1.7

(3.2
)%

(10.0
)%

6.8
%
Constella^®

12.0

10.4

1.6

0.9

0.7

15.4
%

8.7
%

6.7
%
Other Products

79.4

73.5

5.9

1.4

4.5

8.0
%

1.9
%

6.1
%
Other revenues

30.9

43.1

(12.2
)

(12.7
)

0.5

(28.3
)%

(29.5
)%

1.2
%
Net revenues

$
1,812.9

$
1,595.8

$
217.1

$
136.6

$
80.5

13.6
%

8.6
%

5.0
%
Operating expenses:

Cost of sales⁽¹⁾

260.3

225.3

35.0

25.9

9.1

15.5
%

11.5
%

4.0
%
Selling and marketing

491.9

448.4

43.5

19.5

24.0

9.7
%

4.3
%

5.4
%
General and administrative

65.3

58.2

7.1

4.8

2.3

12.2
%

8.2
%

4.0
%
Segment contribution

$
995.4

$
863.9

$
131.5

$
86.4

$
45.1

15.2
%

10.0
%

5.2
%
Segment margin

54.9
%

54.1
%

0.8
%

Segment gross margin⁽²⁾

85.6
%

85.9
%

(0.3
)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.

⁽²⁾Defined as net revenues less segment related cost of sales as a percentage of net revenues.

⁽³⁾Defined as overall change excluding foreign exchange impact.

~~The following table presents our revenue disaggregated by geography for our International segment ($in millions):~~

~~The increase in net revenues was primarily due to the operational growth of total Facial Aesthetics and Eye Care, as well as the LifeCell and Zeltiq acquisitions. Within total Eye Care, Ozurdex~~^® ~~increased $30.0 million, or 29.3% versus the prior year period primarily driven by demand growth and a benefit from foreign currency. Within Facial Aesthetics, Botox~~^® ~~Cosmetics sales grew $49.5 million, or 18.3% driven primarily by demand growth and a benefit from foreign currency. Juvederm~~^® ~~Collection revenues increased $42.7 million, or 16.5% versus the prior year period, primarily resulting from demand growth and a benefit from foreign currency.~~

The increase in cost of sales was primarily due to the increase in net revenues and the LifeCell and Zeltiq acquisitions. Excluding the LifeCell and Zeltiq acquisitions in both periods, segment gross margin was 86.4% in the six months ended June 30, 2018 compared to 86.2% in the prior year period.

~~The increase in selling and marketing expenses is consistent with the increase in net revenues.~~

Corporate represents the results of corporate initiatives as well as the impact of select revenues and shared costs. The following represents the Corporate amounts for the six months ended June 30, 2018 and 2017 ($ in millions):

~~In the six months ended June 30, 2018 and 2017,~~ integration and restructuring charges included costs related to the integration of LifeCell Corporation (“LifeCell’) and ~~Zeltiq.~~

In the ~~six~~three months ended ~~June 30,~~March 31, 2018, the Company incurred charges related to the restructuring of its internal infrastructure. The restructuring programs included charges associated with scaling our manufacturing plants as well as the acceleration of share-based compensation charges for severed employees over their shortened vesting ~~periods of $8.2 million.~~

In the six months ended June 30, 2017, the Company incurred severance and other restructuring costs relating to the commercial organization of $29.9 million as the Company intended to eliminate approximately 400 positions. periods.

Fair value adjustments primarily relate to changes in estimated contingent liabilities ~~which are based on~~for future amounts to be paid based on achievement of sales levels for the respective products.

In the six months ended June 30, 2018, the income in cost of sales relates to the Company’s True Tear product not achieving a milestone event, as well as a corresponding decrease in commercial forecasts. The income recorded in the six months ended June 30, 2017 primarily relating to reduced or delayed revenue forecasts for select products including Rhofade^® ~~and Liletta~~^®.

In the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, ~~and 2017,~~ the Company incurred charges related to the purchase accounting impact on share-based compensation related to the Zeltiq and Allergan, ~~and Forest~~Inc. (“Legacy Allergan”) acquisitions, which increased cost of sales, selling and marketing and general and administrative expenses. ~~A cash share-based compensation charge of $31.5 million associated with the Zeltiq Acquisition was also included in the six months ended June 30, 2017.~~

In the six months ended June 30, 2017, the Company incurred purchase accounting effects of $87.8 million in cost of sales related to the fair value inventory step-up from the LifeCell and Zeltiq acquisitions as products were sold to the Company’s third-party customers.

In the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, ~~the Company recorded milestone revenue related to an on-going intellectual property agreement of $25.0 million. In the six months ended June 30, 2018 and 2017,~~ general and administrative costs included legal settlement charges of ~~$39.3~~$10.4 million and ~~$41.4~~$10.3 million, respectively.

Shared costs primarily include above site and unallocated costs associated with running our global manufacturing facilities and corporate general and administrative expenses.

In the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, the Company incurred transactional foreign exchange losses of ~~$16.1~~$6.8 million ~~compared with transactional foreign exchange losses of $77.8~~and $4.9 million, ~~in the six months ended June 30, 2017.~~respectively.

R&D expenses consist predominantly of personnel-related costs, active pharmaceutical ingredient costs, contract research, license and milestone fees, biostudy and facilities costs associated with product development.

R&D expenses consisted of the following ~~components~~ in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

The ~~decrease~~increase in ongoing operating expenses in the ~~six~~three months ended ~~June 30, 2018 versus the prior year period~~March 31, 2019 is ~~primarily~~mainly due to ~~decreased~~increased product development spending ~~primarily driven by~~in early stage development ~~campaigns~~programs and ~~the Eye Care therapeutic area as well as lower personnel costs offset, in part by,~~ increased spending in the Central Nervous System and Gastrointestinal therapeutic areas.

Acquisition, integration and restructuring charges in the six months ended June 30, 2017 included $26.8 million of severance and restructuring costs related to a then planned internal reduction of approximately 200 R&D positions.

The following represents milestone ~~payments,~~expenses, asset acquisitions and upfront license payments in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, ~~and 2017,~~ respectively ($ in millions):

Amortization in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ was as follows ($ in millions):

Amortization for the three months ended March 31, 2019 decreased as compared to the three months ended March 31, 2018 primarily as a result of a decrease in amortization for Restasis^® due to a reduced book value and remaining life as a result of an anticipated launch of a generic.

~~IPR&D~~other impairments and ~~Asset~~asset sales, ~~and impairments,~~ net consisted of the following ~~components~~ in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

	Six Months Ended June 30,				Change						Three Months Ended March 31,
	2018		2017		Dollars			%			2019			2018		$ Change			% Change
Goodwill impairments											$	2,467.0		$	-	$	2,467.0		n.a
IPR&D impairments	$	798.0	$	1,043.3	$	(245.3	)		(23.5	)%		-			522.0		(522.0	)		(100.0	)%
Asset sales and impairments, net		272.7		21.4		251.3		n.m.				(5.2	)		13.1		(18.3	)	n.m.

Refer to “NOTE 11 – Goodwill, Product Rights and Other Intangible Assets” for the description of the goodwill impairments and IPR&D impairments that the Company recorded in the three months ended March 31, 2019 and 2018.

As of December 31, 2018, the net asset value of the General Medicine Reporting Unit equaled fair value. On March 6, 2019, Allergan announced negative topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major Depressive Disorder (MDD). These results represented a triggering event for the Company’s General Medicine Reporting Unit.

In the ~~six~~three months ended ~~June 30, 2018, the Company recorded the following IPR&D impairments:~~

As of June 30, 2018, the Company determined that certain assets related to a non-strategic medical dermatology product was deemed held for sale based on the Company’s intention and ability to dispose of the related assets. As a result,brazikumab, the Company recorded ana $2,467.0 million goodwill impairment ~~of $252.0 million~~charge to ~~the anticipated sale value and reclassified the “product rights and other intangibles, net” balance of $130.5 million to “non-current assets held for sale.”~~

~~In the six months ended June 30, 2017, the Company recorded the following IPR&D impairments:~~

Interest income in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ was as follows ($ in millions):

Interest income represents interest earned on cash and cash equivalents and marketable securities held during the respective periods.

Interest expense consisted of the following ~~components~~ in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

	Six Months Ended June 30,				Change						Three Months Ended March 31,
	2018		2017		Dollars			%			2019		2018		$ Change			% Change
Fixed Rate Notes	$	438.3	$	550.0	$	(111.7	)		(20.3	)%	$	173.8	$	228.9	$	(55.1	)		(24.1	)%
Euro Denominated Notes												14.9		8.6		6.3			73.3	%
Floating Rate Notes		11.0		12.1		(1.1	)		(9.1	)%		5.0		6.4		(1.4	)		(21.9	)%
Euro Denominated Notes		17.4		3.0		14.4		n.m.
Other		13.9		2.0		11.9		n.m.				8.1		6.7		1.4			20.9	%
Interest expense	$	480.6	$	567.1	$	(86.5	)		(15.3	)%	$	201.8	$	250.6	$	(48.8	)		(19.5	)%

Interest expense in the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 decreased versus the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 due to scheduled maturities and early debt extinguishment of senior secured notes period-over-period, as well as the impact from debt ~~refinancing.~~refinancing in the prior year.

Other income / (expense), net consisted of the following ~~components~~ in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ ($ in millions):

During the six months ended June 30, 2018, the Company recorded the following movements in its investment in Teva securities (defined herein as “Teva Share Activity”) ($ in millions except per share information):

Shares

Carrying Value per Share

Market
Price

Proceeds Received

Value of
Marketable
Securities

Unrealized
Gain / (Loss) as
a Component
of Other
Comprehensive
Income

Gain /
(Loss)
Recognized
in Other
Income/
(Expense),
Net

Derivative Instrument (Liability)/
Asset

Retained Earnings

Teva securities as of
   December 31, 2017

95.9

$
17.60

$
18.95

n.a.

$
1,817.7

$
129.3

$
-

$
(62.9
)

$
-

Impact of ASU No.
   2016-01

-

-

-

-

-

(129.3
)

-

-

129.3

Settlement of initial
   accelerated share
   repurchase ("ASR"), net

(25.0
)

18.95

16.53

*

413.3

(473.8
)

-

2.5

62.9

-

Forward sale entered
   into during the three
   months ended March
   31, 2018

**

n.a.

n.a.

372.3

n.a.

-

19.0

(353.3
)

-

Open market sales

(11.5
)

n.a.

19.95

229.9

(218.5
)

-

11.5

-

-

Other fair value
   movements during the
   three months ended
   March 31, 2018

-

n.a.

n.a.

n.a.

(110.7
)

-

(110.7
)

-

-

Teva securities as of
   and for the
   three months ended
   March 31, 2018

59.4

$
17.09

$
17.09

$
1,015.5

$
1,014.7

$
-

$
(77.7
)

$
(353.3
)

$
129.3

Settlement of forward sale
   entered into during the
   three months ended
   March 31, 2018, net

(25.0
)

17.09

18.61

***

93.2

(427.3
)

-

19.2

353.3

-

Open market sales

(34.4
)

n.a.

20.55

706.8

(587.4
)

-

119.4

-

-

Teva securities as of
   and for the six months
   ended June 30, 2018

-

$
-

$
-

$
1,815.5

$
-

$
-

$
60.9

$
-

$
129.3

* Market price represents average price over the life of the contract.  On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48.

** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares.  The forward sale transaction settled during the second quarter of 2018.  As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities were reported on the Company's balance sheet until the contract settled on May 7, 2018.

*** Market price represents average price over the life of the contract.  On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62.

	Three Months Ended March 31,
	2019			2018			$ Change			% Change
Teva Share Activity	$	-		$	(77.7	)	$	77.7			(100.0	)%
Debt extinguishment other		(0.3	)		-			(0.3	)	n.a
Other income / (expense), net		14.1			(1.1	)		15.2		n.m.
Other income / (expense), net	$	13.8		$	(78.8	)	$	92.6		n.m.

~~During the six months ended June 30, 2017, the Company recorded the following movements in its investment in Teva securities ($ in millions except per share information):~~

Refer to ~~the Sale of Business section in the Three Months Ended June 30, 2018 and 2017 section of Management’s Discussion and Analysis~~“NOTE 6 – Other Income / (Expense)” for further ~~details.~~

~~Refer to~~details regarding the ~~Debt Extinguishment Other section in the Three Months Ended June 30, 2018 and 2017 section~~components of ~~Management’s Discussion and Analysis for further details.~~

~~Refer to the Debt Extinguishment Costs as Part of the Debt Tender Offer section in the Three Months Ended June 30, 2018 and 2017 section of Management’s Discussion and Analysis for further details.~~

~~During the six months ended June 30, 2017, the Company received dividend~~other income ~~of $68.2 million from its equity stake in Teva. On February 8, 2018, Teva suspended all dividends on ordinary shares.~~

(Benefit) for income taxes in the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018 ~~and 2017~~ was as follows: ($ in millions):

	Six Months Ended June 30,						Change					Three Months Ended March 31,
	2018			2017			Dollars		%			2019			2018			$ Change		% Change
(Benefit) for income taxes	$	(687.4	)	$	(1,113.3	)	$	425.9		(38.3	)%	$	(68.6	)	$	(682.2	)	$	613.6		(89.9	)%
Effective tax rate		47.7	%		25.4	%							2.8	%		70.6	%

The effective tax rate for the three months ended March 31, 2018 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by the additional U.S. tax on the earnings of certain non-U.S. subsidiaries which are considered ~~GILTI~~Global Intangible Low Taxed Income (“GILTI”) and the tax impact of amortization of intangible assets at rates less than the Irish statutory rate. Additionally, the tax benefit for the ~~six~~three months ended ~~June 30,~~March 31, 2018 included tax benefits of $421.9 million related to the restructuring of an acquired business, ~~$231.0~~$117.5 million related to the impairment of ~~certain intangible assets~~ an IPR&D project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc. and ~~$79.8~~$89.7 million related to excess tax over book basis in a U.S. subsidiary ~~expected to~~that will reverse in the foreseeable future. ~~This was partially offset by tax detriments of $21.2 million for the gain on sale of investments and $25.9 million related to a change in the applicable tax rate on certain temporary differences.~~

The effective tax rate for the ~~six~~three months ended ~~June 30, 2017~~March 31, 2019 was ~~favorably impacted by income earned in jurisdictions with tax rates~~ lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by a pre-tax charge for the impairment of the Company’s investment in Teva Shares of $1,978.0 million and the tax impact of amortization of intangible assets, both at rates less than the Irish statutory rate. Additionally, the tax benefit for the six months ended June 30, 2017 included tax benefits of $288.1 million relatedcompared to ~~the impairment of certain intangible assets and $69.4 million related to the integration of an acquired business and debt restructuring. During~~ the three months ended June 30, 2017, the Company determined that a temporary difference related to excess tax over book basis in a U.S. subsidiary will reverse in the foreseeable future and recorded a corresponding tax benefit of $179.6 million.

~~The effective tax rate for the six months ended June 30,~~March 31, 2018 ~~was higher compared to the six months ended June 30, 2017~~ primarily due to the goodwill impairment ~~of the Company’s investment in Teva Shares~~recorded in the ~~prior year for which~~first quarter of 2019 with no associated tax benefit ~~was recorded.~~and the absence of certain discrete tax benefits recorded in the first quarter of 2018.

Working capital at ~~June 30, 2018~~March 31, 2019 and December 31, ~~2017~~2018 is summarized as follows ($ in millions):

	June 30,			December 31,		Increase			March 31,			December 31,		Increase
	2018			2017		(Decrease)			2019			2018		(Decrease)
Current Assets:
Cash and cash equivalents	$	1,674.7		$	1,817.2	$	(142.5	)	$	788.5		$	880.4	$	(91.9	)
Marketable securities		21.5			4,632.1		(4,610.6	)		995.2			1,026.9		(31.7	)
Accounts receivable, net		2,760.8			2,899.0		(138.2	)		2,731.2			2,868.1		(136.9	)
Inventories		922.5			904.5		18.0			943.2			846.9		96.3
Current assets held for sale										45.7			34.0		11.7
Prepaid expenses and other current assets		724.2			1,123.9		(399.7	)		785.5			819.1		(33.6	)
Total current assets		6,103.7			11,376.7		(5,273.0	)		6,289.3			6,475.4		(186.1	)
Current liabilities:
Accounts payable and accrued expenses	$	4,683.8		$	5,541.4	$	(857.6	)	$	4,634.4		$	4,787.2	$	(152.8	)
Income taxes payable		93.0			74.9		18.1			126.9			72.4		54.5
Current portion of long-term debt and capital leases		1,348.5			4,231.8		(2,883.3	)
Current portion of long-term debt										3,971.8			868.3		3,103.5
Current portion of lease liability - operating										116.1			-		116.1
Total current liabilities		6,125.3			9,848.1		(3,722.8	)		8,849.2			5,727.9		3,121.3
Working Capital	$	(21.6	)	$	1,528.6	$	(1,550.2	)	$	(2,559.9	)	$	747.5	$	(3,307.4	)
Current Ratio		1.00			1.16					0.71			1.13

Working capital ~~decreased $1,550.2 million~~movements were primarily due to the ~~following uses of working capital:~~following:

	Six Months Ended June 30,						Three Months Ended March 31,
	2018			2017			2019			2018			$ Change
Net cash provided by operating activities	$	2,698.5		$	2,523.1		$	1,234.0		$	1,458.3		$	(224.3	)
Net cash provided by investing activities	$	3,634.4		$	400.0
Net cash (used in) / provided by investing activities							$	(104.8	)	$	2,932.3		$	(3,037.1	)
Net cash (used in) financing activities	$	(6,490.4	)	$	(3,771.7	)	$	(1,227.0	)	$	(5,207.7	)	$	3,980.7

Cash flows from operations represent net income adjusted for certain non-cash items and changes in assets and liabilities. Cash provided by operating activities ~~increased $175.4~~decreased $224.3 million in the ~~six~~three months ended ~~June 30, 2018~~March 31, 2019 versus the prior year period, due to an increase in ~~net income adjusted for non-cash activities, a reduction in interest payments ($106.0 million),~~cash taxes of $69.7 million, reduced accounts receivable collections and ~~lower cash payments for asset acquisitions and milestones ($180.0 million), offset in part by the timing of tax payments versus the tax provision.~~increased inventories.

Management expects that available cash balances and the remaining ~~2018~~2019 cash flows from operating activities will provide sufficient resources to fund our operating liquidity needs and expected capital expenditure funding requirements for at least the next twelve months.

Investing cash flows ~~consist primarily of~~for the three months ended March 31, 2019 reflect the cash used in acquisitions of businesses ~~and intangible assets (primarily product rights), capital expenditures and purchases~~ of ~~investments and marketable securities partially offset by proceeds from~~$80.6 million. Investing cash flows for the ~~sale of a business, investments and marketable securities. Included in the six~~three months ended ~~June 30,~~March 31, 2018 isreflect the net cash provided by the net sale of investments of ~~$4,140.4~~$3,433.6 million offset, in part, by payments to settle Teva related matters of $466.0 million.

Included in the six months ended June 30, 2017 is the net cash provided by the sale of marketable securities of $6,387.1 million, offset, in part, by the cash purchases of LifeCell for $2,874.4 million and Zeltiq of $2,346.7 million, net of cash acquired, and the purchase of intangible assets of $586.3 million.

Financing cash flows consist primarily of borrowings and repayments of debt, repurchases of ordinary shares, dividend payments and proceeds from the exercise of stock options. Cash used in financing activities in the ~~six~~three months ended ~~June 30,~~March 31, 2019 primarily related to the repayment of indebtedness of $159.4 million, the repurchase of ordinary shares of $829.2 million and the payment of dividends of $246.1 million. Cash used in financing activities in the three months ended March 31, 2018 primarily related to the repayment of indebtedness of ~~$5,366.8~~$4,322.1 million, the repurchase of ordinary shares of ~~$1,572.1~~$1,439.6 million, the payment of dividends of ~~$563.7~~$319.5 million and payments to settle ~~Teva-related~~Teva related matters of $234.0 million, which was outstanding greater than one year, offset, in part, by borrowings under the revolving credit facility and other borrowings of $709.0 million and proceeds from the forward sale of Teva ~~Shares~~shares of ~~$465.5~~$372.3 million.

Cash used in financing activities in the six months ended June 30, 2017 primarily related to the repayment of indebtedness of $5,579.2 million, which included debt repurchased under the tender offer completed on May 30, 2017 and the early redemption of certain debt securities, the payment of dividends of $611.9 million and payments relating to contingent consideration and other financing of $505.1 million, offset, in part by the long-term borrowings of $3,023.0 million.

The following table lists certain of our enforceable and legally binding obligations as of ~~June 30, 2018.~~March 31, 2019. Certain amounts included herein are based on management’s estimates and assumptions about these obligations, including their duration, the possibility of renewal of lease agreements, anticipated actions by third parties and other factors. Because these estimates and assumptions are necessarily subjective, the enforceable and legally binding obligation we will actually pay in future periods may vary from those reflected in the table.

~~In addition, such~~The following is a summary of select contractual commitments as of March 31, 2019, including amounts accrued as of the balance sheet date to be paid in future periods ($ in millions):

The table above reflects the anticipated timing of R&D and approval related milestones and sales based milestones. Certain agreements also include royalties based on commercial sales which are excluded from the table above. The following are contractual commitments relating to the R&D and approval related milestones and sales based milestones ($ in millions):

Such milestone payments will only be payable in the event that the Company achieves contractually defined, success-based milestones, such as:

~~The following is a summary of select contractual commitments as of June 30, 2018, including amounts accrued as of the balance sheet date to be paid in future periods ($ in millions):~~

We do not have any material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, net revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

From time to time, we use our website, our Facebook, Instagram, LinkedIn and Twitter accounts and other social media channels as additional means of disclosing public information to investors, the media and others interested in the Company. Additionally, our Chairman, President and Chief Executive Officer, Brent L. Saunders, and our Executive Vice President and Chief Commercial Officer, Bill Meury, may use similar social media channels to disclose public information. It is possible that certain information we post on our website and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information we post on our website and on the social media channels identified above. The information on our website and those social media channels is not incorporated by reference into this Form 10-Q.

Any statements made in this report that are not statements of historical fact or that refer to estimated or anticipated future events are “forward‑looking statements”, as contemplated in the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “intend,” “could,” “would,” “should,” “estimate,” “continue,” or “pursue,” or the negative or other variations thereof or comparable terminology, are intended to identify forward‑looking statements. We have based our forward‑looking statements on management’s beliefs and assumptions based on information available to our management at the time these statements are made. Such forward‑looking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of this filing. The statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of which are beyond our control. We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report.

Actual results may differ materially from our current expectations depending upon a number of factors affecting our business. These factors include, among others:

The following discussion provides forward-looking quantitative and qualitative information about our potential exposure to market risk. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk) and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

We maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including both government and government agency obligations with ratings of A or better and money market funds. Our investments in marketable securities are governed by our investment policy which seeks to preserve the value of our principal, provide liquidity and maximize return on the Company’s investment against minimal interest rate risk. Consequently, our interest rate and principal risk are minimal on our non-equity investment portfolio. The quantitative and qualitative disclosures about market risk are set forth below.

As of ~~June 30, 2018~~March 31, 2019, our total investments in marketable and equity securities of other companies, including equity method investments, but excluding securities considered cash and cash equivalents, were ~~$94.8~~$1,053.1 million (included in marketable securities and investments and other assets). The fair values of these investments are subject to ~~significant~~ fluctuations due to volatility of the stock market and changes in general economic conditions.

We regularly review the carrying value of our investments and identify and recognize losses for income statement purposes.

Our exposure to interest rate risk relates primarily to our non-equity investment portfolio. Our cash is invested in money market securities.

Our ~~portfolio of~~permitted investments in marketable securities ~~includes~~include highly liquid money market securities classified as available-for-sale ~~securities, with no~~securities. No security ~~having~~as of March 31, 2019 has a maturity in excess of one year. These investments include floating rate securities that are exposed to interest rate fluctuations. Because of the short-term nature of these investments, we are subject to minimal interest rate risk and do not believe that an increase in market rates would have a significant negative impact on the ~~realized~~ value of our portfolio.

At ~~June 30, 2018,~~March 31, 2019, borrowings outstanding under the floating rate notes were ~~$1,317.9~~$2,070.6 million. Assuming a one percent increase in the applicable interest rate on the Company’s floating rates notes, annual interest expense would increase by approximately ~~$13.2~~$14.2 million over the next twelve months.

The Company has outstanding borrowings under its fixed rate notes. Changes in market interest rates generally affect the fair value of fixed-rate debt, but do not impact earnings or cash flows.

The Company has outstanding borrowings under its Euro Denominated Notes. Changes in foreign exchange rates may impact cash flows for principal and interest.

The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and its overall cost of borrowing. The Company does not use leveraged swaps and does not leverage any of its fixed income investments that would put principal capital at risk.

Overall, we are a net recipient of currencies other than the U.S. dollar and, as such, benefit from a weaker dollar and are adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect our consolidated revenues or operating costs and expenses as expressed in U.S. dollars.

From time to time, we enter into foreign currency ~~option and~~ forward ~~contracts. Accordingly, we have entered into various~~ contracts which change in value as foreign exchange rates change to allow the Company ~~at its option~~ to economically offset the effect of changes in the value of foreign currency assets and ~~liabilities, commitments and anticipated foreign currency denominated sales and operating expenses.~~liabilities. We have entered into foreign currency ~~option and~~ forward contracts in amounts between minimum and maximum existing or anticipated foreign exchange exposures.

~~From time~~The Company is subject to ~~time, we use foreign currency option contracts,~~transactions which provide for the sale or purchase of foreign currencies, if exercised, to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of our business. Probable but not firmly committed transactions are ~~comprised primarily of sales of products and purchases of raw material~~denominated in currencies other than the ~~U.S. dollar. While these instruments were subject to fluctuations~~functional currency and therefore movements in ~~value, such fluctuations were anticipated to offset changes in the value of the underlying exposures.~~

~~While the Company does not believe it has significant exposure to foreign~~ exchange ~~we are subject to transactional items which~~rates may impact the results of operations. Net foreign currency losses ~~on the results of operations~~reflected in general and administrative expenses were ~~$16.1~~$6.8 million and ~~$77.8~~$4.9 million for the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, respectively.

The currency for Argentina was deemed hyperinflationary in the third quarter of 2018 and ~~2017, respectively.~~is now being accounted for using the Company’s functional currency. The impact is immaterial to the Company’s operations.

The Company is exposed to foreign exchange risk in its international operations from foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business, including the Euro Denominated Notes. In the ~~six~~three months ended ~~June 30, 2018,~~March 31, 2019, we used effective net investment hedges to partially offset the effects of foreign currency on our investments in certain of our foreign subsidiaries. The total notional amount of our instruments designated as net investment hedges was ~~$3.6~~$5.0 billion as of ~~June 30, 2018~~March 31, 2019 and $5.1 billion as of December 31, ~~2017.~~2018. During the ~~six~~three months ended ~~June 30,~~March 31, 2019 and 2018, ~~and 2017,~~ the impact of the net investment hedges onrecorded in other comprehensive (loss) / income was a gain of ~~$102.0~~$110.8 million and a loss of ~~$57.2~~$95.1 million, respectively.

We do not believe that inflation has had a significant impact on our revenues or operations, nor do we have any material commodity price risks.

Allergan plc maintains “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) of the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed in Allergan plc’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Allergan plc’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective.

As required by SEC Rule 13a-15(b), Allergan plc carried out an evaluation, under the supervision and with the participation of Allergan plc’s management, including ~~Allergan’s~~Allergan plc’s Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of Allergan plc’s disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on this evaluation Allergan plc’s Principal Executive Officer and Principal Financial Officer concluded that Allergan plc’s disclosure controls and procedures were effective at the reasonable assurance level as of ~~June 30, 2018.~~March 31, 2019.

Warner Chilcott Limited maintains “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) of the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Warner Chilcott Limited’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective.

As required by SEC Rule 13a-15(b), Warner Chilcott Limited carried out an evaluation, under the supervision and with the participation of Warner Chilcott Limited’s management, including Warner Chilcott Limited’s Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of Warner Chilcott Limited’s disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on this evaluation Warner Chilcott Limited’s Principal Executive Officer and Principal Financial Officer concluded that Warner Chilcott Limited’s disclosure controls and procedures were effective at the reasonable assurance level as of ~~June 30, 2018.~~March 31, 2019.

Changes in Internal Control Over Financial Reporting of Allergan plc and Warner Chilcott Limited

During the quarter ended ~~June 30, 2018,~~March 31, 2019, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, Allergan plc and Warner Chilcott Limited’s internal control over financial reporting.

For information regarding legal proceedings, refer to “PART I, ITEM 3. LEGAL PROCEEDINGS,” of our Annual Report on Form 10-K for the year ended December 31, ~~2017~~2018 and “Legal Matters” in “NOTE 1920 — Commitments and Contingencies” in the accompanying “Notes to the Consolidated Financial Statements” in this Quarterly Report.

There have been no material changes in the Company’s risk factors from those disclosed in the Company’s Form 10-K for the year ended December 31, ~~2017.~~2018.

Recent Sale of Unregistered Securities; Uses of Proceeds from Registered Securities

During the quarter ended ~~June 30, 2018,~~March 31, 2019, we repurchased ~~26,938~~209,527 of Allergan plc’s Ordinary Shares to satisfy tax withholding obligations in connection with the vesting of restricted stock issued to employees and directors. The Company’s Board of Directors previously approved a $2.0 billion share repurchase program in July 2018, of which we repurchased $0.8 billion of our Ordinary Shares in the three months ended March 31, 2019. On ~~September 25, 2017,~~January 29, 2019, the ~~Company’s~~Company announced that its Board of Directors approved a $2.0 billion share repurchase program, all of which ~~we made no repurchases in the three months ended June 30, 2018.~~ remained outstanding as of March 31, 2019.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on ~~August 2, 2018.~~May 7, 2019.

Commission File Number	Exact name of registrant as specified in its charter, principal office and address and telephone number	State of incorporation or organization	I.R.S. Employer Identification No.
001-36867	Allergan plc Clonshaugh Business and Technology Park Coolock, Dublin, D17 E400, Ireland (862) 261-7000	Ireland	98-1114402

001-36887	Warner Chilcott Limited Canon’s Court	Bermuda	98-0496358
	22 Victoria Street
	Hamilton HM 12
	Bermuda
	(441) 295-2244


Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Allergan plc Ordinary Shares, $0.0001 par value	AGN	New York Stock Exchange

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Allergan plc	Large accelerated filer	☒	Accelerated filer	☐
	Non-accelerated filer ~~(Do not check if a smaller reporting company)~~	☐	Smaller reporting company	☐
	Emerging growth company	☐

Warner Chilcott Limited	Large accelerated filer	☐	Accelerated filer	☐
	Non-accelerated filer ~~(Do not check if a smaller reporting company)~~	☒	Smaller reporting company	☐
	Emerging growth company	☐

Allergan plc		YES ☐		NO ☒
Warner Chilcott Limited		YES ☐		NO ☒

		PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (unaudited)	3
	Consolidated Balance Sheets of Allergan plc as of ~~June 30, 2018~~March 31, 2019 and December 31, ~~2017~~2018	3
	Consolidated Statements of Operations of Allergan plc for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and March 31, 2018 ~~and June 30, 2017~~	4
	Consolidated Statements of Comprehensive (Loss) ~~/ Income~~ of Allergan plc for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and March 31, 2018 ~~and June 30, 2017~~	5
	Consolidated Statements of Cash Flows of Allergan plc for the ~~six~~three months ended ~~June 30,~~March 31, 2019 and March 31, 2018 ~~and June 30, 2017~~	6
	Consolidated Statements of Equity of Allergan plc for the three months ended March 31, 2019 and March 31, 2018	7
	Consolidated Balance Sheets of Warner Chilcott Limited as of ~~June 30, 2018~~March 31, 2019 and December 31, ~~2017~~2018	78
	Consolidated Statements of Operations of Warner Chilcott Limited for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and March 31, 2018 ~~and June 30, 2017~~	89
	Consolidated Statements of Comprehensive (Loss) of Warner Chilcott Limited for the three months ended March 31, 2019 and March 31, 2018	10
	Consolidated Statements of Cash Flows of Warner Chilcott Limited for the three months ended March 31, 2019 and March 31, 2018	11
	Consolidated Statements of ~~Comprehensive (Loss) / Income~~Equity of Warner Chilcott Limited for the three ~~and six~~ months ended ~~June 30,~~March 31, 2019 and March 31, 2018 ~~and June 30, 2017~~	9
	~~Consolidated Statements of Cash Flows of Warner Chilcott Limited for the six months ended June 30, 2018 and June 30, 2017~~	1012
	Notes to the Consolidated Financial Statements	1113
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	6753
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	9570
Item 4.	Controls and Procedures	9771
PART II. OTHER INFORMATION		9873
Item 1.	Legal Proceedings	9873
Item 1A.	Risk Factors	9873
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9873
Item 6.	Exhibits	9873
	Signatures	~~100~~75

	Increase / (decrease)
Pronouncement	Accounts receivable, net		Prepaid expenses and other current assets			Accounts payable and accrued expenses			Deferred tax liabilities			Retained earnings		Accumulated other comprehensive income / (loss)
Accounting Standards Update No. 2014-09	$	1.9	$	-		$	(3.6	)	$	-		$	5.5	$	-
Accounting Standards Update No. 2016-01	$	-	$	-		$	-		$	-		$	63.0	$	(63.0	)
Accounting Standards Update No. 2016-16	$	-	$	(44.8	)	$	-		$	(401.0	)	$	356.2	$	-

	Chargebacks			Rebates			Returns and Other Allowances			Cash Discounts			Total
Balance at December 31, 2017	$	77.2		$	1,799.2		$	517.6		$	36.5		$	2,430.5
Provision related to sales in 2018		550.9			2,556.5			859.6			155.4			4,122.4
Credits and payments		(565.6	)		(2,622.2	)		(842.1	)		(161.8	)		(4,191.7	)
Balance at June 30, 2018	$	62.5		$	1,733.5		$	535.1		$	30.1		$	2,361.2
Contra accounts receivable at June 30, 2018	$	62.5		$	67.4		$	42.9		$	30.1		$	202.9
Accounts payable and accrued expenses at June 30, 2018	$	-		$	1,666.1		$	492.2		$	-		$	2,158.3

	Chargebacks			Rebates			Returns and Other Allowances			Cash Discounts			Total
Balance at December 31, 2018	$	61.8		$	1,908.5		$	566.6		$	30.7		$	2,567.6
Provision related to sales in 2019		267.3			1,396.5			400.5			75.4			2,139.7
Credits and payments		(262.9	)		(1,294.5	)		(361.7	)		(78.6	)		(1,997.7	)
Balance at March 31, 2019	$	66.2		$	2,010.5		$	605.4		$	27.5		$	2,709.6
Contra accounts receivable at March 31, 2019	$	66.2		$	69.4		$	41.0		$	27.5		$	204.1
Accounts payable and accrued expenses at March 31, 2019	$	-		$	1,941.1		$	564.4		$	-		$	2,505.5

Product	Therapeutic Area	Indication	Expected Launch Year	Phase
Cariprazine	Central Nervous System	Bipolar Depression	2019	Review
Ubrogepant	Central Nervous System	Acute Migraine	2020	Review
Abicipar	Eye Care	Age Related Macular Degeneration	2020	III
Bimatoprost SR	Eye Care	Glaucoma	2020	III
Atogepant	Central Nervous System	Prophylaxis Migraine	2021	III
Presbysol	Eye Care	Presbyopia	2021	III
Cenicriviroc	Gastrointestinal	NASH	2022	III
Relamorelin	Gastrointestinal	Gastroparesis	2023	III
Brimonidine DDS	Eye Care	Geographic Atrophy	2023	II
Abicipar	Eye Care	Diabetic Macular Edema	2024	II
Botox	Medical Aesthetics	Platysma/Masseter	2025/2023	II
Brazikumab	Gastrointestinal	Crohn's Disease	2025	II
Brazikumab	Gastrointestinal	Ulcerative Colitis	2026	II

	Final Valuation
Cash and cash equivalents	$	36.7
Accounts receivable		47.0
Inventories		59.3
Property, plant and equipment		12.4
Intangible assets		1,185.0
Goodwill		1,211.6
Other assets		17.1
Accounts payable and accrued expenses		(104.6	)
Deferred revenue		(10.6	)
Deferred taxes, net		(47.2	)
Other liabilities		(1.3	)
Net assets acquired	$	2,405.4

IRS Audits		Taxable Years
Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc.		2013, 2014, 2015 and 2016
Warner Chilcott Corporation		2010, 2011, 2012 and 2013
Forest Laboratories, Inc.		2010, 2011, 2012, 2013 and 2014
Allergan, Inc.		2009, 2010, 2011, 2012, 2013, 2014 and 3/7/17/2015

	Allergan plc
Shareholders’ equity as of December 31, 2017	$	73,821.1
Net (loss) attributable to shareholders		(758.6	)
Other comprehensive (loss), net of tax		(264.8	)
Share-based compensation		127.4
Ordinary shares issued under employee stock plans		69.2
Implementation of new accounting pronouncements (Refer to Note 3)		361.7
Dividends declared		(540.4	)
Repurchase of ordinary shares under the share repurchase programs		(1,540.0	)
Repurchase of ordinary shares		(32.1	)
Shareholders’ equity as of June 30, 2018	$	71,243.5

	Warner Chilcott Limited
Members' equity as of December 31, 2017	$	81,266.2
Net (loss) attributable to members		(603.7	)
Other comprehensive (loss), net of tax		(264.8	)
Implementation of new accounting pronouncements (Refer to Note 3)		361.7
Dividends to Parents		(2,103.7	)
Members' equity as of June 30, 2018	$	78,655.7

	Fair Value Measurements as of December 31, 2017 Using:
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents^*	$	1,328.1	$	1,328.1	$	-	$	-
Short-term investments		2,814.4		-		2,814.4		-
Deferred executive compensation investments		112.4	92.9		19.5			-
Investment in Teva ordinary shares		1,817.7		1,817.7		-		-
Investments and other		72.3		72.3		-		-
Total assets	$	6,144.9	$	3,311.0	$	2,833.9	$	-
Liabilities:
Deferred executive compensation liabilities	$	113.8	$	94.3	$	19.5	$	-
Contingent consideration obligations		476.9		-		-		476.9
Total liabilities	$	590.7	$	94.3	$	19.5	$	476.9

* Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.

	Investments in Securities as of June 30, 2018:
Level 1	Carrying amount		Estimated fair value		Cash & cash equivalents		Marketable securities
Money market funds	$	1,249.9	$	1,249.9	$	1,249.9	$	-
Total	$	1,249.9	$	1,249.9	$	1,249.9	$	-

Level 2	Carrying amount		Estimated fair value		Cash & cash equivalents		Marketable securities
Other investments	$	21.5	$	21.5	$	-	$	21.5
Total	$	21.5	$	21.5	$	-	$	21.5

	Investments in Securities as of December 31, 2017:
Level 1	Carrying amount		Unrecognized gain		Unrecognized loss			Estimated fair value		Cash & cash equivalents		Marketable securities
Money market funds	$	1,328.1	$	-	$	-		$	1,328.1	$	1,328.1	$	-
Investment in Teva ordinary shares		1,688.4		129.3		-			1,817.7		-		1,817.7
Total	$	3,016.5	$	129.3	$	-		$	3,145.8	$	1,328.1	$	1,817.7

Level 2	Carrying amount		Unrecognized gain		Unrecognized loss			Estimated fair value		Cash & cash equivalents		Marketable securities
Commercial paper and other	$	1,248.9	$	-	$	(0.7	)	$	1,248.2	$	-	$	1,248.2
Certificates of deposit		1,566.2		-		-			1,566.2		-		1,566.2
Total	$	2,815.1	$	-	$	(0.7	)	$	2,814.4	$	-	$	2,814.4

	LifeCell		Zeltiq		Combined Contribution
Net revenues	$	266.9	$	195.4	$	462.3
Operating expenses:
Cost of sales		50.6		54.3		104.9
Selling and marketing		59.1		90.0		149.1
General and administrative		4.4		3.2		7.6

	Shares			Carrying Value per Share		Market Price			Proceeds Received		Value of Marketable Securities			Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			Gain / (Loss) Recognized in Other Income/ (Expense), Net			Derivative Instrument (Liability)/ Asset			Retained Earnings
Teva securities as of December 31, 2017		95.9		$	17.60	$	18.95		n.a.		$	1,817.7		$	129.3		$	-		$	(62.9	)	$	-
Impact of ASU No. 2016-01		-			-		-			-		-			(129.3	)		-			-			129.3
Settlement of initial accelerated share repurchase ("ASR"), net		(25.0	)		18.95		16.53	*		413.3		(473.8	)		-			2.5			62.9			-
Forward sale entered into during the three months ended March 31, 2018	**			n.a.		n.a.				372.3	n.a.				-			19.0			(353.3	)		-
Open market sales		(11.5	)	n.a.			19.95			229.9		(218.5	)		-			11.5			-			-
Other fair value movements during the three months ended March 31, 2018		-		n.a.		n.a.			n.a.			(110.7	)		-			(110.7	)		-			-
Teva securities as of and for the three months ended March 31, 2018		59.4		$	17.09	$	17.09		$	1,015.5	$	1,014.7		$	-		$	(77.7	)	$	(353.3	)	$	129.3
Settlement of forward sale entered into during the three months ended March 31, 2018, net		(25.0	)		17.09		18.61	***		93.2		(427.3	)		-			19.2			353.3			-
Open market sales		(34.4	)	n.a.			20.55			706.8		(587.4	)		-			119.4			-			-
Teva securities as of and for the six months ended June 30, 2018		-		$	-	$	-		$	1,815.5	$	-		$	-		$	60.9		$	-		$	129.3
* Market price represents average price over the life of the contract. On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48.
** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares. The forward sale transaction settled during the second quarter of 2018. As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities were reported on the Company's balance sheet until the contract settled on May 7, 2018.
*** Market price represents average price over the life of the contract. On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62.

	Shares		Carrying Value per Share		Market Price		Discount			Movement in the Value of Marketable Securities			Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			Gain / (Loss) Recognized in Other Income/ (Expense), Net
Teva securities as of December 31, 2016		100.3	$	53.39	$	36.25		5.4	%	$	3,439.2		$	(1,599.4	)	$	-
Other-than-temporary impairment recognized at March 31, 2017		100.3		32.09		32.09		4.9	%		(378.6	)		1,599.4			(1,978.0	)
Teva securities as of and for the three months ended March 31, 2017		100.3	$	32.09	$	32.09		4.9	%	$	3,060.6		$	-		$	(1,978.0	)
Other fair value movements during the three months ended June 30, 2017		100.3		32.09		33.22		1.9	%		207.8			207.8			-
Teva securities as of and for the six months ended June 30, 2017		100.3	$	32.09	$	33.22		1.9	%	$	3,268.4		$	207.8		$	(1,978.0	)
The Teva stock price was discounted due to the lack of marketability.

	Payments Due by Period
	Total		Nine Months Ending December 31, 2019		2020-2021		2022-2023		Thereafter
Sales based and other milestone obligations		10,222.8		30.0		35.0		41.0		10,116.8
R&D / approval milestone obligations		6,061.9		204.7		1,042.8		540.8		4,273.6
Total	$	16,284.7	$	234.7	$	1,077.8	$	581.8	$	14,390.4

Transaction	Product	Maximum Milestones		R&D / Approval Milestones		Sales Based and Other Milestones
Heptares Therapeutics, Ltd	Neurological disorders	$	3,224.5	$	649.5	$	2,575.0
Assembly Biosciences, Inc.	Gastrointestinal products		2,459.0		1,069.0		1,390.0
AstraZeneca plc License	Brazikumab		1,250.0		210.0		1,040.0
Akarna Therapeutics, Ltd	Inflammatory and fibrotic diseases		975.0		600.0		375.0
Tobira Therapeutics, Inc.	Cenicriviroc		800.1		400.1		400.0
Chase Pharmaceuticals Corporation	Neurodegenerative disorders		800.0		250.0		550.0
Merck & Co.	Ubrogepant & Atogepant		780.0		350.0		430.0
Retrosense Therapeutics, LLC	RST-001		495.0		245.0		250.0
AqueSys, Inc.	Xen Gel Stent		300.0		-		300.0
Topokine Therapeutics, Inc.	XAF5		260.0		110.0		150.0
Oculeve, Inc.	TrueTear^®		150.0		50.0		100.0
Forsight VISION5, Inc.	Bimatoprost Ring		125.0		125.0		-
All Other			4,666.1		2,003.3		2,662.8
Total		$	16,284.7	$	6,061.9	$	10,222.8

	Payments Due by Period
	Total		Six Months Ending December 31, 2018		2019-2020		2021-2022		Thereafter
Sales based and other milestone obligations	$	10,447.6	$	9.0	$	35.0	$	55.0	$	10,348.6
R&D / approval milestone obligations		6,098.3		343.2		598.2		1,207.4		3,949.5
Total	$	16,545.9	$	352.2	$	633.2	$	1,262.4	$	14,298.1

Period	Total Number of Shares Purchased		Total Number of Shares Purchased to Satisfy Tax Withholdings		Average Price Paid per Share		Total Number of Shares Purchased as Part of Share Repurchase Program		Average Price Paid per Share as Part of Share Repurchase Program		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Share Repurchase Program ($ in millions)
April 1 - 30, 2018		15,815		15,815	$	167.97		-	$	-	$	10.0
May 1 - 31, 2018		9,713		9,713	$	199.69		-	$	-	$	10.0
June 1 - 30, 2018		1,410		1,410	$	165.20		-	$	-	$	10.0
April 1 - June 30, 2018		26,938		26,938	$	179.26		-	$	-

Exhibit		Description

31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14a of the Securities Exchange Act of 1934.
31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14a of the Securities Exchange Act of 1934.
32.1**		Certification of Chief Executive Officer pursuant to 18 U.S.C. of Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. of the Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Scheme Document.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Label Definition Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

ALLERGAN PLC WARNER CHILCOTT LIMITED

By:		/s/ Matthew M. Walsh
Name:		Matthew M. Walsh
Title:		Executive Vice President and Chief Financial Officer (Principal Financial Officer)

By:		/s/ James C. D’Arecca
Name:		James C. D’Arecca
Title:		Chief Accounting Officer (Principal Accounting Officer)